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Abstract

Development of In Vitro Tissue Engineered Blood Vessel Mimics in Complex
Geometries for Coronary Stent Testing
Robert Dalton Chavez

Coronary heart disease is the leading cause of death in the United States and
occurs when plaque occludes coronary arteries. Coronary stents, which may be used to
treat coronary occlusions, are small metal tubes that are implanted in coronary arteries to
restore blood flow. After stent implantation, endothelial cells grow over the stent so that
blood contacts the endothelial cells instead of the stent surface; this event is known as reendothelialization. Re-endothelialization prevents blood from clotting on the stent surface
and is a good predictor of stent success. Blood vessel mimics (BVMs) are in vitro tissue
engineered models of human blood vessels that may be used to preclinically test coronary
stents for re-endothelialization. BVMs have been developed in straight geometries, but
the FDA has recommended that coronary devices be preclinically tested in complexshaped simulated vessels when the complex geometries of coronary arteries may
negatively affect device performance. Coronary geometries may negatively affect the
tissue response to coronary stents, therefore BVMs should be developed in complex
geometries.
The goal of this thesis research was to fully develop complex-shaped scaffolds
and bioreactors, to develop complex-shaped BVMs with cells located throughout all
regions of the BVMs, and to develop a complex-shaped BVM with a confluent region of
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cells. First, bioreactors that can house complex-shaped scaffolds were designed,
constructed, and validated. Complex-shaped BVMs were then developed by depositing
cells throughout the entire inner surface of complex-shaped scaffolds, and the average
and median cell densities throughout all regions of the BVMs were shown to be
approximately the same order of magnitude as endothelial cell densities in native blood
vessels. A stent was then successfully deployed in a complex-shaped BVM. The
complex-shaped BVM straightened out to conform to the stent, which also occurs in
native blood vessels. Finally, a confluent region of cells was developed on a complexshaped scaffold. Complex-shaped BVMs could eventually be used to preclinically test
coronary stents, coronary drug-delivery systems, coronary imaging modalities, and other
intravascular technologies.
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1. Introduction

1.1. Overview
The overall goal of this thesis research was to develop a complex-shaped BVM
for coronary stent testing.
New coronary devices are constantly under development for the identification and
treatment of coronary heart disease (CHD). CHD occurs when plaque occludes coronary
arteries, which often requires treatment. Before clinical use of coronary devices, the
devices must be tested. Preclinical testing occurs first and involves in vitro laboratory
studies and in vivo animal studies. Most in vitro studies do not predict complex biologic
responses to three-dimensional coronary devices, and in vivo animal studies are
expensive and time-consuming and may show tissue responses that are quite different
from human tissue responses. Therefore, tissue engineered blood vessel mimics (BVMs)
were recently developed as cost-effective in vitro living models of human blood vessels
that can evaluate a human tissue response to three-dimensional coronary devices. BVMs
have been developed in only straight geometries, but the FDA has recommended that
coronary devices be preclinically tested in complex-shaped simulated vessels when the
complex geometries of coronary arteries may negatively affect coronary device
performance. Complex geometries of coronary arteries may negatively affect the tissue
response to coronary stents, therefore BVMs should be developed in complex geometries.
The rest of this introduction establishes in more detail the reasons that BVMs
should be developed in complex geometries. Specifically, this introduction will describe
the reasons that the complex geometries of coronary arteries are prone to plaque
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formation, the types of coronary devices that have been used to identify and treat CHD,
the preclinical testing methods that have been used to evaluate coronary devices, the FDA
recommendations for coronary device testing, the types of synthetic models and animal
models that have been used for coronary device testing, the need for BVMs, and the
particular need for BVMs in complex geometries.

1.2. Coronary Heart Disease
Coronary heart disease (CHD) is the leading cause of death in the United States,
and an American dies of CHD almost every minute [1]. 17.6 million Americans currently
live with CHD, and costs associated with CHD totaled $177.1 billion in 2010 [1]. CHD
occurs when plaque occludes coronary arteries. Coronary arteries are the blood vessels on
the surface of the heart that deliver oxygen- and nutrient-rich blood to the myocardium,
which is the cardiac tissue responsible for heart contractions. The occlusion of arteries by
plaque is known as atherosclerosis, and atherosclerotic coronary arteries restrict blood
flow to the myocardium, starving the myocardium of essential amounts of oxygen and
nutrients. This condition impairs the heart’s ability to effectively pump blood throughout
the body, which causes peripheral tissues to receive insufficient amounts of oxygen and
nutrients, resulting in death of those peripheral tissues. Restricted coronary blood flow
also causes shortness of breath, myocardial infarction, and death [2]. Because CHD
affects such a large population, researchers devote significant attention to developing
treatments for CHD.
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1.3. Anatomy of Coronary Arteries
When developing treatments for CHD, researchers take into account the complex
geometries of coronary arteries (Figure 1.1). The geometries of coronary arteries are
considered complex because of bends and bifurcations; a bifurcation is defined as the
branching of a main vessel into two smaller vessels [3]. The American College of
Cardiology (ACC) and the American Heart Association (AHA) categorize coronary
arteries based on the severity of their bends: a “non-angulated” coronary artery bends less
than 45 degrees, a “moderately angulated” coronary artery bends 45 degrees to 90
degrees, and an “extremely angulated” coronary artery bends more than 90 degrees [3].
Because coronary arteries are located on the surface of a beating heart, they oscillate
between systolic geometries and diastolic geometries: coronary bends become more
severe during systole and less severe during diastole [4].
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A

B

Figure 1.1. Anatomy of human coronary arteries. (A) Left and right coronary arteries
branch off the aorta from openings known as coronary ostia. The main stem of the left
coronary artery bifurcates into the anterior interventricular artery and the circumflex
artery. (B) The right coronary artery gives rise to various branch arteries, including the
artery supplying the sinus node, the acute marginal artery, the inferior interventricular
artery, and the artery supplying the atrioventricular node. Anatomic variations in
coronary arteries between humans do exist but are rare. [5]
Reprinted from [5] with permission. See Appendix P.

1.4. Blood Flow in Coronary Arteries
Blood flow through the complex geometries of coronary arteries has different
characteristics than blood flow through straight arteries. In straight arteries, blood
velocity is highest in the center of the artery [6]. In bent coronary arteries, blood velocity
is highest near the outer wall of the bend (Figure 1.2 A) [6], and in the branch vessels
after a coronary bifurcation, blood velocity is highest near the medial walls (Figure 1.2 B)
[6]. Also, blood flow characteristics change as the heart beats: blood flows distally
4

through the coronary arteries during diastole as depicted in Figure 1.2 [6], but during
systole, blood momentarily flows proximally, opposite the depiction in Figure 1.2 [7].
High pressures during systole cause blood flow to reverse direction in coronary arteries
[7].

Medial Walls
Bifurcation
Lateral Wall

A

B

Figure 1.2. Schematics of complex-shaped coronary arteries. Blood flows distally (from
left to right). The multiple small gray curves in A are velocity profiles. In bent coronary
arteries, flow velocity is highest near the outer wall of the bend, so velocity curves are
skewed toward the outer wall (A). Branch vessels after a bifurcation have medial walls as
identified in B; flow velocity is highest near the medial walls in branch vessels after a
bifurcation, so velocity curves would be skewed toward the medial walls. [6, 8]

Figure 1.2 A reprinted from [8] with permission. See Appendix P.

1.5. Shear Stress and Atherosclerosis in Coronary Arteries
The unique blood flow that occurs in complex-shaped coronary arteries creates
unique shear stress distributions on the coronary walls. In bent coronary arteries, blood
flows faster near the outer wall of the bend and slower near the inner wall of the bend;
these blood flow characteristics create low shear stress on the inner walls of bent
5

coronary arteries [6]. In the branch vessels after a bifurcation, blood flows faster near the
medial walls and slower near the lateral walls; these blood flow characteristics create low
shear stress on the lateral walls of branch vessels after a bifurcation [6]. Also, blood flow
that changes direction as the heart cycles through diastole and systole is called oscillatory
blood flow and creates oscillatory shear stress on coronary walls [9].
Low and oscillatory shear stresses are associated with atherosclerosis [9, 10]. A
low endothelial shear stress environment is the initiating process of atherosclerosis in an
atherosclerosis-prone host and typically occurs on the inner walls of curved arteries [9].
Oscillatory shear stress is associated with early and continued atherosclerosis and
typically occurs on the lateral walls of branch vessels after a bifurcation [9, 10]. While
normal shear stress magnitudes are more than 15 dynes/cm2 [11], low shear stress
magnitudes are less than 10–12 dynes/cm2 [9].
Endothelial cells line the lumen of coronary arteries, and low shear stress as a
result of the unique blood flow that occurs in complex-shaped coronary arteries directly
affects endothelial cells [12]. Endothelial cells exposed to low shear stress acquire an
atherogenic phenotype and encourage formation of early atherosclerotic plaques by
promoting lipid accumulation [9]. Eventually lipids accumulate in the inner lining of
arteries—the intima—and form large lipid pools that cause cell necrosis [13]. Fibrous
tissue then encapsulates the lipids and necrotic cells, and the encapsulation is known as
an early fibroatheroma, the initial plaque that can develop into more lethal plaques [13].
The kind of plaque that will develop from an early fibroatheroma depends on local
factors (e.g. the magnitude of shear stress on endothelial cells), systemic factors, and
genetic factors. There are three kinds of plaques that can develop from an early
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fibroatheroma: quiescent plaques, stenotic plaques, and thin-cap fibroatheromas (TCFAs)
(Figure 1.3) [9]. Quiescent plaques cause no symptoms in patients, stenotic plaques
restrict blood flow, and TCFAs may rupture and cause thrombosis [9, 13].

Figure 1.3. Plaque development in bent coronary arteries. The inner wall of bent
coronary arteries experiences low endothelial shear stress (ESS), causing formation of
early fibroatheromas. Arteries may then undergo compensatory expansive remodeling
that causes quiescent plaque formation, constrictive remodeling that causes stenotic
plaque formation, or excessive expansive remodeling that causes TCFA formation. [9]
Reprinted from [9] with permission. See Appendix P.

Plaques categorized as stenotic plaques and as TCFAs that ruptured and caused
thrombosis are alike in that they can eventually occlude coronary arteries, which prevents
healthy blood flow to the myocardium and leads to CHD. Because approximately 40% of
early fibroatheromas develop into stenotic plaques and TCFAs [9], and because both
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plaques can eventually cause coronary occlusion, researchers aiming to identify and treat
CHD develop devices specifically for identifying and treating coronary occlusions.

1.6. Devices for Identifying and Treating Coronary Heart Disease
Patients must first receive a diagnosis of CHD before potential treatment for it can
begin. When diagnosing patients, physicians use various imaging technologies that help
visualize narrowed coronary arteries and plaque formations. After compromised coronary
arteries are identified, various treatments may be used to treat coronary occlusions.

1.6.1. Identifying Coronary Heart Disease
Angiography is the standard imaging technique used to identify obstructed
coronary arteries [14]. Angiography involves the insertion of a diagnostic catheter into
the coronary ostia—the openings of the coronary arteries on the aorta—followed by
injection of a radiopaque dye into the coronary arteries, followed by acquisition of an xray image known as an angiogram (Figure 1.4) [15].
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Figure 1.4. Angiogram of coronary arteries. Coronary lumens appear as dark lines, and
the black arrow points to a site of total occlusion in a left circumflex coronary artery. [16]
Reprinted from [16] with permission. See Appendix P.

Although angiography is the standard imaging technique used to identify
obstructed coronary arteries, intravascular ultrasound (IVUS) has the advantage of
revealing more details about the severity and extent of atherosclerosis [17]. IVUS
systems generate intravascular images and consist of a catheter, a miniature transducer on
the catheter, and a console that processes electrical signals and displays the intravascular
images [17]. To obtain an intravascular image of a coronary artery, an IVUS catheter is
inserted into the lumen of the coronary artery and pushed through the lumen until the
catheter tip reaches regions that require assessment. Ultrasound waves are then reflected
off the walls of the artery, and the reflected waves are converted to electrical signals and
processed to generate an image.
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Angiography, IVUS, and other imaging technologies each have advantages when
used individually to visualize compromised coronary arteries, but researchers are
currently combining imaging technologies to create hybrid imaging systems. Such hybrid
systems combine the advantages of individual imaging technologies to generate
extremely useful information. For example, a system that combines IVUS and near
infrared spectroscopy (NIRS) allows specific plaque characteristics in coronary arteries to
be identified, which may allow researchers to study changes in those specific plaque
characteristics in response to new treatments [17]. Researchers then may be able to better
understand the exact effects of the new treatments and then adjust the new treatments to
work more effectively.

1.6.2. Angioplasty
After a physician identifies blockages in a patient’s coronary arteries, the patient
typically receives some sort of intervention that treats the blockages and restores blood
flow through the blockage site. An established treatment for coronary blockages is
percutaneous transluminal coronary angioplasty (PTCA) [18]. PTCA is a minimally
invasive procedure that involves compression of plaque against the coronary walls. The
following steps are carried out during a PTCA procedure in the clinic: injection of local
anesthesia into the groin area; placement of a needle into the femoral artery; placement of
a guide wire through the needle into the femoral artery; movement of the guide wire
proximally through the femoral artery and eventually to the aorta; placement of a
diagnostic catheter over the guide wire and movement of the diagnostic catheter to the
aorta; removal of the guide wire; placement of the diagnostic catheter into an ostium on

10

the aorta; injection of contrast media into the coronary arteries; acquisition of an
angiogram; identification of a treatable blockage in the angiogram; placement of a guide
wire through the blockage site in the coronary arteries; placement, inflation, deflation,
and removal of a balloon at the blockage site (Figure 1.5); use of the balloon at other
blockage sites in the coronary arteries; injection of contrast media and acquisition of an
angiogram to check for improvements in luminal diameters; and removal of the catheter
[15].

Figure 1.5. Placement, inflation, deflation, and removal of a balloon during PTCA. A
guide wire is placed across the blockage site in a coronary artery, then a balloon catheter
is placed at the blockage site (B). A balloon is inflated (C) to widen the lumen and then
deflated. The balloon is repeatedly inflated and deflated with increasing amounts of
pressure during inflation to further widen the lumen and is then removed, leaving behind
a widened coronary artery (D). [19]
Reprinted from [19] with permission. See Appendix P.

11

Although PTCA is an established treatment for coronary occlusions, there is a
notable drawback to PTCA: restenosis [20]. Restenosis is the re-narrowing of a blood
vessel after treatment. Restenosis after PTCA can occur as a result of early elastic recoil,
thrombus formation, neointimal formation, and vascular remodeling [21-23]. Early elastic
recoil occurs when a blood vessel that was widened via PTCA recoils within minutes to
hours after the procedure [24, 25]. Thrombus formation occurs when blood clots at the
treatment site [26]; this event is also known as thrombosis. Neointimal formation occurs
after traumatic balloon injury and involves the migration of proliferating vascular smooth
muscle cells to the intima to form new tissue [27]. Vascular remodeling occurs when the
structure of a blood vessel is altered as a result of changes in cell growth, cell death, cell
migration, and production or degradation of extracellular matrix [28]. To eliminate
restenosis after PTCA, researchers are currently developing new PTCA technology.
One technology currently under development is balloons that deliver drugs to the
walls of coronary arteries to reduce neointimal formation, thereby reducing restenosis.
When designing such balloons, researchers must choose drugs that best reduce neointimal
formation. Some new balloons deliver paclitaxel, which inhibits smooth muscle cell
proliferation and migration [29]. In addition to choosing the best drugs, researchers must
also choose design features that deliver adequate quantities of drugs, minimize injury to
the coronary wall, do not limit blood flow through the treated segment of blood vessel,
and administer drugs for sufficient time to cause a therapeutic effect [18]. An example of
a drug-delivering balloon is found on the GENIETM balloon catheter: the balloon has
proximal and distal occlusive segments to restrict drug delivery to the space between the
occlusive segments, and liquid paclitaxel jets out of the balloon onto the coronary walls
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[18]. Another example of a drug-delivering balloon is found on the Sequent® Please
balloon catheter: the balloon is homogenously coated with paclitaxel that is embedded in
contrast medium; when the balloon is inflated, the contrast medium releases the
paclitaxel into the surrounding coronary artery [18]. More research is being conducted to
further identify the best features for drug-delivering balloons that treat restenosis.

1.6.3. Stents
Another technology for treating coronary occlusions is stents [30]. Stents are
latticed tubes that can be crimped onto catheters, placed into the body in a minimally
invasive way, and then expanded once inside an occluded region of a blood vessel to prop
open the occluded region. Most commercially available coronary stent systems feature
balloon-expandable stents [21], but stents are also made in self-expanding versions.
Balloon-expandable stents can be deployed either after PTCA or simply without PTCA,
whereas self-expanding stents are designed for deployment after PTCA [21, 31]. The
following steps may be carried out during a stenting procedure in the clinic: the PTCA
procedure described previously; placement of a balloon catheter with a crimped stent into
the blockage site; deployment of the stent at the blockage site (Figure 1.6); deployment of
stents at other blockage sites throughout the coronary arteries; and injection of contrast
media and acquisition of an angiogram to check for improvements in luminal diameters
[15]. Stenting is currently the principal method of percutaneous coronary
revascularization for patients with CHD [32].
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Figure 1.6. Deployment of a balloon-expandable stent in a coronary artery. A balloon
catheter with a closed stent is inserted into the blockage site (B), the balloon is inflated to
deploy the stent (C), and the balloon is deflated and removed along with the catheter and
guide wire, leaving behind the implanted stent, the compressed plaque, and the widened
coronary artery (D). The stent lattice is made up of segments known as stent struts. [15]
Reprinted from [15] with permission. See Appendix P.

Although stenting is currently a principal treatment for CHD, there are notable
drawbacks to stenting. The first stents developed were bare metal stents (BMSs) and were
intended to reduce the restenosis that occurs after PTCA. BMSs prevent elastic recoil of
blood vessels and limit negative remodeling of blood vessels [21, 33], but BMSs do not
prevent neointimal formation. Blood vessels treated with BMSs may still experience
neointimal formation, and neointimal formation in the stented region of a blood vessel
causes in-stent restenosis [33]. To ameliorate in-stent restenosis, drug-eluting stents
(DESs) were developed. DESs are metal latticed tubes coated with an agent that prevents
cell proliferation. Because the proliferation of vascular smooth muscle cells in the intima
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causes neointimal formation, blood vessels treated with DESs experience reduced
neointimal formation [18]. But blood vessels treated with DESs may also experience
thrombosis. Therefore, although BMSs and DESs both improve upon previous
technology, they also both have disadvantages. Because of these disadvantages,
researchers continue improving stent technology.
New stent technology currently under development is the dual drug-eluting stent
(DDES). Since blood vessels treated with DESs may experience thrombosis, DDESs
were developed as an improved version of DESs: like DESs, DDESs contain an agent
that prevents cell proliferation, but unlike DESs, DDESs also contain an agent that
prevents thrombosis [34]. Studies on DDESs are promising: one study showed that a
DDES containing sirolimus for treating restenosis and triflusal for treating thrombosis
significantly reduced restenosis compared to BMSs and DESs when implanted in a pig
for 30 days, and the reduction in restenosis was associated with an inhibition of
inflammation and thrombus formation [34]; another study showed that a DDES
containing sirolimus and probucol required less revascularization compared to DESs
when implanted in humans for two years [35]. Therefore, DDESs may be an
improvement over previous stent technology.
Another improvement over previous stent technology may be the bioabsorbable
stent. Bioabsorbable stents prop open occluded blood vessels for a defined period of time,
ideally completely dissolve after the defined period of time, and ideally leave behind a
fully healed natural blood vessel [18]. An advantage of bioabsorbable stents is the
restoration of natural vascular remodeling after stent dissolution: after deployment of
BMSs, DESs, and DDESs, vascular remodeling freezes in the stented region of the blood
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vessel, but after deployment and dissolution of a bioabsorbable stent, natural vascular
remodeling may be restored [36]. Another advantage of bioabsorbable stents is the
minimization of late stent thrombosis: after deployment of DESs, late stent thrombosis
can occur, but after deployment of a bioabsorbable stent, the bioabsorbable stent may
dissolve before late stent thrombosis occurs and may therefore avoid late stent thrombosis
altogether [18]. Studies on bioabsorbable stents are promising: one study showed
complete dissolution of a bioabsorbable stent deployed in human coronary arteries for
two years [37]. Because bioabsorbable devices are currently considered a revolutionary
technology in the field of interventional cardiology [38], researchers continue improving
bioabsorbable stents.

1.7. Coronary Device Testing
There are a number of coronary devices currently under development for the
identification and treatment of CHD, including hybrid intravascular imaging systems,
drug-delivering balloons, DDESs, and bioabsorbable stents. But the Food and Drug
Administration (FDA) requires that these coronary devices be tested before they are
marketed in the United States. The FDA approves a coronary device for market only after
technical data from non-clinical and clinical studies show that the coronary device is safe
and effective. Non-clinical studies, also known as preclinical studies, refer to in vitro
laboratory studies and in vivo animal studies, and clinical studies refer to in vivo human
studies. To help researchers carry out coronary device studies that are well designed in
the eyes of the FDA, the FDA publishes recommendations for the design of coronary
device studies [39]. FDA recommendations emphasize that in various cases coronary
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devices should be preclinically tested specifically under the conditions that exist in
complex-shaped vessels.

1.7.1. FDA Recommendations for In Vitro Studies
FDA recommendations for various in vitro engineering studies emphasize that
coronary devices should be tested in complex-shaped simulated vessels [39, 40]. For
some in vitro studies, the FDA recommends that a coronary stent intended for
deployment in a coronary bend be tested in a simulated vessel that is bent to a worst-case
clinically relevant radius of curvature; the FDA usually recommends a 15-millimeter
radius of curvature because this represents the worst-case radius of curvature in 90% of
patients [40]. For other in vitro studies, the FDA recommends that a coronary stent
intended for deployment in a coronary bifurcation be tested in a simulated vessel that has
a geometry based on relevant clinical situations [40]. For other in vitro studies, the FDA
recommends that coronary delivery catheters be tested in simulated vessels that are
tortuous, and the specific degree of tortuosity is shown in Figure X2.4 of ASTM F2394
[40].

1.7.2. Synthetic Models of Coronary Vasculature
Researchers seeking FDA approval of their coronary devices test their devices in
complex-shaped simulated vessels. Complex-shaped simulated vessels range from simple
tubes that can be bent into desired geometries to physiologically accurate replications of
coronary vasculature [41-43]. One example of a complex-shaped simulated vessel is
found on the Interventional Device Testing Equipment 2000 (IDTE2000) made by
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Machine Solutions, Inc.; the IDTE2000 features simple tubing that can be bent to model
complex geometries of coronary arteries (Figure 1.7 A and B) [41]. Another example of a
complex-shaped simulated vessel is the Angio-Suite Training Model produced by United
Biologics, Inc.; the Angio-Suite Training model is a physiologically accurate replication
of many arteries in the human body, including major coronary arteries (Figure 1.8) [43].
The simple tubing of the IDTE2000, the physiologically accurate Angio-Suite Training
Model, and other complex-shaped simulated vessels may be used to assess various
aspects of coronary devices.

B

A

Figure 1.7. A complex-shaped simulated vessel. The IDTE2000 by Machine Solutions,
Inc. (A) features simple tubing that can be bent into complex geometries (B). [41]
Reprinted from [41] with permission. See Appendix P.
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Figure 1.8. A physiologically accurate complex-shaped simulated vessel. The AngioSuite Training Model by United Biologics, Inc. includes silicone coronary arteries. [43]
Reprinted from [43] with permission. See Appendix P.

Aspects of coronary devices that may be assessed in complex-shaped simulated
vessels include the following: the ability of a coronary stent to conform to a complexshaped vessel after the stent is deployed, also known as flexibility [44]; the ability of a
coronary stent and delivery system to bend when negotiating a complex-shaped vessel,
also known as flexibility [44]; the uniformity of a stent after deployment [44]; the ability
of a balloon to be deflated and withdrawn from a deployed stent, also known as balloon
deflatability [44]; the force needed to move a coronary device through a tortuous path,
also known as track force [41]; the ability of a catheter tip to track over a bent guidewire,
also known as trackability [44]; the force needed to withdraw a coronary device from a
tortuous path, also known as retractability force [41]; the coating integrity of a coronary
DES after deployment of the DES in a complex-shaped vessel [39]; the formation of
particulate matter during tracking and deployment of a coronary DES in a complex-
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shaped vessel [39]; and image distortion that may occur when intravascular imaging
devices negotiate bent vessels [45].
Although these complex-shaped simulated vessels provide researchers with
valuable information about coronary device performance, these bench testing systems do
not predict biologic responses that may occur when using coronary devices in human
patients. One way to predict some biologic responses is to expose coronary devices or
parts of devices to biologic samples in a laboratory. But most in vitro laboratory tests
cannot predict complex biologic responses such as the human tissue response to a threedimensional coronary stent.

1.7.3. In Vivo Animal Models
After coronary devices undergo and “pass” in vitro tests in complex-shaped
simulated vessels and in vitro tests involving exposure to biologic samples, in vivo
animal testing is used to predict complex biologic responses that may occur when using
coronary devices in human patients. Various animals may be used to model complex
biologic responses. Rats have carotid arteries and an abdominal aorta that may be used to
assess thrombus formation and neointimal responses after stent implantation [46, 47];
also, rats may be useful for assessing proliferative responses [48]. Rabbits have iliac
arteries that may be used to assess the mechanisms of repair after injury to an abnormal
artery [48]. Porcine models have a coronary artery system that is similar in size and
structure to humans and that can be used to assess events after stent implantation such as
injury, neointimal development, and thrombosis [49, 50]. Porcine models are currently
the closest to humans [48].
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An ideal animal model would perfectly predict the following human tissue
responses. First, during coronary stent deployment, the stent immediately contacts the
endothelium and removes endothelial cells from the vessel wall, exposing smooth muscle
cells beneath the endothelium [51, 52]; this event is known as endothelial denudation.
Immediately after stent deployment, the stent is susceptible to thrombosis for an acute
period. Acute inflammation then occurs, and inflammatory cells reach the stented site.
Migration and proliferation of vascular smooth muscle cells begin [53], and vascular
smooth muscle cells synthesize extracellular matrix proteins and eventually cause
neointimal formation. Finally, vascular remodeling occurs, and endothelial cells grow
over the entire inner surface of the stented region of blood vessel [51]. This endothelial
cell growth is known as re-endothelialization and is key to successful healing after stent
implantation. A confluent monolayer of endothelial cells modulates local hemostasis and
thrombolysis, protects vascular smooth muscle cells from circulating growth-promoting
factors, synthesizes growth factors that are important in vascular smooth muscle cell
proliferation, and plays a role in the quiescence of smooth muscle cells [52]. Although
researchers use animal models to predict these human tissue responses, animal tissue
responses can vary from human tissue responses (Figure 1.9 A and C) [51, 54].
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Figure 1.9. Re-endothelialization of a stent in a rabbit iliac artery. On the day of stent
implantation, blood cells but not endothelial cells are visible on the stent (A). 28 days
after stenting, a confluent monolayer of endothelial cells has formed, and reendothelialization of the stent is complete (C). In human coronary arteries, complete reendothelialization of coronary stents has been observed 96 days after stenting. [51, 54]
Reprinted from [54] with permission. See Appendix P.

Although animal models are widely used to assess complex biologic responses to
coronary devices, there are notable drawbacks. Sometimes the tissue response of all
available animal models can be quite different from the human tissue response [48, 55,
56]. Also, studies involving animal models are expensive and time-consuming. There are
currently many coronary devices under development that require testing—hybrid
intravascular imaging systems, drug-delivering balloons, DDESs, and bioabsorbable
stents are just a few examples described previously—and possibly many prototypes of
these coronary devices will first be developed, each prototype requiring animal testing to
ensure that the best prototype is selected. But it is not feasible to test all coronary device
prototypes in animals because of the expense and time consumption of animal testing,
therefore some prototypes with outstanding in vivo performance may be overlooked. To
improve in vivo animal testing, these drawbacks should be ameliorated.
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1.7.4. Blood Vessel Mimics
There are a number of drawbacks to all the preclinical testing systems described
so far. Bench tests involving complex-shaped simulated vessels do not predict biologic
responses that may occur when using coronary devices in human patients. Most in vitro
tests involving exposure of coronary devices or parts of devices to biologic samples do
not predict some complex biologic responses such as the human tissue response to a
three-dimensional coronary stent. Animal models may exhibit tissue responses that are
quite different from human tissue responses, and studies involving animal models are
expensive and time-consuming. These drawbacks prevent the best possible preclinical
assessments of coronary devices, therefore researchers aim to develop preclinical testing
systems that ameliorate these drawbacks.
A preclinical testing system was recently developed that ameliorates some of the
previously described drawbacks: the blood vessel mimic (BVM). A BVM is a tissue
engineered blood vessel, consisting of a tubular scaffold that has human endothelial cells
lining the inner surface. Up until now, BVMs have been developed in straight geometries.
BVMs have been used to specifically test the re-endothelialization of stents: stents have
been deployed in BVMs, cells from the BVMs have re-endothelialized the stents, and
BVMs have identified stents that exhibit better re-endothelialization than other stents.
Unlike the in vitro testing methods described previously, BVMs feature the ability to
evaluate re-endothelialization of a three-dimensional stent. Unlike the in vivo animal
models described previously, BVMs feature a human tissue response, cost-effectiveness,
and high-throughput screening. [57-59]
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1.8. Complex-Shaped Blood Vessel Mimics
Although BVMs do ameliorate some of the previously described drawbacks to
preclinical testing systems, these mimics could still be modified to better align with
specific FDA recommendations. As described, the FDA has recommended that in various
cases coronary devices be preclinically tested in simulated vessels that mimic the
complex geometries of coronary arteries [40]. The FDA has made this recommendation
when the complex geometries of coronary arteries create conditions that can negatively
affect coronary device performance. If the complex geometries of coronary arteries
negatively affect re-endothelialization of coronary stents, the FDA may recommend that
BVMs be developed in complex geometries to more accurately assess the unique reendothelialization that occurs.
The complex geometries of coronary arteries may in fact negatively affect reendothelialization of coronary stents. When a coronary stent is deployed in a coronary
bend, the stent may be more rigid than the artery and straighten out the bend [60]. This
straightening skews the blood velocity profile at the bend and creates regions of
decreased endothelial shear stress [61, 62]. In regions of low shear stress, the
endothelium re-establishes itself more slowly [63]. If there are large regions where the
endothelium has not re-established itself, these large areas of endothelial denudation are
associated with intimal thickening [64]. Intimal thickening is the cause of in-stent
restenosis, and coronary arteries that have been straightened with stents are associated
with in-stent restenosis and major adverse clinical events [60]. Also, when a coronary
stent is deployed in a coronary bifurcation, stent struts may remain suspended over the
ostia of branch vessels, not contacting any part of the vessel wall. Stent struts suspended
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over coronary ostia have been shown to not re-endothelialize (Figure 1.10), and stents
deployed in coronary bifurcations have been associated with late stent thrombosis [65].
Therefore, bent and bifurcated coronary geometries may negatively affect reendothelialization of coronary stents and may lead to adverse events after stent
implantation.

Figure 1.10. Re-endothelialization of a stent in a coronary bifurcation. Coronary stents
were implanted in porcine coronary bifurcations. Some stent struts that were suspended
over coronary ostia exhibited no re-endothelialization 7 days after implantation. [65]
Reprinted from [65] with permission. See Appendix P.

Because the complex geometries of coronary arteries may in fact negatively affect
re-endothelialization of coronary stents, the currently straight BVMs should be
redeveloped in complex geometries for coronary stent testing. Complex-shaped BVMs
may more accurately assess the re-endothelialization of coronary stents and may better
align with FDA recommendations.
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1.9. Summary and Aims of This Thesis
Due to the prevalence of coronary heart disease, many new coronary devices are
being developed. The FDA requires that these coronary devices be tested before they are
marketed in the United States, and preclinical tests are carried out first. It is advantageous
to have preclinical testing methods that are high-throughput and cost-effective, that assess
human tissue responses to three-dimensional coronary devices, and that take into account
other conditions such as coronary geometry. Current BVMs have many of these
characteristics but do not mimic the complex geometries of coronary arteries. Therefore,
complex-shaped BVMs should be developed for coronary stent testing.
There are multiple potential challenges that could hinder development of a
complex-shaped BVM. First, complex-shaped scaffolds and bioreactors that can house
complex-shaped scaffolds have not been fully developed. Second, the technique currently
used to deposit cells onto a straight scaffold may result in no cell deposition in certain
regions of complex-shaped scaffolds. Third, when fluid is flowing through scaffolds, an
extremely angulated scaffold exhibits more than 7 times the wall shear stress of a straight
scaffold [66]; higher wall shear stress in a complex-shaped scaffold may reduce cell
retention on the scaffold, possibly hindering formation of any confluent cell lining
throughout the scaffold. Fourth, some current straight BVMs have been developed using
human umbilical vein endothelial cells (HUVECs), which are known to only grow in
monolayers [67], and coronary stents have been shown to completely denude the
endothelium—which is a monolayer—in human coronary arteries [51, 68]; therefore,
stent deployment may completely denude a monolayer of HUVECs in a complex-shaped
BVM. If a complex-shaped BVM that was developed using only HUVECs exhibits
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denudation after stent deployment, it may be advantageous instead to use cell types that
are known to form multiple cell layers so that the cells could eventually be cultivated into
a multilayer that would withstand stent deployment better than a monolayer. Research in
the following chapters addresses all these potential challenges.
The goal of this thesis research was to develop a complex-shaped BVM for
coronary stent testing. To achieve this goal, the following overall hypothesis was
established: a BVM could be developed in the complex geometries of coronary arteries.
This hypothesis was tested by conducting research with the following five specific aims.

1. Design, construct, and validate complex-shaped scaffolds and bioreactors.
a. Hypothesis: complex-shaped scaffolds could be designed and constructed,
bioreactors capable of housing the new scaffolds could be designed and
constructed, and cells would deposit onto the new scaffolds inside the new
bioreactors.
2. Deposit cells throughout the entire inner surface of complex-shaped scaffolds.
a. Hypothesis: after 1 day of cultivation of complex-shaped BVMs, no statistically
significant differences would exist between the cell densities along the length of
the BVMs, between the cell densities in the inner and outer halves of the BVMs,
or between the cell densities in the top and bottom halves of the BVMs.
3. Determine whether HUVECs can reach confluence on a complex-shaped scaffold
using a cultivation protocol similar to the straight-BVM cultivation protocol.
a. Hypothesis: after deposition of HUVECs onto U-shaped scaffolds and cultivation
similar to the straight-BVM protocol, cells would reach confluence.
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4. Determine whether a complex-shaped BVM that was developed using only HUVECs
would exhibit denudation of its cell lining after coronary stent deployment.
a. Hypothesis: a complex-shaped BVM that was developed using only HUVECs
would exhibit no cell lining after coronary stent deployment.
5. Develop a confluent region of cells in a U-shaped BVM.
a. Hypothesis: a confluent region of cells would form in a U-shaped BVM. If
research addressing the fourth specific aim showed that a complex-shaped BVM
that was developed using HUVECs may exhibit denudation of its cell lining after
coronary stent deployment, the confluent region of cells had to be developed
using a cell type known to form multiple cell layers so that the cells could
eventually be cultivated into a multilayer that could withstand stent deployment
better than a HUVEC monolayer.

Experiments were conducted to test all these hypotheses, and findings from these
experiments are described in the following chapters. Chapter 2 describes the design,
construction, and validation of complex-shaped scaffolds and bioreactors that can house
complex-shaped scaffolds. Chapter 3 describes the consistency of cell deposition
throughout various regions of complex-shaped scaffolds. Chapter 4 describes the effect of
flow rate on cell confluence in complex-shaped BVMs. Chapter 5 describes stent
deployment in a complex-shaped BVM. Chapter 6 describes the development of a
confluent region of cells on an extremely angulated scaffold. And chapter 7 concludes
this research with a summary and discussion.
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2. Development of Complex-Shaped Scaffolds and Bioreactors

2.1. Introduction
This chapter addresses the first specific aim of this thesis: design, construct, and
validate complex-shaped scaffolds and bioreactors that can house complex-shaped
scaffolds.
Complex-shaped BVMs will require new scaffolds and new bioreactors. A
bioreactor is a device that allows conditions to be closely controlled to induce specific
behavior in the cells or tissues being cultivated [69, 70]. A BVM is created by first
inserting a scaffold into a bioreactor, then depositing human endothelial cells onto the
scaffold, and then cultivating the cell-lined scaffold in the bioreactor (Figures 2.1 and
2.2). Current BVMs have been developed using only straight scaffolds, and the bioreactor
currently used to cultivate BVMs is capable of housing only these straight scaffolds [71].
Complex-shaped scaffolds and bioreactors that can house complex-shaped scaffolds have
not been fully developed. Therefore, they must be fully designed, constructed, and
validated. The hypothesis in this chapter was that complex-shaped scaffolds could be
designed and constructed, that bioreactors capable of housing the new scaffolds could be
designed and constructed, and that cells would deposit onto the new scaffolds inside the
new bioreactors.
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Figure 2.1. Current BVM bioreactor housing a straight scaffold. The bioreactor is made
entirely of off-the-shelf components. Not pictured here is a snap-on sealable lid for the
container. Not visible here are the O-rings placed on the external tip of the female luer
lug panel mounts and lock nuts that secure the external O-rings in place.
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Figure 2.2. Current straight scaffold and pressure-sodding method. (A) The scaffold for
BVMs is made of expanded polytetrafluoroethylene (ePTFE), a porous synthetic
polymer. The scaffold has a blue double stripe across the top and is sutured to two
fittings. The inner diameter (ID) of human coronary arteries may range between 1.9 and
4.5 mm [72], so the scaffold has an ID of 4 mm. Cells are deposited onto the scaffold
using a method known as pressure-sodding: cells are first suspended in media, and the
cell suspension is then placed in a syringe; the luminal outlet of the bioreactor (B,
Luminal Outlet) is then closed, the syringe is attached to the luminal inlet (B, Luminal
Inlet), the cell suspension is pushed into the scaffold lumen, the entire cell suspension
except the cells is forced out the scaffold pores, and the cells remain lodged in the
scaffold pores.
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2.2. Background Information: Previous Designs
Previous designs were proposed for complex-shaped scaffolds and bioreactors.
Because the ePTFE scaffold currently used to develop straight BVMs is flexible,
previous designs proposed that straight ePTFE scaffolds simply be bent into coronary
geometries. To mimic the specific coronary bends defined by the American College of
Cardiology and the American Heart Association, previous designs proposed three
geometries for bent scaffolds: a scaffold bent less than 45 degrees, a scaffold bent 90
degrees, and a scaffold bent 180 degrees [71]. Some coronary bifurcations observed in
clinical practice are T-shaped [73], and previous designs proposed that two straight
ePTFE scaffolds be sutured together in a T-shape to mimic a T-shaped coronary
bifurcation (Figure 2.3 A). Other coronary bifurcations observed in clinical practice are
Y-shaped [73], and previous designs proposed that three straight ePTFE scaffolds be
sutured together in a Y-shape to mimic a Y-shaped coronary bifurcation (Figure 2.3 B).
Also, previous designs proposed that 5 bioreactors be developed, each tailored to house 1
of the 5 proposed scaffold geometries (Figure 2.4).

A

B

Figure 2.3. Construction methods for a T-shaped scaffold (A) and a Y-shaped scaffold
(B) that were proposed in previous designs. [71]
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D
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E

C
Figure 2.4. Previously proposed designs for bioreactors that can house complex-shaped
scaffolds. Each bioreactor is tailored to house a specific scaffold geometry. A bioreactor
was designed to house a scaffold bent less than 45 degrees, which will now be referred to
as an S-shaped scaffold (A), another bioreactor was designed to house a scaffold bent 90
degrees, which will now be referred to as an L-shaped scaffold (B), another bioreactor
was designed to house a scaffold bent 180 degrees, which will now be referred to as a Ushaped scaffold (C), another bioreactor was designed to house a T-shaped scaffold (D),
and another bioreactor was designed to house a Y-shaped scaffold (E). [71]
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2.3. Materials and Methods
To create new scaffolds and bioreactors, new designs were first established. Then
the scaffolds and bioreactors were constructed, human endothelial cells were deposited
onto the complex-shaped scaffolds, the cell-lined scaffolds were cultivated inside the new
bioreactors, and finally cell coverage of complex-shaped scaffolds was assessed to
determine whether cells deposited on the complex-shaped scaffolds.

2.3.1. Challenges with Previous Designs
There are challenges that could arise during construction and use of the proposed
Y-shaped scaffold. Construction of the proposed bifurcated scaffolds will involve
suturing by hand, and the suturing proposed in Figure 2.3 A and B could be tedious,
especially the suturing proposed for the Y-shaped scaffold, thereby increasing the
difficulty of scaffold construction. Therefore, a simpler scaffold construction method
should be developed at least for the Y-shaped scaffold. Also, the suture sites in bifurcated
scaffolds may be susceptible to unwanted leakage when fluid moves through the
scaffolds, and the Y-shaped scaffold may be more susceptible to leakage than the Tshaped scaffold because the Y-shaped scaffold has more sutures. Therefore, the number
of sutures at least in the Y-shaped scaffold should be reduced.
There are also challenges that could arise during construction and use of the
proposed bioreactors. Researchers may want to run multiple stent-testing trials in each of
the five proposed geometries. For example, trials in T-shaped BVMs could occur one
week, trials in U-shaped BVMs could occur another week, and trials in L-shaped BVMs
could occur another week. Researchers would have to construct, store, and maintain a
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separate set of bioreactors for each scaffold geometry, which could result in significant
bioreactor construction time, need for significant storage space for the many bioreactors,
and significant bioreactor maintenance time. Instead, if researchers had bioreactors that
were each capable of housing all five proposed scaffold geometries, researchers could
construct a smaller number of these multifunctional bioreactors and reuse the same
multifunctional bioreactors each week, which would reduce the number of bioreactors
that must be constructed, stored, and maintained, thereby reducing bioreactor
construction time, the need for storage space, and bioreactor maintenance time.
Therefore, a multifunctional bioreactor was developed.
Because of the challenges that could arise during construction and use of
particularly the Y-shaped scaffold proposed in previous designs and during construction
and use of the five bioreactors proposed in previous designs, a new design was created
for the Y-shaped scaffold, and a design was created for a multifunctional bioreactor.
Dimensions and materials were then specified for all designs, resulting in final designs
for complex-shaped scaffolds in all five geometries and final designs for bioreactors that
could house all five scaffold geometries.

2.3.2. Final Designs for Complex-Shaped Scaffolds
The new design for the Y-shaped scaffold is described as follows: two straight
ePTFE scaffolds were sutured together to form a T-shaped scaffold using the same
method as depicted in Figure 2.3 A, then each end of the crossbar of the “T” was bent
upwards so that the “T” became a “Y”, resulting in a Y-shaped scaffold with fewer
sutures than the Y-shaped scaffold proposed in previous designs. With a reduced number
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of sutures, this new design for a Y-shaped scaffold may make Y-shaped scaffold
construction less tedious and may reduce the chance of unwanted leakage. Because this
new design reduced the possible challenges that could occur with the previous design for
a Y-shaped scaffold, this new design became the final design for a Y-shaped scaffold.
The previous designs for the other four complex-shaped scaffolds became the final
designs for those scaffolds.
Dimensions of the complex-shaped scaffolds are listed as follows. The total
lengths of S-, L-, and U-shaped scaffolds were 7 cm, 5 cm, and 5.5 cm respectively. The
stem of the “T” on a T-shaped scaffold was 2.5 cm long, and the crossbar of the “T” was
6 cm long. Another T-shaped scaffold was bent into a Y-shape without changing any
dimensions to create a Y-shaped scaffold. All scaffolds had 4-mm IDs.

2.3.3. Final Designs for Bioreactors That Can House Complex-Shaped Scaffolds
A multifunctional bioreactor was designed (Figure 2.5). Because this
multifunctional bioreactor design eliminates the possible challenges that could occur with
the previous bioreactor designs, this design became a final bioreactor design. The
multifunctional bioreactor was designed without the ability to house Y-shaped scaffolds
because additional inlets, outlets, or tubing would crowd the bioreactor, making it
difficult to use; therefore, the previous design for a bioreactor capable of housing only a
Y-shaped scaffold also became a final bioreactor design (Figure 2.6). To be able to
develop BVMs in all five proposed geometries, two bioreactors were constructed: a
multifunctional bioreactor and a bioreactor capable of housing only a Y-shaped scaffold.
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Figure 2.5. Multifunctional Bioreactor. New positions for inlets and outlets and new
tubing arrangements and dimensions were designed (A–C); all inlets and outlets are the
same distance from the top of the container, the luminal outlet is horizontally centered on
its wall, and C represents both short sides of the container. The multifunctional bioreactor
houses one scaffold at a time, and any inlets or outlets not being used when a scaffold is
inserted will be capped off with luer plugs (D–G). Since the FDA has recommended that
vessels simulating a worst-case bend for coronary stent testing have a 15-mm radius of
curvature, any inserted U-shaped scaffold will have a 15-mm radius of curvature.
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Figure 2.6. Bioreactor capable of housing only a Y-shaped scaffold. The general
arrangement of inlets, outlets, and tubing for this bioreactor were established in previous
designs, but specific dimensions were not established. Therefore, the design was updated
to include tubing dimensions (A) and specific locations for all inlets and outlets: the
luminal outlets will be 3 cm apart, the luminal inlet is horizontally centered on its wall,
the extraluminal outlet is 3 cm horizontal from the centerline on its wall, and all inlets
and outlets are located the same distance away from the top of the container as depicted
in Figure 2.5 C. (B).
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2.3.4. Construction of Complex-Shaped Scaffolds
All scaffolds were made of tubular ePTFE with 4-mm IDs (Impra Bard, Inc.,
Tempe, AZ). Latex gloves were worn when handling the ePTFE. All bent scaffolds were
constructed by simply bending straight pieces of ePTFE into complex shapes: a straight
ePTFE scaffold that was 7 cm in length was bent into an S-shape, creating an S-shaped
scaffold; a straight ePTFE scaffold that was 5 cm in length was bent into an L-shape,
creating an L-shaped scaffold; and a straight ePTFE scaffold that was 5.5 cm in length
was bent into a U-shape, creating a U-shaped scaffold. A T-shaped scaffold was
constructed as follows: first, a hole that was 4 mm in diameter was cut out of the center
of a straight ePTFE scaffold that was 6 cm in length, then the end of another straight
ePTFE scaffold that was 2.5 cm in length was sutured (6.0 silk suture) onto the hole,
creating a T-shaped scaffold (Figure 2.7). Another T-shaped scaffold was constructed
identically to the first one, and each end of the crossbar of the “T” was bent upward to
form a “Y”, creating a Y-shaped scaffold. The ends of all scaffolds were sutured (2.0 silk
suture) onto female luer thread barbed fittings (white nylon, 200 series barb, 1/8” ID,
Value Plastics, Part Number FTLL230-1) as shown in figure 2.2 A.
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A
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Crossbar

B

C

Needle

Figure 2.7. Construction of T-shaped scaffold. To suture together two straight pieces of
ePTFE, the following procedure was followed. First, a suture needle was used to puncture
the stem (A). The needle was then pushed through the puncture and pulled out the stem
end that was being sutured. The needle tip was then used to puncture the crossbar as
shown in B, and the needle tip was pulled through the puncture. The needle tip was then
used to puncture the stem again in a location that was 1 mm next to the previous puncture
in the stem, and this technique was repeated around the entire suture site (C). The suture
was then pulled taut, and 6 overhand knots were tied to secure the suture.

2.3.5. Construction of Bioreactors to House Complex-Shaped Scaffolds
The bioreactor that currently houses only straight BVMs (Figure 2.1) is made of
an off-the-shelf polypropylene container, a number of small off-the-shelf plastic parts
known as fittings, and silicone tubing. Detailed assembly instructions for that bioreactor
are located in Design and Optimization of a Blood Vessel Mimic Bioreactor System for
the Evaluation of Intravascular Devices in Simple and Complex Geometries on pages 84–
93 and 212–218 [71]. Those assembly instructions detail the methods for drilling holes in
the container, attaching fittings, and attaching tubing to the fittings. Identical assembly
methods were used for construction of the multifunctional bioreactor and for construction
of the bioreactor capable of housing only Y-shaped scaffolds. But in the case of the
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multifunctional bioreactor and the bioreactor capable of housing only Y-shaped scaffolds,
holes were drilled for inlets and outlets in the locations described in Figures 2.5 A and 2.6
A, fittings were attached in the locations depicted in those figures, and tubing was cut
with the dimensions depicted in those figures and was placed in the locations depicted in
those figures. All holes were drilled with a handheld power drill and a 15/64” drill bit.
The exact materials used to construct each bioreactor are listed in Tables 2.1 and 2.2. A
protocol for maintenance of multifunctional bioreactors is located in Appendix B.
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Table 2.1. Materials for Multifunctional Bioreactor
Component

Company

Part Number

Quantity

Polypropylene Container

Lock & Lock

HPL806

1

Tygon® Silicone Tubing
(1/8” ID)

Cole-Parmer

WU-95702-06

25.5 inches cut
according to
Figure 2.5 A

D100 455980

3

Discofix® 1-Way Stopcock B. Braun Medical
3-Way Stopcock

Value Plastics

VPB1000062N

3

Female Luer Lug Panel
Mount (1/8” Barb)

Value Plastics

FTLB230-1

6

Buna N O-Ring

McMaster-Carr

2418T112

12

Lock Nut

Value Plastics

LNS-1

6

Luer Plug

Value Plastics

MTLLP-1

3

Female Luer Thread Fitting
(1/8” Barb)

Value Plastics

FTLL230-1

5

Male Luer Lock Fitting
(1/8” Barb)

Value Plastics

MTLL230-1

3

Y-Connector (1/8” Barb)

Value Plastics

Y230-1

2

17644

2 or 3 for bent
or T-shaped
scaffold
respectively

Rotating Luer Lock
Connector

Qosina
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Table 2.2. Materials for Bioreactor Capable of Housing Only Y-shaped Scaffolds
Component

Company

Part Number

Quantity

Polypropylene Container

Lock & Lock

HPL806

1

Tygon® Silicone Tubing
(1/8” ID)

Cole-Parmer

WU-95702-06

21.5 inches cut
according to
Figure 2.6 A

D100 455980

3

Discofix® 1-Way Stopcock B. Braun Medical
3-Way Stopcock

Value Plastics

VPB1000062N

1

Female Luer Lug Panel
Mount (1/8” Barb)

Value Plastics

FTLB230-1

4

Buna N O-Ring

McMaster-Carr

2418T112

8

Lock Nut

Value Plastics

LNS-1

4

Female Luer Thread Fitting
(1/8” Barb)

Value Plastics

FTLL230-1

3

Male Luer Lock Fitting
(1/8” Barb)

Value Plastics

MTLL230-1

3

Y-Connector (1/8” Barb)

Value Plastics

Y230-1

2

Rotating Luer Lock
Connector

Qosina

17644

3

2.3.6. Validation of New Scaffolds and Bioreactors
After construction, the new scaffolds and bioreactors were tested for the ability to
generate complex-shaped BVMs. If cell deposition occurred on the new scaffolds inside
the new bioreactors, the designs for the new scaffolds and bioreactors would be validated.
Only bent scaffolds and multifunctional bioreactors were tested for the ability to
generate complex-shaped BVMs, and the reason for this is as follows. To be useful for
coronary stent testing, complex-shaped BVMs need other characteristics in addition to
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cells deposited on their scaffolds, such as a confluent cell lining and a cell lining that is
not completely denuded after coronary stent deployment. Development of these other
characteristics will be discussed in future chapters. But the laboratory techniques for
developing these other characteristics are likely similar, regardless of the geometry.
Therefore, instead of testing techniques in all five scaffold geometries, only some
geometries were first tested to discover techniques that could be used with all scaffold
geometries. This saved significant time and resources and allowed faster discovery of
successful techniques. Bent scaffolds were chosen as the scaffolds to first test because the
suture sites of bifurcated scaffolds presented potential challenges, and these potential
challenges could prolong discovery of successful techniques that could be used with all
scaffold geometries.
To test bent scaffolds and multifunctional bioreactors for the ability to generate
complex-shaped BVMs, the following steps were carried out. (Note: the following steps
only summarize the many tissue engineering laboratory steps that must be carried out
when generating BVMs and that were carried out for this validation test; the many tissue
engineering laboratory steps will be discussed in future chapters.) First, an S-, L-, and Ushaped scaffold were each inserted into a multifunctional bioreactor. The scaffolds and
bioreactors were primed with media, and HUVECs were pressure-sodded onto each
scaffold. The bioreactors were attached to media reservoirs, placed in an incubator at
37˚C and 5% CO2, and connected to an 8-roller pump that circulated media through the
BVMs for 1 day. Then each vessel was removed from its bioreactor, fixed in Histochoice,
cut in half longitudinally, and stained with the fluorescent nuclear stain bisbenzimide
(BBI). A fluorescent microscope was used to capture en face images of the luminal
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surface of each scaffold, and the images were used to determine whether cells deposited
on each scaffold.

2.4. Results
Construction of all five complex-shaped scaffolds and the two new bioreactors
yielded prototypes that will be discussed here. The BBI images that resulted from the
validation testing of all three bent scaffolds will also be discussed here.

2.4.1. Prototypes of New Scaffolds and Bioreactors
Construction of bent scaffolds involved nothing more than bending straight
scaffolds into complex geometries, which was easy. Construction of bifurcated scaffolds
was also easy: cutting a hole in the middle of a straight scaffold with a razor, puncturing
ePTFE with a suture needle, placing ePTFE punctures 1 mm next to each other, and tying
6 overhand knots to secure the sutures were all easy steps. Suturing together two straight
pieces of ePTFE was a successful method for attaching the two pieces and for creating a
T-shaped scaffold. Bending both ends of the crossbar of a T-shaped scaffold upward was
an easy and successful method for creating a Y-shaped scaffold. Placing female luer
thread barbed fittings inside the ends of all scaffolds and suturing the ends of all scaffolds
to the female luer thread barbed fittings was also easy.
Construction of the multifunctional bioreactor and the bioreactor capable of
housing only Y-shaped scaffolds was similarly easy. Construction of these new
bioreactors varied only slightly from construction of the current straight-BVM bioreactor:
for the new bioreactors, additional holes were drilled into the polypropylene container,
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tubing was cut in different dimensions and attached at different locations, a few more
stopcocks were added, and luer plugs were used to cap off any inlets or outlets not being
used when complex-shaped scaffolds were inserted. All stopcocks on both bioreactors
were easily accessible, therefore the additional tubing on both bioreactors did not crowd
the bioreactors to the point of stopcocks being difficult to access.
Insertion of all five complex-shaped scaffolds into the new bioreactors was a
success. The female luer thread barbed fittings on the ends of each complex-shaped
scaffold were easy to secure into position on the male-to-male rotating fittings. In the
multifunctional bioreactor, luer plugs were easy to attach to inlets or outlets not being
used, and no media flowed through any of the capped-off inlets or outlets in any of the
three bioreactors throughout the entire validation test. No scaffolds experienced any
kinking. Prototypes of the new scaffolds and bioreactors are shown in Figure 2.9.
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Figure 2.9. Prototypes of the new scaffolds and bioreactors. The multifunctional
bioreactor houses an S-shaped scaffold (A1–A2), an L-shaped scaffold (B1–B2), a Ushaped scaffold (C1–C2), and a T-shaped scaffold (D1–D2). The bioreactor in E1–E2
houses only a Y-shaped scaffold. Bioreactor lids were removed for scaffold visibility.
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2.4.2. Cell Deposition on Complex-Shaped Scaffolds
The bent scaffolds and multifunctional bioreactor generated S-, L-, and U-shaped
BVMs, and all BVMs exhibited cell deposition in BBI images (Figure 2.10).

100 µm
Figure 2.10. BBI image showing cell deposition on U-shaped scaffold. BBI causes cell
nuclei to fluoresce, and en face BBI images show many small dots that each correspond
to the nucleus of a cell. The many small dots are usually colored blue, but because this is
a black-and-white image, the many small dots are gray. Five en face BBI images were
taken of each complex-shaped scaffold, and all 5 images for each scaffold showed cell
deposition similar to that shown in this image.
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2.5. Discussion and Conclusions
Multiple initial steps were taken toward the development of BVMs in complex
geometries. Previous designs for complex-shaped scaffolds and bioreactors were
modified and given specific dimensions. The Y-shaped scaffold was redesigned to make
construction less tedious and to reduce unwanted leakage when fluid moves through the
Y-shaped scaffold. A multifunctional bioreactor was designed to reduce bioreactor
construction time, the need for bioreactor storage space, and bioreactor maintenance time.
Construction of the new scaffolds and bioreactors, insertion of the new scaffolds into the
new bioreactors, and capping off unused inlets or outlets in multifunctional bioreactors
were all easily performed. Cells deposited on S-, L-, and U-shaped scaffolds inside
multifunctional bioreactors, validating the design of these scaffolds and the
multifunctional bioreactor. These findings support the hypothesis that complex-shaped
scaffolds could be designed and constructed, that bioreactors capable of housing the new
scaffolds could be designed and constructed, and that cells would deposit onto the new
scaffolds inside the new bioreactors.
Although BBI images showed cell deposition on each bent scaffold, nothing else
about the cell linings was assessed. It is possible that the cell lining on each bent scaffold
has characteristics that do not make it useful for coronary stent testing. For example, cells
may have densely deposited in some regions of each bent scaffold but sparsely deposited
in other regions. Regions of sparse cell deposition may lead to formation of subconfluent
cell linings in those regions, which could lead to inaccurate assessments of reendothelialization of coronary stents. Therefore, the cell lining on each bent scaffold
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should be evaluated more closely to determine how well it actually mimics the
endothelium of native blood vessels.
Before the cell lining on each bent scaffold is evaluated more closely, an
alternative step is to validate the bifurcated scaffolds. But at this point, validation of the
bifurcated scaffolds may simply prolong the development of any fully functional
complex-shaped BVM. Closer evaluation of the cell lining on each bent scaffold may
provide information that is vital to the development of successful techniques that could
be used with all scaffold geometries, thereby expediting development of a fully
functional complex-shaped BVM. Therefore, bifurcated scaffolds were not validated at
this point.
In conclusion, complex-shaped scaffolds can be constructed, bioreactors capable
of housing complex-shaped scaffolds can be constructed, and endothelial cells can be
deposited within complex-shaped scaffolds. The validated bent scaffolds and validated
multifunctional bioreactors were next used to further develop complex-shaped BVMs.
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3. Consistency of Cell Deposition on Complex-Shaped Scaffolds

3.1. Introduction
This chapter addresses the second specific aim of this thesis: deposit cells
throughout the entire inner surface of complex-shaped scaffolds.
There are multiple characteristics of straight BVMs that make them useful for
stent testing. One of these characteristics is a confluent cell lining [31]. A native human
blood vessel features an endothelium, which is a confluent lining of endothelial cells on
the inner surface of the blood vessel. When a coronary stent is deployed in a coronary
artery, the stent denudes the endothelium in the stented region [51, 68]. Endothelial cells
in the intact region of endothelium next to the stented region begin to migrate into the
denuded region and eventually onto the stent [74], and this migration of endothelial cells
is the predominant source of cells involved in re-endothelialization [74]. When a stent is
deployed in a straight BVM, cells that have not been denuded from the cell lining of the
BVM re-endothelialize the stent [31]. Therefore, complex-shaped BVMs should also be
developed with a confluent endothelial cell lining so that a stent can denude some
endothelial cells but still leave behind intact endothelial cells that will re-endothelialize
the stent.
A confluent cell lining may be difficult to form on a complex-shaped scaffold,
and the reason for this is described as follows. A confluent cell lining in a straight BVM
does not form as soon as cells are pressure-sodded onto the ePTFE scaffold [59]. When
endothelial cells are first deposited onto the scaffold, the cells are balled-up, and the cell
lining is not confluent (Figure 3.1 A) [59]. After a few days of cultivation under flow, the
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balled-up cells begin to spread out [59], the cells begin to physically contact each other,
and a confluent cell lining forms when no visible gaps exist between any cells (Figure 3.1
B). Although cells have deposited on each bent scaffold as described in the previous
chapter, the consistency of that cell deposition throughout the inner surface of each
scaffold is unknown—it is possible that cells deposited unevenly. Cells in regions with
possibly dense cell deposition may have to only spread out to contact neighboring cells,
whereas cells in regions with sparse cell deposition may have to spread out but also
migrate to contact neighboring cells. Therefore, regions of dense cell deposition may
form a confluent cell lining faster than regions of sparse cell deposition, possibly
resulting in a complex-shaped BVM with a cell lining that is confluent in some regions
and subconfluent in other regions. If a stent were deployed in one of these unevenly
confluent complex-shaped BVMs, subconfluent regions of the BVM may not fully reendothelialize the stent, while confluent regions may fully re-endothelialize the stent,
resulting in uneven re-endothelialization and possibly an inaccurate portrayal of that
stent’s ability to re-endothelialize. Therefore, it is desirable for cells to deposit evenly on
a complex-shaped scaffold.
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A

B

Figure 3.1. Cross-sections of straight BVM. The ePTFE scaffold is the large beige curve
in each image, and the cells are small dark dots in A and a very thin dark line on the inner
surface of the scaffold in B. (A) After 1 day of cultivation, cells appear balled-up, cell
coverage on the scaffold is sparse, and the cell lining is not confluent. (B) After 7 days of
cultivation, cells appear spread out, and the cell lining is confluent. [59]

There are various ways that cells may deposit unevenly on a complex-shaped
scaffold. HUVECs will be pressure-sodded onto complex-shaped scaffolds, and when the
cell suspension is injected into the complex geometries, cells may not deposit evenly
along the length of the scaffolds. In a bent scaffold, cells may deposit only at the
proximal portion of the bend, resulting in no cell lining at the distal end of the bend
(Figure 3.2). In a bifurcated scaffold, the cell suspension could completely leak out of the
suture sites and never reach the vessel segments after the bifurcation, resulting in no cell
lining after the bifurcation. On L- and U-shaped scaffolds, cells may deposit more
densely on the outer wall of the bends than on the inner wall of the bends. When all
complex-shaped scaffolds are inserted horizontally into their bioreactors, cells may
deposit more densely on the bottom half of the scaffolds than on the top half of the
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scaffolds due to the force of gravity pulling cells downward during pressure-sodding. For
these reasons, cell deposition on complex-shaped scaffolds was assessed in more detail in
this chapter.

Figure 3.2. Possible cell deposition in bent scaffolds. Black arrows indicate the flow
direction of the injected cell suspension. Cells may deposit only in the proximal blue
regions.

To save time and resources and allow for faster discovery of successful laboratory
techniques as in the previous chapter, only L- and U-shaped scaffolds were assessed
because bifurcated scaffolds had not undergone validation testing and because the FDA
has recommended testing coronary stents in simulated vessels with worst-case
angulations and the American College of Cardiology and the American Heart Association
do not define the S-shaped scaffold geometry as “angulated” [3, 40]. The hypothesis in
this case was that, after 1 day of cultivation of complex-shaped BVMs, no statistically
significant differences would exist between the cell densities along the length of the
BVMs, between the cell densities in the inner and outer halves of the BVMs, or between
the cell densities in the top and bottom halves of the BVMs.
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3.2. Materials and Methods
3 L-shaped BVMs and 3 U-shaped BVMs were tissue-engineered, using
laboratory techniques that will be detailed in this section. The laboratory techniques were
carried out over a 2-week period, and a protocol that identifies when the laboratory
techniques were used is located in Appendix H. The density of cells in various regions
throughout each BVM was quantified, and it was determined whether cell densities were
statistically significantly different along the length of each scaffold geometry, between
the inner and outer halves of each scaffold geometry, and between the top and bottom
halves of each scaffold geometry.

3.2.1. Cell Culture
HUVECs (Lonza) were cultured and expanded in T75 and T225 BD cell culture
flasks. Cells were cultured in HUVEC media; the components of the HUVEC media and
steps that were carried out to make the media are located in Appendix C. The cells were
maintained at 37˚C and 5% CO2 in a small incubator with 80–100% humidity (Shellab
CO2 Series Incubator, Sheldon Manufacturing, Inc.). During each passage from one flask
to another flask, cells were monitored using an inverted light microscope (Olympus
CKX31 with IX2–SLP contrast slider). When cells were pressure-sodded onto scaffolds,
cells were no more than P8. Enough cells were cultured so that approximately 1.5 million
cells/cm2 were sodded onto each scaffold.
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3.2.2. Sterilization and Media Preparation
All scaffolds were made of 4-mm-ID ePTFE. 3 straight pieces of ePTFE were cut
to lengths of 5 cm to serve as L-shaped scaffolds, and 3 straight pieces of ePTFE were cut
to lengths of 5.5 cm to serve as U-shaped scaffolds. Female luer thread barbed fittings
were inserted into both ends of each scaffold, and both ends of each scaffold were sutured
onto the fittings using 2.0 silk suture as described in Section 2.3.4. The scaffolds were
then placed in sterilization pouches, were sterilized in an autoclave for 30 minutes at
250˚C, and were then dried for 30 minutes. 3 forceps and a degassing flask with a rubber
stopper were also sterilized in the autoclave. 3 luer plugs and 2 rotating male-to-male luer
lock connectors were placed loose inside each of the polypropylene containers of 6
multifunctional bioreactors. The bioreactors with their loose fittings, 6 lids for each of the
bioreactors, and 6 two-port lids for media reservoirs were sterilized with ethylene oxide
gas (EtO) at the Cal Poly Veterinary Clinic.
Throughout the tissue engineering of straight BVMs, three types of media are
used, and these three types of media were also used for L- and U-shaped BVMs in this
study. The three types of media are bioreactor media, conditioning media, and HUVEC
media. 2 bottles of bioreactor media were made for use in this study, 1 bottle of
conditioning media was made for use in this study, and 1 bottle of HUVEC media in
addition to the bottle used during cell culture was made for use in this study. The
components included in each type of media and the steps that were carried out to make
each type of media are located in Appendices C, D, and E.
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3.2.3. Denucleation and Protein-Coating of Scaffolds
All 6 scaffolds were denucleated and coated with protein. First, 60 mL of
conditioning media was warmed in a water bath at 37˚C, placed in the sterilized
degassing flask, and placed under vacuum. 6 15-mL conicals were each filled with 10 mL
of sterile 70% ethanol (EtOH), and each scaffold was placed fully submerged in one of
the 15-mL conicals for 10 minutes. During the first 30 seconds of submersion, the
conicals were tapped to dislodge air bubbles on the scaffolds. 6 other 15-mL conicals
were each filled with 10 mL of sterile 100% EtOH, and each scaffold was moved from
the 70% EtOH directly into the 100% EtOH using forceps. The scaffolds were fully
submerged again, and the conicals were tapped again during the first 30 seconds of
submersion to dislodge air bubbles on the scaffolds. 6 other 15-mL conicals were each
filled with 10 mL of degassed conditioning media, and each scaffold was moved from the
100% EtOH directly into the degassed conditioning media; scaffolds were gently
submerged in the degassed conditioning media to prevent formation of air bubbles during
submersion. The scaffolds were placed in an incubator at 37˚C overnight.

3.2.4. Insertion of Scaffolds into Bioreactors and Priming
All media was warmed in a water bath at 37˚C. The 6 sterilized multifunctional
bioreactors, the 6 sterilized lids for each bioreactor, the 6 sterilized two-port lids for
media reservoirs, and 2 sterilized forceps were gathered. The 6 15-mL conicals,
containing 6 scaffolds that had been denucleated and protein-coated, were placed inside a
laminar flow hood (Nuaire Labgard Class II Type A2 Biological Safety Cabinet). Two
sterile bioreactors were placed inside the laminar flow hood, and approximately 200 mL
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of bioreactor media were poured into both bioreactors. Forceps were used to transfer each
scaffold out of its conical and into a bioreactor. Sterile gloves were then donned, the
loose luer plugs were secured into position to cap off any inlets or outlets that would not
be used when a U-shaped scaffold was inserted, rotating male-to-male luer lock
connectors were secured into position for a U-shaped scaffold, and the scaffold was
secured into position to form a U-shape (Figure 3.3). Securement of luer plugs, rotating
male-to-male luer lock connectors, and U-shaped scaffold was also carried out in the
other bioreactor. Lids were then placed on both bioreactors, and sterile gloves were
removed.
The scaffolds were then primed with conditioning media. A syringe was filled
with 10 mL of conditioning media and attached to the inlet of the U-shaped scaffold on
one of the bioreactors. The syringe was used to inject 5 mL of conditioning media into
the lumen of the scaffold, removing all air bubbles from the lumen. The luminal outlet of
the scaffold was then closed off, and the remaining 5 mL of conditioning media in the
syringe were forced into the lumen of the scaffold but also through the pores of the
scaffold. These priming steps were repeated for the U-shaped scaffold in the other
bioreactor.
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Figure 3.3. Insertion of U-shaped scaffold into bioreactor. All fittings were secured into
place, and the scaffold was secured in a U-shape. All scaffolds were positioned with the
blue double stripe upward (see double blue stripe on top of scaffold in image).

The reservoirs with two-port lids were then primed. 45 mL of conditioning media
were placed into a 50-mL conical for each reservoir. Two-port lids were then attached to
each conical, and the conicals were inverted so that media flowed through the tubing
attached to the conicals, removing all air from inside the tubing. Each two-port lid was
then connected to one of the bioreactors so that the inlet and outlet of the two-port lids
were correctly connected to the inlet and outlet of the bioreactors (Figure 3.4).
The bioreactors and their respective two-port lids were placed in a large incubator
(Shellab CO2 Incubator) at 37˚C and 5% CO2 and attached to a peristaltic pump (ColeParmer Masterflex L/S Model 8-Roller) (Figure 3.5). First, the luminal outlets and
luminal inlets of both bioreactors were opened so that media could be pumped through
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the complex-shaped BVM system to remove any remaining air bubbles from the systems.
The pump was turned on to 10 rpm, which corresponds to 0.8 mL/min, media was
pumped through the systems, and all air bubbles were removed from the systems. The
luminal outlet was then closed, and media was pumped transmurally through the systems
for 10 minutes at 150 rpm, which corresponds to 12 mL/min. All inlets and outlets were
then closed to prevent media backflow. The two systems were left in the large incubator.

Reservoirs
Tubing that connects reservoirs
to bioreactors

Bioreactors

Figure 3.4. Media reservoirs. After air bubbles are removed from the reservoir tubing,
the tubing is connected to a bioreactor.
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Reservoirs

Bioreactors
Pump
Figure 3.5. Complex-shaped BVM systems connected to a pump. The pump circulates
media through the 3 complex-shaped BVM systems shown here. Media flows from the
reservoirs to the pump to the bioreactors.

These steps were repeated with two more bioreactors, one bioreactor housing a Ushaped scaffold and the other bioreactor housing an L-shaped scaffold. These steps were
then repeated a third time with the last two bioreactors, both bioreactors housing Lshaped scaffolds. Completion of all the steps resulted in 6 primed complex-shaped BVM
systems: 3 complex-shaped BVM systems containing U-shaped scaffolds and 3 complexshaped BVM systems containing L-shaped scaffolds.

3.2.5. Pressure-Sodding of HUVECs
Cell culture was carried out so that 6 confluent T225 flasks would be available on
the day that cells were sodded onto the scaffolds. 1 T225 flask of HUVECs was allotted
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for each scaffold. After all 6 complex-shaped BVM systems were primed, the 6 flasks
were removed from the small incubator, and the cells in each flask were inspected. Cells
were removed from the bottom of each flask using trypsin. The suspensions of cells in
each flask were transferred to their own 50-mL conicals. Each conical was centrifuged on
setting 4 for 4 minutes to pellet all cells at the bottom of each conical.
After a pellet of cells formed, the conical was taken to the laminar flow hood, and
the supernatant was aspirated out of the conical without aspirating out the pellet of cells.
The cells were resuspended in 4 mL of HUVEC media. A complex-shaped BVM system
was then brought out of the large incubator and into the laminar flow hood. The reservoir
was placed to the side in the hood so that the bioreactor could be easily accessible during
pressure-sodding. The bioreactor outlet was disconnected from the tubing that leads to
the reservoir and was placed into a media trough so that media could flow out of the
bioreactor outlet and into the media trough. The luminal outlet was closed, and the
extraluminal outlet was opened. Two other troughs were prepared: one trough containing
10 mL of HUVEC media and another trough containing the 4 mL of cell suspension. A
syringe was filled with 5 mL of HUVEC media and attached to the stopcock proximal to
the scaffold, and all 5 mL of HUVEC media in the syringe were injected into the tubing
proximal to the scaffold to remove conditioning media from the proximal tubing. Then
another syringe was filled with the 4 mL of cell suspension, the syringe was attached to
the stopcock proximal to the scaffold, and all 4 mL of cell suspension were injected
transmurally into the scaffold. The syringe used to previously inject HUVEC media was
used to inject the remaining HUVEC media transmurally into the scaffold. Then all inlets
and outlets were closed to prevent media backflow, and the bioreactor outlet was
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reconnected to the reservoir tubing. The reservoir containing conditioning media was
replaced with a reservoir containing HUVEC media. The complex-shaped BVM system
was reattached to the pump in the large incubator, and the pump was immediately turned
on to a setting of 10 rpm (0.8 mL/min) and administered transmural flow.
These pressure-sodding steps were repeated for each of the 6 scaffolds.

3.2.6. Cultivation
Transmural flow at 10 rpm (0.8 mL/min) was maintained on all complex-shaped
BVMs for 1 hour. Then the luminal outlet on all bioreactors was opened, and luminal
flow at 10 rpm (0.8 mL/min) was maintained for another hour. Luminal flow was then
increased to 15 rpm (1.2 mL/min) and maintained overnight until the complex-shaped
BVMs were harvested the next day.

3.2.7. Harvesting and Fixation
After 1 day of cultivation, all complex-shaped BVMs were harvested from their
bioreactors. First, all inlets and outlets on each bioreactor were closed off. Then the pump
was turned off. All bioreactors were removed from the large incubator to a nonsterile
surface. Six 15-mL conicals were each filled with 8 mL of Histochoice and labeled for a
specific complex-shaped BVM; the bottom end of each conical was marked “Proximal,”
and the top end of each conical was marked “Distal” to keep track of proximal and distal
ends of each complex-shaped BVM. The lid of each bioreactor was removed, and a razor
blade was used to cut the ends of each complex-shaped BVM off the female luer thread
barbed fittings, making sure to not do anything that could disrupt the cell lining of each
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BVM. Forceps were used to transfer each complex-shaped BVM into the corresponding
15-mL conical of Histochoice, orienting each complex-shaped BVM to align with the
orientation markings on the outside of each conical. All complex-shaped BVMs remained
in Histochoice overnight to ensure that fixation occurred. All media in each bioreactor
and reservoir was disposed of, residual ePTFE scraps on the female luer thread barbed
fittings in each bioreactor were disposed of, and all bioreactors, bioreactor lids, two-port
lids, and tubing were cleaned with hot water, dried, and stored for future experiments.

3.2.8. BBI Imaging
After 1 day of fixation in Histochoice, all complex-shaped BVMs were cut into
smaller pieces for analysis of cell deposition in various regions. First, each BVM was cut
into 5 segments (Figure 3.6 A and B). Recall that during scaffold insertion into the
bioreactors, the blue double stripe on each piece of ePTFE was positioned upward. Each
scaffold segment was cut in half longitudinally so that each half had one of the blue lines
that originally formed the double blue stripe. Enough 15-mL conicals were wrapped in
foil so that each cut segment was individually stored in its own conical; each conical was
labeled with information that identified the specific segment that would be stored in that
conical (e.g. “L-Shaped BVM #1, P1, inner”). A BBI solution was prepared as described
in Appendix G, 1 mL of BBI solution was placed in each conical, and 1 scaffold segment
was placed in each conical. En face BBI images were taken of each scaffold segment on a
fluorescent microscope (Olympus BX41) using the protocol included in Appendix G. 4
images were taken of each scaffold segment: 2 images on the top half of each segment
and two images on the bottom half of each segment (Figure 3.6 C).
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Figure 3.6. Cutting of L- and U-shaped BVMs into segments for evaluation. L- and Ushaped BVMs were first cut into 5 segments: Proximal 1 (P1), Proximal 2 (P2), Middle
(M), Distal 1 (D1), and Distal 2 (D2); black arrows indicate the direction of flow (A and
B). C shows an alternate view of segment P1 from both scaffold geometries; the black
arrow indicates the direction of flow, the vertical red line indicates the demarcation
between inner and outer halves of the BVMs, and the 4 black boxes indicate the location
of 4 BBI images that were captured on each BVM segment. Because 6 complex-shaped
BVMs were tissue-engineered for this study, and because each BVM was cut into 10
segments, there were a total of 60 scaffold segments that were evaluated. Because 4 BBI
images were captured on each segment, a total of 240 BBI images were captured for this
study.
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3.2.9. Cell Counting in BBI Images
After BBI images were obtained for all segments of all complex-shaped BVMs,
cells were counted in the images. Instead of counting all cells in every image, a template
was applied to every image that highlighted the same small 5 regions in each image
(Figure 3.7). One person counted cells in these regions by identifying cells with the naked
eye and keeping a tally of the number of cells that were identified.

Figure 3.7. Cell counting in BBI images. 5 small white boxes were placed across the
center of each image; each small white box has an area of 10,000 µm2. Each blue dot
represents the nucleus of a cell, and the blue dots were counted in each small white box.
Note that cells in the top edge of the image are blurry; no small white boxes contained
any blurry cells, and no blurry cells were counted. The counts from the small white boxes
were averaged to yield a representative count for the image, and the average was
converted to a representative density in units of cells/cm2.
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Just before images were taken of each scaffold segment, the edge of each scaffold
segment was blotted on a Kimwipe to wick residual BBI solution from the luminal
surface of the scaffold segments; this method was repeatedly used with any scaffold
segments whose blue dots were difficult to visualize on the microscope. Even after
repeated blotting with a Kimwipe, the blue dots in 20 images taken on the outer half of
one of the U-shaped BVMs were still difficult to visualize. Therefore, cells were not
counted in those 20 images. Of the total 240 images that were captured in this study, cells
were counted in 220 images, and the 20 images taken on that outer half of one of the Ushaped BVMs were not included in the following statistical analysis.

3.2.10. Statistical Analysis of BBI Images
After representative cell densities were determined for the 220 BBI images, the
cell densities in different regions of the complex-shaped BVMs were compared to each
other to determine whether any cell densities were statistically significantly different
from each other. The number of images taken for L-shaped BVMs totaled to 120, and the
number of images taken for U-shaped BVMs totaled to 100. Since a representative cell
density was associated with each image, the number of representative cell densities for Lshaped BVMs totaled to 120, and the number of representative cell densities for Ushaped BVMs totaled to 100. To determine if the data set for L-shaped BVMs and the
data set for U-shaped BVMs were each normally distributed, normal probability plots
were generated for both data sets using Minitab 16.1.1. If a data set was normally
distributed, a one-way analysis of variance (ANOVA) was used to determine whether
statistically significant differences existed between the cell densities in various regions of
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the scaffold. If a data set was not normally distributed, the Kruskal-Wallis test was used
to determine whether statistically significant differences existed between the cell
densities in various regions of the scaffold. Boxplots and individual value plots were
created so that the differences between cell densities in various regions of each scaffold
could be better visualized.

3.3. Results
A sample BBI image for each of the 6 complex-shaped BVMs is shown in Figure
3.8, and some representative cell counts are summarized in Table 3.1. Appendix I
includes additional BBI images, the representative cell counts that were established for
all 220 BBI images, and the method used to convert representative cell counts into cell
densities with units of cells/cm2.
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A

B
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D
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F

Figure 3.8. Sample BBI images from the 6 complex-shaped BVMs in this study. A
sample BBI image is shown for each of the three L-shaped BVMs (A–C) and each of the
three U-shaped BVMs (D–F). D shows blue splotches instead of blue dots.

Table 3.1. Average Cell Counts ± SD for an Area of 10,000 µm2 Along Length of BVMs
BVM

Distal 2

Distal 1

Middle

Proximal 2

Proximal 1

L-shaped

31 ± 2

33 ± 2

33 ± 3

32 ± 2

30 ± 2

U-shaped

27 ± 4

30 ± 4

30 ± 3

29 ± 3

26 ± 5
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Almost all BBI images showed blue dots whose edges could be clearly identified.
But the 20 BBI images taken on the outer half of one of the U-shaped BVMs showed
blue splotches instead of blue dots (Figure 3.8 D), and the edges of the splotches were
much less identifiable than the edges of the dots, therefore those 20 images were not
quantified or included in any statistical analyses.
The normal probability plots showed that the data set for L-shaped BVMs was not
normal and that the data set for U-shaped BVMs was normal (Figure 3.9). Because the
data set for L-shaped BVMs was not normal, the Kruskal-Wallis test was used to
determine whether statistically significant differences existed between the cell densities
in various regions of L-shaped scaffolds. Because the data set for U-shaped BVMs was
normal, a one-way ANOVA was used to determine whether statistically significant
differences existed between the cell densities in various regions of U-shaped scaffolds.
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Figure 3.9. Probability plots of data sets for L- and U-shaped BVMs. A 95% confidence
interval was used. A normal data set has all data points inside the outer blue lines and has
p > 0.05. The L-shaped BVM data set had p < 0.005 and was therefore not normal. The
U-shaped BVM data set had p = 0.146 and was therefore normal.
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For L-shaped BVMs, there was a statistically significant difference between the
cell densities of the 5 regions along the length of the BVMs, there was a statistically
significant difference between the cell densities in the inner and outer halves of the
BVMs, and there was no statistically significant difference between the cell densities in
the top and bottom halves of the BVMs. For U-shaped BVMs, there was a statistically
significant difference between the cell densities in the 5 regions along the length of the
BVMs, there was no statistically significant difference between the cell densities in the
inner and outer halves of the BVMs, and there was no statistically significant difference
between the cell densities in the top and bottom halves of the BVMs. Table 3.2 shows the
p-values for each statistical comparison; when p < 0.05, a statistically significant
difference existed. Appendix J contains the Minitab output that shows each p-value.

Table 3.2. P-Values for All Statistical Comparisons
Comparison

L-Shaped
BVM

U-Shaped
BVM

5 Regions Along
Length of BVM

0.000

0.008

Inner vs. Outer

0.011

0.057

Top vs. Bottom

0.607

0.810

Boxplots allowed for better visualization of the differences between cell densities
in various regions of the complex-shaped BVMs. While the one-way ANOVA compared
averages in the U-shaped BVM data set, the Kruskal-Wallis test compared medians in the
L-shaped BVM data set. Therefore, U-shaped BVM boxplots were constructed based on
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averages, while L-shaped BVM boxplots were constructed based on medians. In some
cases, individual value plots were constructed to show the specific data points that were
used to construct boxplots. Although the cell densities were statistically significantly
different between the 5 regions along the length of both L- and U-shaped BVMs and
between the inner and outer halves of L-shaped BVMs, boxplots showed that all the
median cell densities throughout L-shaped BVMs and all the average cell densities
throughout U-shaped BVMs fell between 250,000 cells/cm2 and 350,000 cells/cm2
(Figures 3.10–3.17).
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Figure 3.10. Boxplot of cell density along length of L-shaped BVMs. Asterisks mark
outliers, and the center line of each structure corresponds to a median cell density.

Figure 3.11. Individual value plot of cell density along length of L-shaped BVMs. The
cell densities in this plot were used to create the boxplot in Figure 3.10.
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Figure 3.12. Boxplot of cell density in inner and outer halves of L-shaped BVMs. The asterisk
marks an outlier, and the centerline of each structure corresponds to a median cell density.

Figure 3.13. Boxplot of cell density in top and bottom halves of L-shaped BVMs. Asterisks
mark outliers, and the center line of each structure corresponds to a median cell density.

75

Figure 3.14. Boxplot of cell density along length of U-shaped BVMs. The center line of
each structure corresponds to an average cell density.

Figure 3.15. Individual value plot of cell density along length of U-shaped BVMs. The
cell densities in this plot were used to create the boxplot in Figure 3.14.
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Figure 3.16. Boxplot of cell density in inner and outer halves of U-shaped BVMs. Asterisks
mark outliers, and the center line of each structure corresponds to an average cell density.

Figure 3.17. Boxplot of cell density in top and bottom halves of U-shaped BVMs. The
center line of each structure corresponds to an average cell density.
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3.4. Discussion and Conclusions
Consistency of cell deposition throughout complex-shaped scaffolds was
quantitatively assessed in this chapter. Consistent cell deposition may lead to
development of a cell lining that is consistently confluent throughout BVMs, which may
more accurately predict re-endothelialization of coronary stents. Cells were deposited
onto L- and U-shaped scaffolds, and cell density after 1 day of cultivation was
statistically significantly different between various regions in both L- and U-shaped
BVMs. In L-shaped BVMs, cell density was statistically significantly different between 5
regions along the length of the BVMs and between the inner and outer halves of the
BVMs. In U-shaped BVMs, cell density was statistically significantly different in 5
regions along the length of the BVMs. In other cases, cell density was not statistically
significantly different. In L-shaped BVMs, cell density was not statistically significantly
different between the top and bottom halves of the BVMs. In U-shaped BVMs, cell
density was not statistically significantly different between the inner and outer halves of
the BVMs and between the top and bottom halves of the BVMs. These findings do not
support the hypothesis that, after 1 day of cultivation of complex-shaped BVMs, no
statistically significant differences would exist between the cell densities along the length
of the BVMs, between the cell densities in the inner and outer halves of the BVMs, or
between the cell densities in the top and bottom halves of the BVMs.
Although cell densities in some regions of the BVMs were statistically
significantly different from each other, boxplots showed that the median cell density in Lshaped BVMs and the average cell density in U-shaped BVMs still fell between 250,000
cells/cm2 and 350,000 cells/cm2. Human native cell densities may vary, and animals have
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exhibited a range of endothelial cell densities within the confluent endothelium of a
single blood vessel: canines have exhibited endothelial cell densities of 95,000 cells/cm2
in the ventral wall of the aortic arch orifice region but 155,000 cells/cm2 in the lesser
curvature of the aortic arch orifice region [75], and rabbits have exhibited endothelial cell
densities of 381,700 cells/cm2 in their thoracic aorta but 401,600 cells/cm2 in their
abdominal aorta [76]. Because a range of endothelial cell densities has been observed in
the endothelium of native blood vessels, and because the cell densities in all L- and Ushaped BVMs were approximately the same order of magnitude as native endothelial cell
densities, a complex-shaped BVM with the range of cell deposition that was identified in
this chapter may still result in the development of a confluent cell lining in all regions of
the complex-shaped BVM. Therefore, the statistically significantly different cell densities
observed in this study may not necessarily lead to formation of unevenly confluent cell
linings.
The statistical analysis of cell deposition that was presented in this chapter could
be used in future studies. Future studies may result in the development of confluent cell
linings in complex-shaped BVMs, and the statistical analysis from this chapter could be
compared to the confluent cell linings to determine whether statistically significant
differences in cell deposition affect the development of confluent cell linings. If
statistically significant differences in cell deposition do affect development of confluent
cell linings, cell deposition methods could be altered to improve development of
confluent cell linings.
An issue occurred with the BBI imaging of cells in the outer half of one of the Ushaped BVMs: the edges of the cells were not clearly defined. A possible explanation for
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this is as follows. The surface of ePTFE consists of nodes and internodal fibrils (Figure
3.18), and the cells in Figure 3.8 D appeared to organize in stripes on the scaffold. The
cells may have settled into the internodal regions, and BBI solution may have also settled
into the internodal regions and been resistant to blotting with a Kimwipe. The BBI
solution may not have been completely removed from the internodal regions, resulting in
BBI images that showed blurry blue dots. Although some BBI images were blurry, most
showed clearly identifiable blue dots, and the exclusion of the blurry BBI images from
statistical analyses was not detrimental to obtaining useful information in this study.

Fibrils
Node

50 µm

Figure 3.18. Luminal surface of eTPFE scaffold. Nodes are separated by fibrils. [77]

Although exclusion of the few blurry images was not detrimental to this study,
there was a possible drawback to the exclusion. The statistical comparison between the
cell densities in the inner and outer halves of U-shaped BVMs yielded a p-value of 0.057,
conveying that no statistically significant difference existed between the cell densities in
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the inner and outer halves of U-shaped BVMs. But 0.057 was only slightly outside the
range of p-values that would have conveyed that there was a statistically significant
difference (p < 0.05), and inclusion of the omitted cell density data may have reduced
0.057 to a p-value less than 0.05. To confirm or refute these results, a larger batch of Ushaped BVMs could be tissue-engineered, and the statistical comparison could be
performed again on the new U-shaped BVMs. But additional experiments that assess cell
deposition should not be attempted before development of a confluent cell lining is
attempted because development of a confluent cell lining on a complex-shaped scaffold is
more useful for coronary stent testing than additional cell deposition information.
In conclusion, statistically significant differences existed between 5 regions along
the length of L-shaped BVMs, between the inner and outer halves of L-shaped BVMs,
and between 5 regions along the length of U-shaped BVMs. But cells deposited with
average or median densities between 250,000 cells/cm2 and 350,000 cells/cm2 throughout
all regions of L- and U-shaped BVMs, which may be sufficient for formation of a
confluent cell lining throughout all regions of these complex-shaped BVMs. Therefore,
development of a confluent cell lining in complex-shaped BVMs was attempted.

81

4. Effect of Flow Rate on Cell Confluence in U-Shaped BVMs

4.1. Introduction
This chapter addresses the third specific aim of this thesis: determine whether
HUVECs can reach confluence on a complex-shaped scaffold using a cultivation protocol
similar to the straight-BVM cultivation protocol.
A potential first step toward determining whether HUVECs could reach
confluence on a complex-shaped scaffold was to cultivate complex-shaped BVMs using
the protocol that causes cells in the current straight BVM to reach confluence.
Development of a confluent cell lining in the current straight BVM involved cultivation
of the straight BVM over a period of more than 1 day and also involved adjustment of the
flow rate of media moving through the straight BVM lumen [59]. After pressure-sodding
HUVECs onto straight ePTFE scaffolds, straight BVMs were first cultivated for 1 day at
a flow rate of 1.6 mL/min, and this cultivation yielded cells that appeared balled-up, cell
coverage that was sparse, and cells that did not reach confluence [59]. After this 1 day of
cultivation, the flow rate was increased by 1.2 mL/min every hour until the flow rate
reached 12 mL/min [59]. Straight BVMs were then harvested after 3, 5, and 7 days of
cultivation [59]. After 3 days of cultivation, some cells were still balled-up, but cells
started to reach confluence [59]. After 5 and 7 days of cultivation, cells were no longer
balled-up, and cells had reached confluence [59].
Use of the straight BVM protocol to cause cells to reach confluence in complexshaped BVMs could present a challenge. In the previous chapter, cells were deposited
onto L- and U-shaped scaffolds at a density of 1.5 million cells/cm2, but the average or
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median cell density in the complex-shaped BVMs after 1 day of cultivation under a flow
rate of 1.2 mL/min was 250,000–350,000 cells/cm2, conveying that approximately 1.2
million cells/cm2 that were introduced into the complex-shaped scaffolds were not
adhered to the scaffolds after the 1 day of cultivation under flow. One potential
explanation for this is that flow pushes cells off complex-shaped scaffolds during
cultivation. Also, previous work has shown that a 4-mm-ID straight ePTFE scaffold
exhibits a wall shear stress of 0.225 dynes/cm2 when fluid that has a viscosity similar to
the viscosity of media flows luminally through the scaffold at a flow rate of 12 mL/min,
whereas a 4-mm-ID U-shaped ePTFE scaffold exhibits a wall shear stress of 1.75
dynes/cm2 when the same fluid flows luminally through the scaffold at the same flow
rate—the wall shear stress of a U-shaped scaffold is more than 7 times the wall shear
stress of a straight scaffold in this case [66]. Because flow may push cells off complexshaped scaffolds, and because U-shaped scaffolds experience higher wall shear stress
than straight scaffolds under a flow rate of 12 mL/min, a potential outcome after
cultivation of U-shaped and straight BVMs for 7 days at 12 mL/min is that fewer cells
remain adhered to U-shaped scaffolds than to straight scaffolds. If this potential outcome
is true, the fewer cells of U-shaped BVMs may then not be able to reach confluence. To
safeguard against this potential outcome, slower cultivation flow rates should be tested in
U-shaped BVMs in addition to testing the 12 mL/min that has been used to cultivate
straight BVMs.
The slower cultivation flow rates that are tested should be the least likely flow
rates that would push cells off scaffolds. A flow rate that would exert no force on cells is
0 mL/min. No flow may allow more cells to remain adhered to complex-shaped
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scaffolds, which may result in cells reaching confluence. Another flow rate that may be
least likely to push cells off scaffolds is a gradually increasing flow rate. Gradually
increasing flow rates are associated with better retention of cells on scaffolds than
abruptly increasing flow rates [78, 79]. The protocol for straight BVMs already includes
a gradually increasing flow rate: after 1 day of cultivation, the flow rate is increased by
1.2 mL/min every hour until the flow rate reaches 12 mL/min. But a flow rate that
increases even more gradually could further reduce the chance that flow pushes cells off
scaffolds. Therefore, complex-shaped BVMs were cultivated for 1 day using a cultivation
protocol identical to the cultivation protocol described in the previous chapter, then the
complex-shaped BVMs were further cultivated for up to 7 days at either 0 mL/min, a
flow rate that gradually increased over multiple days, or almost identical flow rates used
to cultivate straight BVMs. Cell confluence on the complex-shaped BVMs was assessed
after 4 and 7 days of cultivation with the goal of showing development of a confluent cell
lining over time.
To save time and resources and allow for faster discovery of successful laboratory
techniques as in the previous two chapters, these experiments were only attempted in Ushaped BVMs. U-shaped BVMs were chosen because the FDA in various cases has
recommended that coronary stents be tested in a worst-case clinically relevant radius of
curvature. The hypothesis in this case was that after deposition of HUVECs onto Ushaped scaffolds and cultivation similar to the straight-BVM protocol, cells would reach
confluence.
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4.2. Materials and Methods
6 U-shaped BVMs were cultivated in this study. For the first day of cultivation for
all 6 BVMs, the cultivation protocol described in Section 3.2.6 was used. After the first
day of cultivation, the BVMs were cultivated as follows: 2 BVMs at 0 mL/min (1 BVM
for 4 days, 1 BVM for 7 days), 2 BVMs at an increasing flow rate (1 BVM for 4 days, 1
BVM for 7 days), and 2 BVMs at 12 mL/min (1 BVM for 4 days, 1 BVM for 7 days).
Each pair of BVMs was tissue-engineered during separate weeks so that each pair of
BVMs could be attached to a separate pump with pump settings unique to that pair of
BVMs. Cell culture, BVM cultivation, and BVM evaluation were all performed within a
3-week period, and a protocol that identifies when various laboratory techniques were
used throughout the 3-week period is located in Appendix H. Each BVM was evaluated
using histology, BBI imaging, and scanning electron microscopy (SEM).

4.2.1. Cell Culture
HUVECs (Lonza) were cultured and expanded in T75 and T225 BD cell culture
flasks. Cells were cultured in HUVEC media, using the components and steps described
in Appendix C. The cells were maintained at 37˚C and 5% CO2 in the same small
incubator described in Section 3.2.1. During each passage from one flask to another flask,
cells were monitored using the same inverted light microscope described in Section 3.2.1.
When cells were pressure-sodded onto scaffolds, cells were no more than P8. Enough
cells were cultured so that approximately 1.5 million cells/cm2 were sodded onto each
scaffold.
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4.2.2. Sterilization and Media Preparation
The 6 scaffolds were made of 4-mm-ID ePTFE, each piece cut to a length of 5.5
cm. Female luer thread barbed fittings were inserted into both ends of each scaffold, and
both ends of each scaffold were sutured onto the fittings as described in Section 2.3.4.
The scaffolds, multifunctional bioreactors and associated fittings, bioreactor lids, twoport lids, forceps, and a degassing flask were all packaged and sterilized as described in
Section 3.2.2. Media was prepared as described in Section 3.2.2.

4.2.3. Scaffold Preparation and Priming
All scaffolds were denucleated and coated with protein as described in Section
3.2.3. Media was warmed in a water bath at 37˚C. The sterilized multifunctional
bioreactors, lids, two-port lids for media reservoirs, and forceps were gathered. The
scaffolds were inserted into multifunctional bioreactors in U-shapes using the same
techniques as described in Section 3.2.4.
Scaffolds and reservoirs were primed with conditioning media as described in
Section 3.2.4. Two-port lids were then connected to the bioreactors so that the inlets and
outlets of the two-port lids were correctly connected to the inlets and outlets of the
bioreactors. The complex-shaped BVM systems were attached to a peristaltic pump and
primed for 10 minutes at 150 rpm (12 mL/min). All inlets and outlets were closed, and
the complex-shaped BVM systems were left in the large incubator.
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4.2.4. Pressure-Sodding of HUVECs
Cell culture was carried out so that 1 T225 flask of HUVECs was devoted to each
scaffold. After the complex-shaped BVM systems were primed, the T225 flasks were
removed from the small incubator, and the cells were inspected. Cells were removed
from the bottom of the flasks using trypsin, and after all cells appeared to detach from the
flask bottom, trypsin in the flasks was deactivated. The suspension of cells in each flask
was transferred to its own 50-mL conical, and the conicals were centrifuged for 4
minutes. After centrifugation, the supernatant in the conicals was aspirated out, and the
pellets of cells were resuspended as described in Section 3.2.5.
Complex-shaped BVM systems were then brought out of the large incubator and
into the laminar flow hood as described in Section 3.2.5. Syringes were each filled with a
volume of 4 mL of cell suspension, and all 4 mL of cell suspension were injected
transmurally onto each scaffold. 5 mL of HUVEC media were then injected transmurally
onto each scaffold. Then all inlets and outlets were closed to prevent media backflow
from dislodging cells from scaffold pores, and the bioreactor outlets were reconnected to
the reservoir tubing. The reservoirs containing conditioning media were replaced with
reservoirs containing HUVEC media, the complex-shaped BVM systems were reattached
to the peristaltic pump in the large incubator, and the pump was immediately turned on to
a setting of 10 rpm (0.8 mL/min) to administer transmural flow.

4.2.5. Cultivation
Transmural flow at 10 rpm (0.8 mL/min) was maintained on all U-shaped BVMs
for 1 hour. Then the luminal outlet on all bioreactors was opened, and luminal flow at 10
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rpm (0.8 mL/min) was maintained for another hour. Luminal flow was then increased to
15 rpm (1.2 mL/min) and maintained overnight. After the first day of cultivation, each
pair of BVMs was cultivated according to one of the following protocols. For the pair of
BVMs allotted for cultivation at 0 mL/min, all inlets and outlets of the bioreactors were
closed, and the pump was turned off and unplugged; 1 of the BVMs was harvested after 4
days, and 1 of the BVMs was harvested after 7 days. With the latter BVM, new media
was placed in its reservoir after 3 days, and for 30 minutes every day until harvesting, the
pump was turned on to 0.8 mL/min (10 rpm) to circulate new media through the lumen of
the latter BVM. For the pair of BVMs allotted for cultivation at a gradually increasing
flow rate, the flow rate was increased by 1.2 mL/min (15 rpm) each day until 9 mL/min
(100 rpm) was achieved after 4 days; 1 of the BVMs was harvested after 4 days, and 1 of
the BVMs was harvested after 7 days with its media being changed after 3 days. For the
pair of BVMs allotted for cultivation at 12 mL/min, the flow rate was increased by 1.2
mL/min (15 rpm) every hour until 12 mL/min (150 rpm) was achieved; 1 of the BVMs
was harvested after 4 days, and 1 of the BVMs was harvested after 7 days with its media
being changed after 3 days.

4.2.6. Harvesting and Fixation
At the end of each time point, BVMs were harvested as described in Section
3.2.7, including removal of the complex-shaped BVM systems from the large incubator,
placement of the complex-shaped BVM systems on a nonsterile surface, removal of the
BVMs from the bioreactors using a razor blade, and fixation of the BVMs in Histochoice.
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4.2.7. Histologic Analysis, BBI Imaging, and SEM Imaging
Imaging of all BVMs was conducted with the goal of assessing whether a
confluent cell lining developed. All BVMs were first cut into the five segments shown in
Figure 3.6 B. Segments P2 and D1 were histologically analyzed using the protocol located
in Appendix L. Segments P1, M, and D2 were each cut in half longitudinally so that each
half had one of the blue lines that originally formed the double blue stripe on the ePTFE
scaffold. Segments P1, M, and D2 were analyzed via BBI imaging using the protocol
located in Appendix G, and segment M was analyzed a second time via SEM imaging
using the protocol located in Appendix K.
Segments allotted for histologic analysis were each embedded in paraffin wax at
the Cal Poly Tissue Analysis Laboratory. The segments were oriented in the paraffin wax
so that cross-sections could be sectioned. Cross-sections of the segments were then
sectioned at 6–8 µm and stained with hematoxylin and eosin. White light microscopy was
used to capture histology images of the entire circumference of the cross-sections. The
detailed protocol used for these histology procedures is located in Appendix L.
Segments allotted for BBI imaging were stained with BBI solution. The BBI
solution was prepared according to the protocol located in Appendix G. First, 1 mL of
BBI solution was placed in enough foil-wrapped 15-mL conicals so that each segment
was allotted a conical. The conicals were labeled with information that identified the
specific segment that was stored in that conical (e.g. “U-Shaped BVM, 0 mL/min, 4-day,
P1, inner”). The segments were left in the BBI solution overnight and then imaged
according to the protocol located in Appendix G. 4 images were taken of each scaffold
segment as described in Figure 3.6 C.
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Segments allotted for SEM imaging were first dehydrated in various dilutions of
ethanol as described in Appendix K. The segments were then dried overnight in a
dessicator. Segments were secured onto the specimen stand of a scanning electron
microscope, and 3 SEM images were captured evenly along the length of each segment.

4.3. Results
Multiple histologic cross-sections were obtained from each BVM, and a
representative histologic cross-section from each BVM was selected for inclusion in this
results section. A representative BBI image and a representative SEM image from each
BVM were also selected for inclusion in this results section. Histologic cross-sections,
BBI images, and SEM images for all BVMs showed cells that had not reached
confluence. Figures 4.1–4.18 show histologic images, BBI images, and SEM images for
all 6 BVMs, and a summary of the results is located in Table 4.1.

Table 4.1. Effect of Flow Rate on Confluence of Cell Lining in U-shaped BVMs
Flow Rate

4 Days of
Cultivation

7 Days of
Cultivation

Cells Reached
Confluence?

Sparse cell coverage Sparse cell coverage
(Figures 4.1–4.3)
(Figures 4.4–4.6)

No

Increasing over Sparse cell coverage Sparse cell coverage
multiple days
(Figures 4.7–4.9)
(Figures 4.10–4.12)

No

Sparse cell coverage Sparse cell coverage
(Figures 4.13–4.15) (Figures 4.16–4.18)

No

0 mL/min

12 mL/min
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Scaffold

Cells

Figure 4.1. Histologic cross-section of a U-shaped BVM cultivated at 0 mL/min for 4
days. The thick beige porous circle is the ePTFE scaffold, and the small dark purple spots
on the inner surface of the scaffold are cells. Around the entire circumference of the
cross-section, cells appear balled-up, cell coverage is sparse, and cells have not reached
confluence.
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100 µm
Figure 4.2. BBI image of a U-shaped BVM cultivated at 0 mL/min for 4 days. Sparse
blue dots confirm the sparse cell coverage shown in Figure 4.1.

Cell coverage

Fibrils
Node
100 µm

Figure 4.3. SEM image of a U-shaped BVM cultivated at 0 mL/min for 4 days. Thick
vertical lines are a part of the scaffold known as nodes, and the nodes are separated by
scaffold fibrils. The few cells confirm the sparse cell coverage shown in Figure 4.1.

92

Figure 4.4. Histologic cross-section of a U-shaped BVM cultivated at 0 mL/min for 7
days. Around the entire circumference of the cross-section, cells appear balled-up, cell
coverage is sparse, and cells have not reached confluence.

93

100 µm
Figure 4.5. BBI image of a U-shaped BVM cultivated at 0 mL/min for 7 days. Sparse
blue dots confirm the sparse cell coverage shown in Figure 4.4.

100 µm
Figure 4.6. SEM image of a U-shaped BVM cultivated at 0 mL/min for 7 days. The few
cells confirm the sparse cell coverage shown in Figure 4.4.
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Figure 4.7. Histologic cross-section of a U-shaped BVM cultivated at an increasing flow
rate for 4 days. Around the entire circumference of the cross-section, cells appear balledup, cell coverage is sparse, and cells have not reached confluence.
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100 µm
Figure 4.8. BBI image of a U-shaped BVM cultivated at an increasing flow rate for 4
days. Sparse blue dots confirm the sparse cell coverage shown in Figure 4.7.

100 µm
Figure 4.9. SEM image of a U-shaped BVM cultivated at an increasing flow rate for 4
days. The few cells confirm the sparse cell coverage shown in Figure 4.7.
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Figure 4.10. Histologic cross-section of a U-shaped BVM cultivated at an increasing
flow rate for 7 days. Air was in the lumen of this BVM just before harvest. Around the
entire circumference of this cross-section, cells appear fragmented, cell coverage is
sparse, and cells have not reached confluence.
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100 µm
Figure 4.11. BBI image of a U-shaped BVM cultivated at an increasing flow rate for 7
days. Sparse blue dots confirm the sparse cell coverage shown in Figure 4.10.

100 µm
Figure 4.12. SEM image of a U-shaped BVM cultivated at an increasing flow rate for 7
days. The few cells confirm the sparse cell coverage shown in Figure 4.10.
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Figure 4.13. Histologic cross-section of a U-shaped BVM cultivated at a flow rate of 12
mL/min for 4 days. Around the entire circumference of the cross-section, cells appear
balled-up, cell coverage is sparse, and cells have not reached confluence.
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100 µm
Figure 4.14. BBI image of a U-shaped BVM cultivated at a flow rate of 12 mL/min for 4
days. Sparse blue dots confirm the sparse cell coverage shown in Figure 4.13.

100 µm
Figure 4.15. SEM image of a U-shaped BVM cultivated at a flow rate of 12 mL/min for
4 days. The few cells confirm the sparse cell coverage shown in Figure 4.13.
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Figure 4.16. Histologic cross-section of a U-shaped BVM cultivated at a flow rate of 12
mL/min for 7 days. Around the entire circumference of the cross-section, cell coverage is
still sparse, and cells have not reached confluence. But cells have flattened out.
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100 µm
Figure 4.17. BBI image of a U-shaped BVM cultivated at a flow rate of 12 mL/min for 7
days. Sparse blue dots confirm the sparse cell coverage shown in Figure 4.16.

100 µm
Figure 4.18. SEM image of a U-shaped BVM cultivated at a flow rate of 12 mL/min for
7 days. The few cells confirm the sparse cell coverage shown in Figure 4.16.
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Throughout this study, two issues occurred with the complex-shaped BVM
systems. First, an O-ring inside one of the multifunctional bioreactors broke apart during
the first day of cultivation. Second, the two-port lid associated with the BVM that was
exposed to increasing flow and that was harvested after 7 days leaked during priming of
the two-port lid. Two-port lids have two fittings that are connected to tubing, and media
leaked from the fittings of the two-port lid during priming of the reservoir.

4.4. Discussion and Conclusions
Whether HUVECs could reach confluence on a complex-shaped scaffold using a
cultivation protocol that was similar to the straight-BVM cultivation protocol was
determined in this chapter. A confluent cell lining has been achieved in a straight BVM
by pressure-sodding HUVECs onto a straight ePTFE scaffold, then cultivating the
straight BVM for 1 day at a flow rate of 1.6 mL/min, then increasing the flow rate by 1.2
mL/min every hour until the flow rate reaches 12 mL/min, and then cultivating the
straight BVM at 12 mL/min for 6 more days [59]. An identical cultivation protocol was
used to cultivate U-shaped BVMs, but cells did not reach confluence. Because flow in Ushaped scaffolds may push more cells off the scaffolds than flow in straight scaffolds,
possibly resulting in subconfluent cell linings in U-shaped scaffolds, slower flow rates
were also used to cultivate U-shaped BVMs. But after cultivating U-shaped BVMs using
0 mL/min and a gradually increasing flow rate that did not exceed 12 mL/min, cells still
did not reach confluence. Therefore, these findings did not support the hypothesis that
after deposition of HUVECs onto U-shaped scaffolds and cultivation similar to the
straight-BVM protocol, cells would reach confluence.
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These findings do reveal information about the effect of flow rate on cells in Ushaped BVMs. As seen in the previous chapter, after 1 day of cultivation at a flow rate of
1.2 mL/min, U-shaped BVMs exhibited dense cell coverage (Figure 4.19 A). Then after 3
more days of cultivation at a flow rate of 12 mL/min, U-shaped BVMs exhibited
noticeably sparser cell coverage (Figure 4.19 B). Therefore, U-shaped BVMs may exhibit
a loss of cells when cultivated at 12 mL/min after the first day of cultivation. But even
when the 3 additional days of cultivation occurred under no flow at all, U-shaped BVMs
still exhibited a noticeable loss of cells (Figure 4.19 C). Therefore, flow may not cause
the noticeable loss of cells; instead, the scaffold may cause the noticeable loss of cells.
But, although the loss of cells with flow (Figure 4.19 B) does not appear significantly
larger than the loss of cells without flow (Figure 4.19 C), the loss of cells could be
statistically significantly larger with flow than without flow. If the loss of cells is
statistically significantly larger with flow than without flow, flow may still be pushing
cells off the scaffold even though it may not be noticeable to the naked eye in Figures
4.19 B and C.

104

A

100 µm
B

100 µm
C

100 µm
Figure 4.19. Cell loss after first day of cultivation of U-shaped BVMs. With 1 day of
cultivation, U-shaped BVMs exhibit dense cell coverage (A). After an additional 3 days
of cultivation at a flow rate of 12 mL/min, U-shaped BVMs exhibited a noticeable loss of
cells (B). But even after the additional 3 days of cultivation under no flow at all, Ushaped BVMs still exhibited a noticeable loss of cells (C).
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If flow pushes cells off the scaffold, flow may also be responsible for cells not
reaching confluence in U-shaped BVMs after 7 days of cultivation. When straight BVMs
are cultivated for 1 day at a flow rate of 1.6 mL/min and then for 2 additional days at a
flow rate of 12 mL/min, straight BVMs exhibit sparse cell coverage [59], and sparse cell
coverage also occurs around the same time point in U-shaped BVMs that have been
cultivated at almost identical flow rates. But straight BVMs then go on to exhibit a
confluent cell lining after 7 days of cultivation, while U-shaped BVMs go on to still
exhibit sparse cell coverage after 7 days of cultivation. A potential explanation for this is
described as follows. The unique flow in a U-shaped scaffold that results in higher wall
shear stress may push more cells off the scaffold than the flow in a straight scaffold that
results in lower wall shear stress, resulting in more spaces of bare scaffold between cells
on the U-shaped scaffold. Cells on a straight scaffold may then only have to spread out to
contact neighboring cells, whereas cells on a U-shaped scaffold may have to spread out
but also migrate to contact neighboring cells. During 7 days of cultivation, cells on the Ushaped scaffold may have been continuously pushed off the scaffold before contacting
any neighboring cells and therefore may never have been able to reach confluence,
whereas cells on the straight scaffold may have been pushed off the scaffold less often,
were therefore able to contact neighboring cells more easily, and were therefore able to
reach confluence. Again, this explanation is possible only if the loss of cells between 1
and 4 days of cultivation is statistically significantly larger with flow than without flow.
A limitation of the experimental design of this study was that no 1-day U-shaped
BVMs were developed as controls to monitor cell deposition on the scaffolds. Although
the multiple 1-day U-shaped BVMs in the previous chapter all exhibited average or
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median densities between 250,000 cells/cm2 and 350,000 cells/cm2, it is still possible that
the BVMs described in the current chapter exhibited significantly less cell deposition,
resulting in subconfluent cell linings. For example, any missteps during pressure-sodding
may have resulted in significantly less cell deposition. Therefore, it is possible that
significantly less cell deposition—not high wall shear stress nor the scaffold—caused the
subconfluent cell linings seen in this chapter. Future studies that aim to assess cell lining
development over time should therefore always include 1-day control BVMs so that cell
deposition is monitored.
Because the protocols for tissue-engineering a U-shaped BVM that were proposed
in this chapter did not cause cells to reach confluence, one of the proposed protocols must
be selected as the best proposed protocol and then altered in a way that will likely cause
cells to reach confluence. The U-shaped BVMs that were cultivated with the flow rate of
12 mL/min did exhibit flattened cells (Figure 4.16), while U-shaped BVMs that were
cultivated with the other protocols exhibited no flattened cells. Therefore, the protocol
that utilized the flow rate of 12 mL/min was selected as the best of the three protocols
proposed in this chapter.
Three issues occurred during this study: (1) an O-ring inside one of the
multifunctional bioreactors broke apart during the first day of cultivation, (2) the two-port
lid associated with the BVM shown in Figure 4.10 leaked during priming of the two-port
lid, and (3) cells appeared fragmented in the BVM shown in Figure 4.10. Air was found
in the lumen of the BVM shown in Figure 4.10, and the cells may have died and
fragmented as a result of exposure to the air; the air could have entered the complex-
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shaped BVM system via the leak in the two-port lid. Replacement of O-rings in complexshaped BVM systems could ameliorate issues 1 and 2 and is described in Appendix B.
In conclusion, this study showed that cultivation of complex-shaped BVMs using
the protocol from current straight BVMs does not cause cells to reach confluence. This
study also showed that U-shaped BVMs may exhibit a noticeable loss of cells between
the first and fourth days of cultivation whether cultivated at a flow rate of 12 mL/min or
under no flow at all between the first and fourth days of cultivation. Lastly, this study
resulted in the development of a cultivation protocol that yielded a U-shaped BVM with
flattened cells; potential alterations to this protocol were therefore proposed, and an
alteration was selected and implemented as described in the following chapters.
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5. Possible Cell Denudation After Stent Deployment in a U-Shaped BVM

5.1. Introduction
This chapter addresses the fourth specific aim of this thesis: determine whether a
complex-shaped BVM that was developed using only HUVECs would exhibit denudation
of its cell lining after coronary stent deployment.
Two criteria that should be considered when evaluating a potential alteration to
the selected protocol from the previous chapter are: (1) the ability of the alteration to
cause cells to reach confluence on U-shaped scaffolds and (2) the ability of the alteration
to generate U-shaped BVMs capable of exhibiting re-endothelialization of a coronary
stent. Two potential alterations are (1) the coating of U-shaped scaffolds with something
that improves cell retention on the scaffold and (2) the use of other cell types that exhibit
better retention on U-shaped scaffolds than HUVECs.
Whether the proposed alterations potentially meet the first criterion has been
determined in previous work. When polytetrafluorethylene (PTFE) is coated with either
fibronectin, RGD-containing peptide, laminin, or gelatin, attachment of HUVECs
significantly improves [80]. When PTFE is coated with either fibronectin, RGDcontaining peptide, laminin, gelatin, or collagen type I and/or III, proliferation of
HUVECs significantly improves [80]. Therefore, coatings affect HUVEC behavior in
ways that could lead to confluence. Also, the formation of a thick (140-µm) confluent
cell lining has resulted from the use of human umbilical vein smooth muscle cells
(HUVSMCs) in combination with HUVECs on straight ePTFE scaffolds: a confluent cell
lining formed after pressure-sodding HUVSMCs and HUVECs onto straight ePTFE
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scaffolds, cultivating the cell-sodded scaffolds at a flow rate of 1.6 mL/min for 1 day,
increasing the flow rate by 1.2 mL/min every hour until a flow rate of 12 mL/min was
achieved, and cultivating the cell-sodded scaffolds for 6 more days at a flow rate of 12
mL/min [59]. Therefore, a cell type other than HUVECs may result in the formation of a
confluent cell lining. These examples show that both proposed alterations may meet the
first criterion.
Whether the coating of U-shaped scaffolds potentially meets the second criterion
can be determined by examining the effect of stent deployment on the native
endothelium. The native endothelium is a monolayer—a cell lining that is only 1 cell
thick. When stent deployment was studied in human coronary arteries via SEM, no
endothelial cells could be found in the implantation zone during the acute phase (< 6
weeks) [68]. Stent deployment also disrupts the internal elastic lamina beneath the
endothelium [81], exposing smooth muscle cells beneath the internal elastic lamina [82].
Therefore, stent deployment in a U-shaped BVM may completely denude a HUVEC
monolayer and thin scaffold coating in the implantation zone, resulting in an implantation
zone that consists of simply a bare scaffold exhibiting poor retention of HUVECs. The
bare scaffold may then exhibit no re-endothelialization of a coronary stent, suggesting
that the stent would exhibit poor re-endothelialization when implanted in a native
coronary artery even though the stent may actually re-endothelialize very well in a native
artery. Therefore, the coating of U-shaped scaffolds may not meet the second criterion
and therefore may not be the best alteration to the selected protocol.
Complete denudation of a HUVEC monolayer in the implantation zone of a Ushaped BVM is only a prediction. But this prediction may be supported by deploying a
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stent in a U-shaped BVM that was developed using one of the three proposed protocols
from the previous chapter and by assessing whether denudation occurs in that BVM.
Although cell coverage was sparse after cultivation using the three proposed protocols
from the previous chapter, cells still remained on all the scaffolds. Deployment of a stent
in one of those U-shaped BVMs could result in images that simply show a bare scaffold,
suggesting complete denudation of the sparse monolayer of cells, or images that show an
intact sparse monolayer, suggesting that stent deployment does not cause complete
denudation. Therefore, to determine whether complete denudation actually occurs, a stent
was deployed in a U-shaped BVM that was developed using a protocol similar to one of
the protocols from the previous chapter. The hypothesis in this case was that a complexshaped BVM that was developed using only HUVECs would exhibit no cell lining after
coronary stent deployment.
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5.2. Materials and Methods
Two U-shaped BVMs were cultivated in this study using a protocol similar to the
protocol from the previous chapter that utilized a flow rate of 0 mL/min. After cultivation
of both BVMs, a stent was deployed in one of the BVMs, while no stent was deployed in
the other BVM. Cell culture, BVM cultivation, stent deployment, and evaluation of the
BVMs and stent were all performed within a 4-week period. Both BVMs were evaluated
using BBI imaging, and the stent was evaluated using SEM imaging.

5.2.1. Cell Culture
HUVECs (Lonza) were cultured and expanded in T75 and T225 BD cell culture
flasks. Cells were cultured in HUVEC media (Appendix C). The cells were maintained at
37˚C and 5% CO2 in a small incubator and monitored using an inverted light microscope.
When cells were pressure-sodded onto scaffolds, cells were no more than P8. Enough
cells were cultured so that approximately 1.5 million cells/cm2 were sodded onto each
scaffold.

5.2.2. Scaffold Sterilization, Scaffold Preparation, and Priming
The 2 scaffolds were prepared and sterilized as described in Section 4.2.2. The
scaffolds were denucleated and coated with protein as described in Section 3.2.3. The
scaffolds were inserted into multifunctional bioreactors in U-shapes. Scaffolds and
reservoirs were primed with conditioning media as described in Section 3.2.4. Two-port
lids were then connected to the bioreactors so that the inlets and outlets were correctly
connected to the inlets and outlets of the bioreactors. The complex-shaped BVM systems
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were attached to the 8-roller peristaltic pump and primed for 10 minutes at 150 rpm (12
mL/min). All inlets and outlets were closed, and the complex-shaped BVM systems were
left in the large incubator.

5.2.3. Pressure-Sodding of HUVECs
Cell culture was carried out so that 1 T225 flask of HUVECs was devoted to each
scaffold. After the complex-shaped BVM systems were primed, the T225 flasks were
removed from the small incubator, and the cells were inspected. The cells were removed
from the flasks, centrifuged so that they formed a pellet, and resuspended. Syringes were
filled with the cell suspension, the cell suspension was injected transmurally onto each
scaffold. All inlets and outlets were closed to prevent media backflow from dislodging
cells from scaffold pores. The reservoirs containing conditioning media were replaced
with reservoirs containing HUVEC media, the complex-shaped BVM systems were
reattached to the peristaltic pump in the large incubator, and the pump was immediately
turned on to a setting of 10 rpm (0.8 mL/min) to administer transmural flow.

5.2.4. Cultivation
Transmural flow at 10 rpm (0.8 mL/min) was maintained on both U-shaped
BVMs for 1 hour. Then the luminal outlet on both bioreactors was opened, and luminal
flow at 10 rpm (0.8 mL/min) was maintained for another hour. Luminal flow was then
increased to 15 rpm (1.2 mL/min) and maintained overnight. After the first day of
cultivation, all inlets and outlets of the bioreactors were closed, and the pump was turned
off and unplugged. New media was placed in the reservoirs for each BVM every 3 days.
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After 4, 5, 6, 7, 9, 11, and 13 days of cultivation, the pump was turned on to 0.8 mL/min
(10 rpm) for 30 minutes to circulate new media through the lumen of the BVMs. After 14
days of cultivation, one of the BVMs was harvested as described in Section 4.2.6, and a
stent was deployed in the other BVM as described in the following section.

5.2.5. Stent Deployment
A bare metal stent (4.0 mm x 38 mm coronary stent, Guidant Corporation) was
deployed into one of the BVMs after 14 days of BVM cultivation. First, the BVM was
detached from the pump and taken into the laminar flow hood, and the lid of the
bioreactor was removed and set aside in the hood. The stent was deployed by inserting a
stent-loaded balloon catheter into the luminal inlet of the multifunctional bioreactor. The
stent was visible through the silicone tubing and through the BVM. The tip of the catheter
scraped the inside of the BVM as the tip negotiated the U-shape. The stent was not
completely inserted into the BVM—as it did not reach the distal 1 cm of the BVM. The
inflation device was then triggered in an attempt to inflate the balloon, but instead 15 mL
of saline solution was injected directly into the BVM lumen because the catheter was set
up incorrectly. The catheter was reconfigured, the balloon was successfully inflated to 8
atm, and the pressure was maintained for 10 seconds. The balloon was then deflated, and
the catheter was removed, leaving behind the deployed stent in the BVM. The lid was
placed back on the bioreactor, and the complex-shaped BVM system now containing the
deployed stent was placed back into the large incubator and connected to the pump.
Luminal flow was maintained at 0.8 mL/min (10 rpm) for 1.5 hours and was then
increased to 1.2 mL/min (15 rpm) and allowed to run overnight. The next day, the flow
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rate was increased to 25 rpm and maintained for 1 hour, then increased to 35 rpm and
maintained for 1 hour, then increased to 60 rpm and maintained for 1 hour, then increased
to 75 rpm and maintained for 1 hour, and then increased to 100 rpm and maintained for 2
days. After the 2 days, the pump was turned off, the complex-shaped BVM system was
removed from the pump, and the stented BVM was harvested from the bioreactor and
fixed in Histochoice.

5.2.6. BBI and SEM Imaging
Both BVMs were cut in half longitudinally. After cutting the stented BVM in
half, the stent halves fell out of the BVM halves. All BVM halves were stained with BBI,
and en face fluorescent images were captured along the length the BVM halves using a
fluorescent microscope. Both stent halves underwent the dehydration protocol for SEM
imaging (Appendix K). The stent halves were then dried overnight in a dessicator, and en
face images of the stent struts were captured using a scanning electron microscope.

5.3. Results
A coronary stent was successfully deployed in a U-shaped BVM that was housed
in a multifunctional bioreactor: the catheter was easily fed into the bioreactor, the stent
was visible through the silicone tubing and through the U-shaped BVM, and the tip of the
catheter was able to negotiate the U-shape of the BVM. When the stent was deployed, the
stent straightened out the U-shaped BVM (Figure 5.1). When the stented BVM was cut in
half longitudinally, the BVM relaxed away from the more rigid stent (Figure 5.2).
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A

B

Figure 5.1. Stent deployment in a U-shaped BVM. Before stent deployment, the Ushaped BVM is not straightened out (A). After stent deployment, the stent straightens out
the U-shape (B).

BVM separated
from stent

BVM

Stent

Figure 5.2. Separation of a U-shaped BVM from a rigid coronary stent. The U-shaped
BVM relaxed away from the stent halves, and eventually the BVM completely separated
from the stent.

BBI images of the non-stented BVM showed a sparse cell lining similar to the Ushaped BVMs in the previous chapter (Figure 5.3), whereas BBI images of the stented
BVM showed no cells (Figure 5.4). SEM images of the stent showed no cell coverage
(Figure 5.5).
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100 µm
Figure 5.3. BBI image of a U-shaped BVM with no implanted stent. A sparse cell lining
developed similar to the sparse cell lining of U-shaped BVMs in the previous chapter.

100 µm
Figure 5.4. BBI image of a U-shaped BVM after stent implantation. No cells are present
on the scaffold.
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100 µm
Figure 5.5. Stent strut after implantation in a U-shaped BVM. No cells are visible on the
stent strut. All stent struts appeared this way.

5.4. Discussion and Conclusions
Deployment of a stent in a U-shaped BVM was performed as described in this
chapter to determine whether a stent denudes cells from the luminal surface of a Ushaped BVM. Two U-shaped BVMs were cultivated, and a stent was implanted in one of
the BVMs. After harvesting, the non-stented BVM exhibited a sparse cell lining similar
to the sparse cell lining of U-shaped BVMs in the previous chapter, whereas the stented
BVM exhibited no cell lining of any kind. These findings support the hypothesis that a
complex-shaped BVM that was developed using only HUVECs would exhibit no cell
lining after coronary stent deployment, although the cause of the cell loss was not
determined. Also, no cells appeared on any stent struts, conveying that cells absent from
the stented BVM were not located on the stent struts. Therefore, stent deployment may
denude cells from a U-shaped BVM.
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This study did not show whether stent deployment actually denuded cells from a
U-shaped BVM because the stented BVM was assessed 2 days after stent deployment. To
show whether stent deployment actually denuded cells, the stented BVM should have
been assessed immediately after stent deployment. But regardless of how stent
deployment immediately affected the cell lining, no cell lining regenerated anywhere
throughout the stented BVM 2 days after stent deployment. For a U-shaped BVM to
convey any information about the tissue response multiple days after stent deployment,
cells must be present on the scaffold multiple days after stent deployment. Therefore, the
selected protocol from the previous chapter should be altered in a way that allows at least
some cells to remain on the scaffold multiple days after stent deployment.
Since stent deployment may denude a monolayer of cells from a U-shaped BVM,
possibly resulting in no regeneration of any cell lining multiple days after stent
deployment, U-shaped BVMs should be developed to better withstand stent deployment.
A cell type that can form multiple cell layers may allow U-shaped BVMs to withstand
denudation of a monolayer of cells and then still exhibit re-endothelialization of a stent,
whereas a thin layer of coating that improves formation of a HUVEC monolayer on Ushaped scaffolds may be denuded during stent deployment and result in areas of the
scaffold that exhibit poor retention of HUVECs, possibly leading to a lack of cell
migration onto the stent and therefore an inaccurate portrayal of the stent’s ability to reendothelialize. For these reasons, the first alteration that should be made to the selected
protocol from the previous chapter should not involve coatings but instead should involve
a modification of the cell type that is used to tissue-engineer U-shaped BVMs.
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This study generated other useful information about stent deployment in a Ushaped BVM. A coronary stent was successfully deployed, which validated the complexshaped BVM system for coronary stent testing. Also, during stent deployment, the stent
straightened out the U-shape of the BVM, and this straightening also occurs when a
coronary stent is deployed in human coronary arteries [60]. The straightening in human
coronary arteries creates areas of low endothelial shear stress [61, 62], which may cause
the endothelium to re-establish itself more slowly [63]. Therefore, the ability of the Ushaped BVM to mimic the straightening that occurs in native human coronary arteries
may yield more accurate assessments of stent re-endothelialization.
A potential issue in this study was that the U-shaped BVM separated from the
rigid stent when the stented BVM was cut in half. With future U-shaped BVMs that have
confluent cell linings and that are fully capable of testing stents for re-endothelialization,
it may be desirable for the stent to remain completely apposed to the BVM wall after
being cut in half. Cell coverage on the stent may in fact keep the stent completely
apposed to the BVM wall after cutting, but if cell coverage alone does not secure the
stent in place, the U-shaped BVM may separate from the rigid stent. This separation
could disrupt cell coverage on the stent, and the disrupted cell coverage could be falsely
interpreted as the stent’s poor ability to re-endothelialize. A possible solution to this
separation is to suture the BVM to the stent struts at various locations along the length of
the BVM just before cutting so that the two entities do not separate. Also, the separation
could be avoided altogether by performing plastic embedding instead of the previously
described cutting method.
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In conclusion, this study showed that a U-shaped BVM may exhibit cell
denudation after stent implantation, possibly resulting in no regeneration of any cell
lining multiple days after stent deployment, this study validated the complex-shaped
BVM system for coronary stent testing, and this study showed that a U-shaped BVM
mimics the straightening effect that occurs when coronary stents are implanted into
human coronary arteries. Because a U-shaped BVM may exhibit cell denudation after
stent deployment, a U-shaped BVM will next be tissue-engineered using a cell type that
can form multiple cell layers so that the top layer of cells may be denuded while layers
beneath remain intact after stent deployment.
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6. Development of a Confluent Region of Cells in a U-Shaped BVM

6.1. Introduction
This chapter addresses the fifth specific aim of this thesis: develop a confluent
region of cells in a U-shaped BVM. Because a complex-shaped BVM may exhibit
denudation of its cell lining after coronary stent deployment, the confluent region of cells
must be developed using a cell type that is known to form multiple cell layers.
To achieve the fifth specific aim of this thesis, two cell types were used. Although
a cell type that forms multiple layers may allow a U-shaped BVM to better withstand
stent deployment, cell types that form multiple layers are typically not endothelial cells—
endothelial cells are contact inhibited and form only monolayers [67]. But throughout this
thesis, BVMs have been developed with the goal of modeling re-endothelialization of
coronary stents, therefore endothelial cells still must be included in the U-shaped BVM.
Therefore, to satisfy the new requirement of being able to withstand denudation of a top
layer of cells, but to still satisfy the original requirement of being able to model reendothelialization, two cell types must be used.
Previous work has resulted in the successful development of straight BMVs by
sodding two cell types onto a straight scaffold: HUVECs and HUVSMCs. The protocol
that was used to develop the dual-sodded straight BVM is described as follows. First,
HUVSMCs were pressure-sodded onto a straight ePTFE scaffold, and the straight BVM
was transmurally cultivated at a flow rate of 0.8 mL/min (10 rpm) for 30 minutes [59].
HUVECs were then pressure-sodded onto the scaffold, and the dual-sodded BVM was
transmurally cultivated at a flow rate of 0.8 mL/min (10 rpm) for 30 more minutes [59].
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The dual-sodded BVM was then luminally cultivated at a flow rate of 0.8 mL/min (10
rpm) for an hour and then at a flow rate of 1.6 mL/min (20 rpm) overnight [59]. After
dual-sodded straight BVMs were cultivated for just 1 day, they were harvested [59].
Additional dual-sodded straight BVMs were cultivated for more than 1 day, where the
flow rate was increased by 1.2 mL/min every hour until 12 mL/min (150 rpm) was
achieved [59]. These dual-sodded straight BVMs were then cultivated for either 3, 5, or 7
days [59]. After all periods of cultivation—1, 3, 5, and 7 days—confluent cell linings
formed [59]. After 7 days of cultivation, a multilayer cell lining formed [59]. Because the
protocol for developing a dual-sodded straight BVM resulted in formation of a confluent
cell lining, the protocol was used to develop a U-shaped BVM with the goal of
specifically developing a confluent multilayer region of cells. The hypothesis in this case
was that a confluent region of cells would form in a U-shaped BVM.

6.2. Materials and Methods
Dual-sodded straight BVMs exhibited total cell coverage after 1 day of
cultivation. To be able to compare the results of this study to the dual-sodded straight
BVMs, dual-sodded U-shaped BVMs were cultivated for 1 day. Previous HUVEC-only
U-shaped BVMs exhibited dense cell coverage after 1 day of cultivation but sparse cell
coverage after 4 days of cultivation. To be able to compare the results of this study to
previous HUVEC-only U-shaped BVMs, additional dual-sodded U-shaped BVMs were
cultivated for 4 days. In total, 6 dual-sodded U-shaped BVMs were cultivated in this
study: 3 were cultivated for 1 day, and 3 were cultivated for 4 days. All 6 were cultivated
using a protocol almost identical to the protocol described in the introduction of this

123

chapter. Cell culture, BVM cultivation, and BVM evaluation were all performed within a
3-week period. A protocol that identifies when various laboratory techniques were used
throughout the 3-week period is located in Appendix O. After cultivation, the BVMs
were evaluated via histology, fluorescence imaging, and SEM imaging. Also, SEM
images of a previous 1-day HUVEC-only U-shaped BVM were captured so that 1-day
dual-sodded U-shaped BVMs could be compared to 1-day HUVEC-only U-shaped
BVMs.

6.2.1. Cell Culture
HUVECs and HUVSMCs were each cultured and expanded in T75 and T225 BD
cell culture flasks. HUVECs were cultured in HUVEC media (Appendix C). HUVSMCs
were cultured in HUVSMC media using the components and steps described in Appendix
M. The cells were maintained at 37˚C and 5% CO2 in a small incubator and monitored
using an inverted light microscope. When cells were pressure-sodded onto scaffolds,
HUVECs were no more than P8, and HUVSMCs were no more than P16. Enough
HUVECs were cultured so that approximately 1.5 million cells/cm2 were sodded onto
each scaffold, and enough HUVSMCs were cultured so that approximately 1.5 million
cells/cm2 were sodded onto each scaffold. To identify HUVECs and HUVSMCs via
fluorescence microscopy after BVM cultivation, Cell Tracker™ Red dye (Invitrogen,
catalog number C34522) and Cell Tracker™ Green dye (Invitrogen, catalog number C
7025) were administered to the T225 flasks of HUVECs and HUVSMCs respectively just
before the cells were centrifuged. Cell Tracker™ dyes pass freely through cell
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membranes but then transform into cell-impermeable reaction products. The use of Cell
Tracker™ will be discussed further in later subsections of this chapter.

6.2.2. Scaffold Sterilization, Scaffold Preparation, and Priming
6 scaffolds were prepared and sterilized as described in Section 4.2.2. All
scaffolds were denucleated and coated with protein as described in Section 3.2.3. The
scaffolds were inserted into multifunctional bioreactors in U-shapes. Scaffolds and
reservoirs were primed with conditioning media as described in Section 3.2.4. The
complex-shaped BVM systems were attached to an 8-roller peristaltic pump and primed
for 10 minutes at 150 rpm (12 mL/min). All inlets and outlets were closed, and the
complex-shaped BVM systems were left in the large incubator.

6.2.3. Pressure-Sodding of HUVSMCs
Cell culture was carried out so that 1 T225 flask of HUVSMCs was devoted to
each scaffold. While complex-shaped BVM systems were being primed, dual-sodding
media was prepared by simply combining HUVSMC media and HUVEC media,
resulting in a media that was 25% HUVSMC media and 75% HUVEC media; this
specific media was used to successfully cultivate previous dual-sodded BVMs [83]. After
the complex-shaped BVM systems were primed, the HUVSMC T225 flasks were
removed from the small incubator, and the cells were inspected. The cells were removed
from the flasks, centrifuged so that they formed a pellet, and resuspended. Syringes were
filled with the cell suspension, the cell suspension was injected transmurally onto each
scaffold. All inlets and outlets were closed to prevent media backflow from dislodging
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cells from scaffold pores. The reservoirs containing conditioning media were replaced
with reservoirs containing dual-sodding media, the complex-shaped BVM systems were
reattached to the peristaltic pump in the large incubator, and the pump was immediately
turned on to 10 rpm (0.8 mL/min) to administer transmural flow for 30 minutes.

6.2.4. Pressure-Sodding of HUVECs
During the 30 minutes of transmural flow, the HUVEC T225 flasks were removed
from the small incubator, and the cells were inspected. The cells were removed from the
flasks, centrifuged so that they formed a pellet, and resuspended. The complex-shaped
BVM systems were taken off the peristaltic pump, and the cell suspension was injected
transmurally onto each scaffold. All inlets and outlets were closed, the complex-shaped
BVM systems were reattached to the peristaltic pump in the large incubator, and the
pump was immediately turned on to 10 rpm (0.8 mL/min) to administer transmural flow
for 30 more minutes.

6.2.5. Cultivation
After the 30 additional minutes of transmural flow, the luminal outlet on all
bioreactors was opened, and luminal flow at 10 rpm (0.8 mL/min) was maintained for 1
hour. Luminal flow was then increased to 20 rpm (1.2 mL/min) and maintained
overnight. After the overnight cultivation, 3 BVMs were harvested, and the flow rate of
the 3 other BVMs was increased by 15 rpm (1.2 mL/min) every hour until 150 rpm (12
mL/min) was achieved. This flow rate was maintained until the BVMs were harvested
after 4 days of cultivation.
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6.2.6. Histologic Analysis, Fluorescence Imaging, and SEM Imaging
Imaging of all BVMs was conducted with the goal of assessing whether a
confluent multilayer cell lining developed. All BVMs were first cut into the 5 segments
shown in Figure 3.6 B. Segments P2 and D1 were histologically analyzed using the
protocol located in Appendix K. Segments P1, M, and D2 were cut in half longitudinally
so that each half had one of the blue lines that originally formed the double blue stripe on
the ePTFE scaffold. Segments P1, M, and D2 were analyzed via fluorescence imaging
using the protocol located in Appendix G, and segment M was analyzed a second time
via SEM imaging using the protocol located in Appendix K.
The Cell Tracker™ dyes were intended to identify HUVSMCs and HUVECs in
the cell lining that developed in the BVMs. HUVSMCs were stained with Cell Tracker™
Green dye (Invitrogen, catalog number C 7025), and HUVECs were stained with Cell
Tracker™ Red dye (Invitrogen, catalog number C34522). Stock solutions of Cell
Tracker™ were prepared by following a previously established protocol [84]; appendix N
describes the preparation of Cell Tracker™ in more detail. Briefly, Cell Tracker™
powder was diluted to a concentration of 10 mM using DMSO to create a stock solution,
and the stock solution was mixed with media to yield a desired concentration of working
solution. When white light images of histologic cross-sections were being captured using
an Olympus BX41 microscope, 2 fluorescent images of the identical fields of view of the
histologic cross-sections were also captured: 1 fluorescent image was captured so that
structures fluoresced green, and a second fluorescent image was captured so that
structures fluoresced red. The white light image and the 2 fluorescent images were then
compared to determine the location of HUVSMCs and HUVECs in the cell lining.
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Segments allotted for BBI imaging were stained with BBI solution. The BBI
solution was prepared according to the protocol located in Appendix G. First, 1 mL of
BBI solution was placed in enough foil-wrapped 15-mL conicals so that each segment
was allotted a conical. The conicals were labeled with information that identified the
specific segment that was stored in that conical. The segments were left in the BBI
solution overnight and then imaged according to the protocol located in Appendix G. 4
images were taken of each scaffold segment as described in Figure 3.6 C.
Segments allotted for SEM imaging were first dehydrated in various dilutions of
ethanol as described in Appendix K. The segments were then dried overnight in a
dessicator. Segments were secured onto the specimen stand of a scanning electron
microscope, and 3 SEM images were captured evenly along the length of each segment.
Also, SEM images of a previous 1-day HUVEC-only U-shaped BVM were captured.

6.3. Results
Multiple histologic cross-sections were obtained from each BVM, and two
representative histologic cross-sections were selected for inclusion in this results section:
1 histologic cross-section that represents the BVMs cultivated for 1 day, and 1 histologic
cross-section that represents the BVMs cultivated for 4 days. Representative BBI images
and SEM images were selected the same way. A dual-sodded U-shaped BVM cultivated
for 1 day exhibited a confluent region of cells (Figure 6.1), but all other histologic crosssections, BBI images, and SEM images for all BVMs showed subconfluent cell linings
similar to the cell linings in chapter 4. Figures 6.2–6.7 show images for dual-sodded Ushaped BVMs cultivated in this study for 1 and 4 days.
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100 µm
Figure 6.1. Confluent region of cells in a U-shaped BVM cultivated for 1 day. A fully
confluent region of cells formed on the outer half of segment M in a dual-sodded Ushaped BVM. All other SEM images from this BVM and from all other 1-day dualsodded U-shaped BVMs showed cell coverage as depicted in Figure 6.4.
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Figure 6.2. Histologic cross-section of a dual-sodded U-shaped BVM cultivated for 1
day. The entire circumference of the cross-section is covered with cells, and cells appear
mostly spread-out.
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100 µm
Figure 6.3. BBI image of a dual-sodded U-shaped BVM cultivated for 1 day. Entire
image is filled with blue dots—no dark spaces devoid of cells appear between blue dots.

100 µm
Figure 6.4. SEM image of a dual-sodded U-shaped BVM cultivated for 1 day. Cell
coverage is sparse compared to the confluent region of cells in Figure 6.1.
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Figure 6.5. Histologic cross-section of a dual-sodded U-shaped BVM cultivated for 4
days at a flow rate of 12 mL/min. The entire circumference of the cross-section is
covered with cells, and many cells appear spread-out. More cell coverage is apparent in
this 4-day dual-sodded U-shaped BVM compared to the 4-day HUVEC-only U-shaped
BVMs shown in Figures 4.1, 4.7, and 4.13.
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100 µm
Figure 6.6. BBI image of a dual-sodded U-shaped BVM cultivated for 4 days at a flow
rate of 12 mL/min. Blue dots indicate cells.

100 µm
Figure 6.7. SEM image of a dual-sodded U-shaped BVM cultivated for 4 days at a flow
rate of 12 mL/min. More cell coverage appears in this BVM compared to the 4-day
HUVEC-only U-shaped BVMs shown in Figures 4.3, 4.9, and 4.15.
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In the fluorescent images that were intended to show HUVSMCs fluorescing
green and HUVECs fluorescing red, the structures that fluoresced green also fluoresced
red. Therefore, HUVSMCs could not be distinguished from HUVECs in the cell linings
of any BVMs (Figure 6.8).
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Figure 6.8. Histologic cross-section showing identical structures fluorescing green and
red. HUVSMCs were dyed with Cell Tracker™ Green, and HUVECs were dyed with
Cell Tracker™ Red. The top image is a white light image.
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6.4 Discussion and Conclusions
A dual-sodded U-shaped BVM was developed as described in this chapter in an
attempt to develop a confluent region of cells. After sodding a U-shaped scaffold with
HUVSMCs and then HUVECs and cultivating the dual-sodded BVM for 1 day, a
confluent region of cells developed on the outer wall of the middle segment. These
findings support the hypothesis that a confluent region of cells would form in a U-shaped
BVM, although it was not consistent throughout the BVM.
The cell linings on the dual-sodded U-shaped BVMs shown in this chapter were
the most confluent cell linings developed in a complex-shaped BVM so far, although the
cell linings were still subconfluent. Dual-sodded U-shaped BVMs exhibited more cell
coverage than HUVEC-only U-shaped BVMs after both 1 and 4 days of cultivation
(Figure 6.9). This was likely because HUVSMCs adhere to the U-shaped scaffold better
than HUVECs. But twice as many cells were sodded onto the U-shaped scaffold through
the dual-sodding process, therefore dual-sodded U-shaped BVMs also may have
exhibited more cell coverage because twice as many cells were sodded onto the scaffold.
Future work should determine whether the HUVSMC cell type or the larger number of
sodded cells improved cell coverage.
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1-Day

4-Day

HUVECOnly

100 µm

100 µm

100 µm

100 µm

Dual-Sodded

Figure 6.9. Comparison of HUVEC-only U-shaped BVMs to dual-sodded U-shaped
BVMs. Dual-sodded U-shaped BVMs exhibited more cell coverage than HUVEC-only
U-shaped BVMs after 1 and 4 days, but cell coverage is still sparse in both.

When an almost identical dual-sodding protocol is used to cultivate dual-sodded
straight BVMs and dual-sodded U-shaped BVMs, the dual-sodded straight BVMs exhibit
confluent cell linings after 1 day of cultivation, while the dual-sodded U-shaped BVMs
do not. The same issues(s) that resulted in a lack of confluent cell linings in HUVEC-only
U-shaped BVMs may have also resulted in a lack of confluent cell linings in dual-sodded
U-shaped BVMs. One of these issues may be that the unique flow in a U-shaped scaffold
that results in higher wall shear stress may push more cells off the scaffold than the flow

137

in a straight scaffold that results in lower wall shear stress, resulting in more spaces of
bare scaffold between cells on the U-shaped scaffold.
An issue with the Cell Tracker™ occurred during this study: although HUVSMCs
were dyed with Cell Tracker™ Green and HUVECs were dyed with Cell Tracker™ Red,
the structures that fluoresced green also fluoresced red. A potential explanation for this
issue is that the BVMs underwent fixation, processing, paraffin-embedding, and staining
for histology, and this may have affected the Cell Tracker™ in a way that caused the
outcome in Figure 6.8. Therefore, future work should be carried out to improve Cell
Tracker™ performance in BVMs that have undergone histology procedures.
In conclusion, after sodding a U-shaped scaffold with HUVSMCs and then
HUVECs and cultivating the dual-sodded BVM, a confluent region of cells did develop
in one area of the dual-sodded U-shaped BVM, but this result was inconsistent.
Therefore, it is possible that further development of this protocol will result in a confluent
lining of cells in a U-shaped BVM.
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7. Discussion and Conclusions

7.1. Review of the Purpose of Complex-Shaped BVMs
The complex geometries of coronary arteries are prone to lethal plaque formations
that cause CHD. As a result, CHD is the leading cause of death in the United States, and
new coronary devices are constantly under development to identify and treat this disease.
The FDA requires that these devices be tested, but current in vitro and in vivo testing
methods have drawbacks. In response to these drawbacks, BVMs were developed in
straight geometries and have been used to identify stents that re-endothelialize better than
other stents. But in certain cases where the complex geometries of coronary arteries may
negatively affect coronary device performance, the FDA has specifically recommended
that coronary devices be tested in complex-shaped simulated vessels. Therefore, BVMs
should be developed in the complex geometries of coronary arteries.

7.2. Summary of Thesis Work
The work in this thesis describes the development of complex-shaped scaffolds
and bioreactors, the development of complex-shaped BVMs with cells located throughout
all regions of the BVMs, and the development of a U-shaped BVM with a confluent
region of cells.
The first aim of this work was to design, construct, and validate complex-shaped
scaffolds and bioreactors. The hypothesis in this case was that complex-shaped scaffolds
could be designed and constructed, that bioreactors capable of housing the new scaffolds
could be designed and constructed, and that cells would deposit onto the new scaffolds
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inside the new bioreactors. Complex-shaped scaffolds were constructed, bioreactors
capable of housing the new scaffolds were constructed, and cells deposited on the new
scaffolds. These results supported the hypothesis.
The second specific aim was to deposit cells throughout the entire inner surface of
complex-shaped scaffolds. The hypothesis in this case was that, after 1 day of cultivation
of complex-shaped BVMs, no statistically significant differences would exist between the
cell densities along the length of the BVMs, between the cell densities in the inner and
outer halves of the BVMs, or between the cell densities in the top and bottom halves of
the BVMs. Although statistically significant differences did exist between 5 regions
along the length of L-shaped BVMs, between the inner and outer halves of L-shaped
BVMs, and between 5 regions along the length of U-shaped BVMs, cells did deposit with
average or median densities between 250,000 cells/cm2 and 350,000 cells/cm2 throughout
all regions of L- and U-shaped BVMs. Results did not support the hypothesis, but results
did confirm that cells can deposit throughout all regions of complex-shaped BVMs at
densities that are approximately the same order of magnitude as endothelial cell densities
in various native blood vessels.
The third specific aim was to determine whether HUVECs would reach
confluence on a complex-shaped scaffold using a cultivation protocol similar to the
straight-BVM cultivation protocol. The hypothesis in this case was that after deposition
of HUVECs onto U-shaped scaffolds and cultivation similar to the straight-BVM
protocol, cells would reach confluence. Cells did not reach confluence using three
different cultivation protocols, therefore results did not support the hypothesis. But the
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protocol utilizing the constant flow rate of 12 mL/min did result in development of a Ushaped BVM with flattened cells.
After none of the proposed cultivation protocols resulted in development of any
region of confluence in a U-shaped BVM, the best proposed cultivation protocol was
selected, and multiple alterations to the protocol were proposed. Alterations that focused
on coating the U-shaped scaffold or developing a monolayer of endothelial cells on the
U-shaped scaffold were not desirable because it was suspected that stent deployment
would denude a thin coating or thin cell lining from the U-shaped scaffold. But because
denudation after stent deployment in a complex-shaped BVM was only a suspicion, the
fourth specific aim of this thesis was to determine whether a complex-shaped BVM
developed using only HUVECs would exhibit denudation of its cell lining after coronary
stent deployment. The hypothesis in this case was that a complex-shaped BVM that was
developed using only HUVECs would exhibit no cell lining after coronary stent
deployment. A U-shaped BVM did exhibit no cell lining after coronary stent deployment,
therefore the results supported the hypothesis, and potential alterations that involved thin
coatings or thin cell linings were avoided. The stent deployment study also validated the
complex-shaped BVM system for coronary stent testing and revealed the U-shaped
BVM’s important ability to mimic the straightening effect that occurs when coronary
stents are implanted in human coronary arteries.
The fifth specific aim of this thesis was to develop a confluent region of cells in a
U-shaped BVM. Because a complex-shaped BVM exhibited possible denudation of its
cell lining after coronary stent deployment, the confluent region of cells had to be
developed using a cell type that was known to form multiple cell layers so that the cells
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could eventually be cultivated into a multilayer that would withstand stent deployment
better than a monolayer. The hypothesis in this case was that a confluent region of cells
would form in a U-shaped BVM. A confluent region of cells did develop in one area of a
U-shaped BVM, although this result was inconsistent. Therefore, results supported the
hypothesis. These results revealed that a confluent region of cells can develop in a Ushaped BVM even though a U-shaped scaffold exhibits more than 7 times the wall shear
stress of a straight scaffold. Overall, the results from all five aims support the hypothesis
that a BVM could be developed in the complex geometries of coronary arteries.

7.3. Limitations and Future Work
Although this thesis has culminated with the development of a confluent region of
cells in a U-shaped BVM, a confluent cell lining throughout all regions of a complexshaped BVM is necessary to predict re-endothelialization of a coronary stent. Therefore,
future work should focus on the development of a confluent cell lining throughout all
regions of a U-shaped BVM. Future steps may involve sodding U-shaped scaffolds with
more cells, sodding a single U-shaped scaffold multiple days in a row so that cells can
fall off the scaffold but be replaced with new cells, or allowing HUVSMCs to develop
into a thick cell lining over a longer period and then sodding HUVECs on top of the thick
HUVSMC lining. No matter what alterations are made to the protocol for the tissue
engineering of complex-shaped BVMs, a main criterion that should be considered when
evaluating potential alterations is the ability of the alteration to withstand stent
deployment and still function usefully after stent deployment.

142

Other future work on complex-shaped BVMs could involve the complete
development of BVMs in the other proposed geometries. Complete development includes
validation of the bifurcated scaffolds and the bioreactor capable of housing only Yshaped scaffolds, quantification of cell deposition on S-, T-, and Y-shaped scaffolds,
development of a confluent cell lining on all the complex-shaped scaffolds, successful
stent deployment in fully functional complex-shaped BVMs, and a repeatable, consistent
BVM tissue response to coronary stents.

7.4. Conclusions
In conclusion, complex-shaped scaffolds and bioreactors were fully developed,
complex-shaped BVMs were developed with cells located throughout all regions of the
BVMs, and a U-shaped BVM was developed with a confluent region of cells. In addition
to preclinically testing coronary stents, potential applications of complex-shaped BVMs
include preclinical testing of drug-delivery systems, coronary imaging modalities, and
other coronary technologies. Complex-shaped BVMs may eventually improve the
accuracy of preclinical coronary device testing and result in the development of improved
coronary devices, which could directly benefit CHD patients.
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Appendix A: Abbreviations
ACC – American College of Cardiology
AHA – American Heart Association
ANOVA – Analysis of variance
BBI – Bisbenzimide
BMS – Bare metal stent
BVM – Blood vessel mimic
CHD – Coronary heart disease
DDES – Dual drug-eluting stent
DES – Drug-eluting stent
D1 – Distal 1
D2 – Distal 2
ePTFE – expanded polytetrafluoroethylene
ESS – Endothelial shear stress
EtO – Ethylene oxide
FBS – Fetal bovine serum
FDA – Food and Drug Administration
GA-1000 – gentamicin sulfate amphotericin B
hEGF – human epidermal growth factor
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
hFGF-B – human fibroblast growth factor B
HUVEC – Human umbilical vein endothelial cell
HUVSMC – Human umbilical vein smooth muscle cell
ID – Inner diameter
IDTE2000 – Interventional Device Testing Equipment
IVUS – Intravascular ultrasound
M – Middle
NIRS – Near infrared spectroscopy
OD – Outer diameter
P1 – Proximal 1
P2 – Proximal 2
P/S – penicillin/streptomycin
PTCA – Percutaneous transluminal coronary angioplasty
PTFE – polytetrafluoroethylene
R3-IGF-1 – long R insulin-like growth factor 1
SEM – Scanning electron microscopy
TCFA – thin-cap fibroatheroma
VEGF – vascular endothelial growth factor
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Appendix B: Protocol for Maintaining Multifunctional Bioreactor
Purpose
The O-rings of multifunctional bioreactors may degrade and cause leakage during
bioreactor use, which could ruin an experiment. Therefore, it is important to replace Orings on multifunctional bioreactors when the O-rings seem to have started to degrade.
The following protocol describes how to replace O-rings on multifunctional bioreactors.
A similar protocol could be used to possibly repair leaky two-port lids.
Components
•
•
•

Razor blade (rib-back carbon steel, Bard-Parker)
Hemostats
New O-rings

Picture-Protocol

Figure B.1. Locate degraded O-rings.

Figure B.2. Wedge razor blade between UV glue and polypropylene container, and start
to pry off UV glue.
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Figure B.3. Leave razor blade wedged in place, and wedge hemostats between UV glue
and polypropylene container.

Figure B.4. Remove razor blade. Use hemostats to pry off UV glue from polypropylene
container. Use hemostats to unscrew lock nut and to start unscrewing femal luer lug panel
mount. Finish unscrewing female luer lug panel mount by hand. Replace O-rings. Screw
female luer lug panel mount back in place. Screw lock nut back in place. Re-apply UV
glue.
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Appendix C: HUVEC Media Preparation
Purpose
The following was the list of components used to make HUVEC media and the protocol
that was followed to make this media. This protocol yielded a single bottle of 515.2 mL
of HUVEC media. The HUVEC media consisted of 500 mL of endothelial cell basal
medium and EGM™-2 SingleQuots® made by Lonza with catalog number CC-4176.
Components
•
•
•
•
•
•
•
•
•
•

500 mL endothelial cell basal medium
10 mL fetal bovine serum (FBS)
0.2 mL hydrocortisone
2 mL human fibroblast growth factor B (hFGF-B)
0.5 mL vascular endothelial growth factor (VEGF)
0.5 mL long R insulin-like growth factor 1 (R3-IGF-1)
0.5 mL ascorbic acid
0.5 mL human epidermal growth factor (hEGF)
0.5 mL gentamicin sulfate amphotericin B (GA-1000)
0.5 mL heparin

Protocol
1. In a laminar flow hood, attach filter to bottle.
2. Attach vacuum to filter. Turn on vacuum.
3. Pour approximately 400 mL of endothelial cell basal medium into filter, leaving the
remaining 100 mL to wash down other components from sides of filter.
4. Add the remaining components into the filter, using a pipette to verify the exact
quantities of each component.
5. Wash the filter with the remaining 100 mL of endothelial cell basal medium.
6. Detach the filter from the bottle. Cap the bottle. Place Lonza label on bottle, and place
tape label on bottle that includes date and initials.
7. Place labeled bottle in refrigerator (4˚C).
8. Before using media from refrigerator, warm media to 37˚C in water bath.
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Appendix D: Bioreactor Media Preparation
Purpose
The following was the list of components used to make bioreactor media and the protocol
that was followed to make this media. This protocol yielded a single bottle of 569.4 mL
of bioreactor media.
Components
•
•
•
•
•
•

500 mL M199
56 mL fetal bovine serum (FBS)
5 mL L-glutamine
5 mL penicillin/streptomycin solution (P/S)
0.6 mL fungizone
2.8 mL 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)

Protocol
1. In a laminar flow hood, attach filter to bottle.
2. Attach vacuum to filter. Turn on vacuum.
3. Pour approximately 400 mL of M199 into filter, leaving the remaining 100 mL to
wash down other components from sides of filter.
4. Add the remaining components into the filter, using a pipette to verify the exact
quantities of each component.
5. Wash the filter with the remaining 100 mL of M199.
6. Detach the filter from the bottle. Cap the bottle. Place tape label on bottle that
includes “Bioreactor Media,” date, and initials.
7. Place labeled bottle in refrigerator (4˚C).
8. Before using media from refrigerator, warm media to 37˚C in water bath.

160

Appendix E: Conditioning Media Preparation
Purpose
The following was the list of components used to make conditioning media and the
protocol that was followed to make this media. This protocol yielded a single bottle of
588.6 mL of conditioning media.
Components
•
•
•
•

500 mL M199
83 mL fetal bovine serum (FBS)
5 mL penicillin/streptomycin solution (P/S)
0.6 mL fungizone

Protocol
1. In a laminar flow hood, attach filter to bottle.
2. Attach vacuum to filter. Turn on vacuum.
3. Pour approximately 400 mL of M199 into filter, leaving the remaining 100 mL to
wash down other components from sides of filter.
4. Add the remaining components into the filter, using a pipette to acquire the exact
quantities of each component.
5. Wash the filter with the remaining 100 mL of M199.
6. Detach the filter from the bottle. Cap the bottle. Place tape label on bottle that
includes “Conditioning Media,” date, and initials.
7. Place labeled bottle in refrigerator (4˚C).
8. Before using media from refrigerator, warm media to 37˚C in water bath.
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Appendix F: Complex-Shaped BVM Harvesting Protocol
Purpose
The following was the protocol used to remove complex-shaped BVM systems from the
large incubator and pump and to harvest complex-shaped BVMs from multifunctional
bioreactors.
Components
•
•
•
•

Razor blade (rib-back carbon steel, Bard-Parker)
Forceps
8 mL of Histochoice per complex-shaped BVM
Complex-shaped BVM system, including complex-shaped BVM

Protocol
1. Put on gloves.
2. Close all stopcocks on bioreactor, and clamp off inlet and outlet on reservoir.
3. Detach the complex-shaped BVM system from pump, and move complex-shaped
BVM system out of large incubator and onto nonsterile surface.
4. Acquire 15-mL conical for each BVM, and label each 15-mL conical with all
information necessary to identify the BVM that will be placed in conical and to
identify the orientation of the BVM after placement in conical.
5. Fill each conical with 8 mL of Histochoice. Leave conicals uncapped.
6. Remove bioreactor lid.
7. Place razor blade at edge of BVM, and cut entirely through BVM, making sure to not
do anything that could disrupt the cell lining of BVM. Cut other end of BVM.
8. Use forceps to gently grab end of BVM, and transfer to conical. Place lid on conical.
9. Remove ePTFE scraps that remain on female luer thread barbed fittings.
10. Dispose of all media in bioreactor and reservoir.
11. Clean all bioreactors, bioreactor lids, two-port lids, and tubing with hot water. Dry
and store equipment for future experiments.
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Appendix G: BBI Imaging Protocol
Purpose
The following was the protocol used for staining complex-shaped BVMs with BBI and
for acquiring fluorescent en face BBI images using an Olympus BX41 microscope. The
BBI stain that was used Hoechst 33258 pentahydrate by Invitrogen.
Components
•
•
•
•
•

10 µL BBI stock solution
10 mL milli-Q water
Forceps
Foil
15-mL conicals for each sample

Protocol
1. Wrap nonsterile 15-mL conicals in foil. Thoroughly label conicals for all samples.
2. Make BBI solution. Always keep stock solution wrapped in foil!
a. Use small tube of stock solution and dilute 1:1000 with milli-Q water (10 µL
stock solution in 10 mL water). Use pipette aid from room 209 hood for milli-Q
water; spray pipette aid before placing back in hood.
b. Mix by inverting.
3. Put on safety glasses. Cut samples with blade or scissors, being careful to not disrupt
cell lining inside lumen (squeezing, touching, and scraping can all disrupt lining and
ruin experiment).
4. Use washed forceps to place samples in corresponding 15-mL conicals that contain
BBI solution. Carefully keep track of samples. Leave foil on conicals.
a. Let samples soak for at least 15 minutes (longer is better).
5. Put away extra stock solution. Clean up preparation area.
6. With permission or help from Dr. Cardinal, use fluorescent microscope to obtain en
face images. Take forceps to use at microscope. See figure G.1 for pictures of steps
below.
a. Log into notebook (fluorescence; initials; date; time and lamp hours).
b. Turn turret to setting 4.
c. Turn on Olympus lamp (green switch).
d. Turn on Optiscan wheels (black switch).
e. Turn on camera (black switch).
f. Set filter wheel 1 to 1, and set filter wheel 2 to 1.
g. Open shutter:
h. Set Prior keypad to shutter S1.
i. Dial objectives to desired magnification (typically 4x and 10x for BBI images).
j. Set thin bar to icon of eye and camera.
k. Sign into computer by clicking Dr. Cardinal’s account (password can be obtained
from Dr. Cardinal).
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l.
m.
n.
o.
p.
q.
r.

Click QCapture Pro (on desktop).
Click camera icon at top of QCapture Pro window:
Place slide on microscope. Place sample on slide.
See figure G.2.
Manually adjust microscope to clarify image.
If scaffold is too wet, carefully blot end of scaffold on Kim wipe.
Take pictures. Save pictures if desired (labeled with sample info, initials, and
magnification).
s. Quit QCapture Pro. Log out of computer.
t. Shut down microscope by switching off Olympus lamp, switching off Optiscan
wheels, switching off camera (on top of microscope), and closing shutter.
u. Log out of notebook.

Figure G.1. Microscope anatomy. Letters correspond to step 6 in the protocol.
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Figure G.2. QCapture Pro control panel.
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Appendix H: Protocol for Developing HUVEC-Sodded Complex-Shaped BVMs
Purpose
The following protocol was used to tissue-engineer HUVEC-only S-, L-, and U-shaped
BVMs. This protocol has not been used to tissue-engineer bifurcated BVMs.
Components
•
•
•
•
•
•
•
•
•
•
•
•

ePTFE scaffold(s)
1.5 million HUVECs/cm2 of scaffold
Conditioning media (See Appendix E)
Bioreactor media (See Appendix D)
HUVEC media (See Appendix C)
Sterile 70% EtOH and sterile 100% EtOH
Silk Suture
Forceps
Degassing flask with rubber stopper
Multifunctional bioreactor (including 3 luer plugs and 2 rotating male-to-male luer
lock connectors)
Peristaltic pump
Sterile gloves

Protocol
Preparation (Approximately 1.5 weeks prior to “Setup”)
1. Wash all multifunctional bioreactors, bioreactor lids, and two-port lids with water,
and dry overnight.
2. Sterilize multifunctional bioreactors, bioreactor lids, and two-port lids by placing
them in individual sterilization bags and taking them to the Cal Poly Vet Clinic for
EtO gassing.
3. Thaw, plan out calendar of cell culture, and begin cell culture.
4. Cut ePTFE scaffolds to the dimensions described in Section 2.3.2, and wear gloves
while doing so.
Preparation (Approximately 1 day prior to “Setup”)
5. Sterilize ePTFE scaffolds, forceps, and degassing flask
6. Make media (listed in components list above).
7. Degass conditioning media
8. Denucleate scaffolds by placing first placing them in 70% EtOH for 10 minutes and
then 100% EtOH for 10 minutes.
9. Protein-coat scaffolds by placing them in the degassed conditioning media overnight
in the small incubator at 37˚C.
“Setup” Day
10. Warm up bioreactor media, conditioning media, and HUVEC media in water bath.
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11. Fill biochamber with bioreactor media.
12. Insert sterile graft into biochamber using sterile gloves.
13. Number biochamber lids with tape and marker.
14. Using syringe, flush lumen with conditioning media to prime scaffold.
15. Clamp lumen and continue to prime scaffold.
16. Repeat for all scaffolds.
17. Prime 2-port reservoirs with conditioning media.
18. Attach primed biochamber to 2-port reservoir and condition scaffold for 10 minutes.
Administer flow through lumen first to remove air, then clamp lumen and condition
transmurally on 150-rpm setting.
19. Leave primed biochambers in large incubator until ready for sodding step.
20. Prime 2-port reservoirs with HUVEC. Prepare a reservoir for each vessel. Be sure
that drip is visible and outlet is submerged. Clamp tubing and leave in big incubator.
21. Take primed biochambers and reservoirs to hood.
22. Attach outlet of reservoir to inlet stopcock of biochamber.
23. Leave reservoir inlet unattached and biochamber outlet facing trough.
24. Harvest HUVECs from T225: apply trypsin; deactivate with HUVEC media.
25. Pellet cell suspension (on centrifuge setting 4 for 4 minutes).
26. Resuspend pellet in 4 mL HUVEC media.
27. Prepare one trough of 10 mL HUVEC media and one trough of 4 mL cell suspension.
28. Prime tubing by capping off proximal stopcock so fluid will flow back into reservoir.
Inject 5 mL HUVEC media. Immediately replace stopcock to 45-degree angle.
Detach syringe.
29. Sod cells.
a. Take up 4 mL cell solution in syringe.
b. Slightly twist stopcock so fluid bulges out of tip of stopcock.
c. Attach syringe to stopcock.
d. Toggle stopcock to allow fluid to flow only distally through graft.
e. Inject 4 mL cell solution.
f. While still pressuring syringe, cap off stopcock to 45-degree angle. Detach
syringe.
30. Chase cells by repeating step 29 with 4 mL HUVEC media instead of 4 mL cell
solution.
31. Replace old reservoir with new HUVEC media reservoir. Tighten reservoir cap.
32. Move complex-shaped BVM system to large incubator.
33. Maintain transmural flow at 10 rpm for 30 minutes.
34. Stop transmural flow, and maintain luminal flow at 15 rpm for 24 hours.
35. Repeat steps 22 through 34 for each bioreactor.
Day After “Setup Day”
36. Take down 1-day BVMs (Appendix F).
37. Perform desired adjustment of flow rate depending on the experiment being
performed.
38. Take down BVMs at correct time points.
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Appendix I: Raw Data for Cell Deposition Study
Purpose
This appendix includes BBI images from each region along the length of the 6 complexshaped BVMs of Chapter 3 (Figures I.1–I.6), raw cell counts for L- and U-shaped BVMs
(Tables I.1–I.2 respectively), and a description of the method used to convert raw cell
counts to cell densities with units of cells/cm2.
Figures
A

B

100 µm

100 µm
C

D

100 µm

100 µm

E

100 µm
Figure I.1. L-Shaped BVM 1. A BBI image is shown for each segment along the length
of the BVM: Proximal 1 (A), Proximal 2 (B), Middle (C), Distal 1 (D), and Distal 2 (E).

168

A

B

100 µm
C

100 µm
D

100 µm

100 µm

E

100 µm
Figure I.2. L-Shaped BVM 2. A BBI image is shown for each segment along the length
of the BVM: Proximal 1 (A), Proximal 2 (B), Middle (C), Distal 1 (D), and Distal 2 (E).
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A

B

100 µm
C

100 µm
D

100 µm

100 µm

E

100 µm
Figure I.3. L-Shaped BVM 3. A BBI image is shown for each segment along the length
of the BVM: Proximal 1 (A), Proximal 2 (B), Middle (C), Distal 1 (D), and Distal 2 (E).
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A

B

100 µm
C

100 µm
D

100 µm

100 µm

E

100 µm
Figure I.4. U-Shaped BVM 1. A BBI image is shown for each segment along the length
of the BVM: Proximal 1 (A), Proximal 2 (B), Middle (C), Distal 1 (D), and Distal 2 (E).
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A

B

100 µm
C

100 µm
D

100 µm

100 µm

E

100 µm
Figure I.5. U-Shaped BVM 2. A BBI image is shown for each segment along the length
of the BVM: Proximal 1 (A), Proximal 2 (B), Middle (C), Distal 1 (D), and Distal 2 (E).
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A

B

100 µm
C

100 µm
D

100 µm

100 µm

E

100 µm
Figure I.6. U-Shaped BVM 3. A BBI image is shown for each segment along the length
of the BVM: Proximal 1 (A), Proximal 2 (B), Middle (C), Distal 1 (D), and Distal 2 (E).
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Tables
Table I.1. Raw Cell Counts for 3 L-Shaped BVMs
BVM

Distal 2

Distal 1

Middle

Proximal 2

Proximal 1

1: Inner
Top

30

28

30

30

30

28

29

35

31

30

Bottom

29

30

33

32

29

27

29

26

30

30

Top

32

31

30

31

32

30

31

30

28

29

Bottom

37

35

32

33

32

30

29

32

30

28

Top

34

30

32

32

33

31

31

31

29

29

Bottom

31

31

32

31

33

31

31

31

29

31

Top

29

32

31

35

34

34

33

33

32

30

Bottom

28

29

35

31

33

37

33

34

30

33

Top

29

32

33

36

35

37

33

31

30

29

Bottom

27

33

32

32

36

36

33

32

30

28

Top

27

31

33

33

36

36

34

35

28

33

Bottom

28

31

40

36

35

39

35

33

33

34

1: Outer

2: Inner

2: Outer

3: Inner

3: Outer
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Table I.2. Raw Cell Counts for 3 U-Shaped BVMs
BVM

Distal 2

Distal 1

Middle

Proximal 2

Proximal 1

1: Inner
Top

31

32

34

30

24

24

25

30

29

26

Bottom

31

35

35

24

32

27

30

33

22

24

1: Outer (Cells were not counted in the outer half of U-shaped BVM 1)
Top
Bottom
2: Inner
Top

25

22

22

23

28

27

24

28

25

27

Bottom

23

22

27

31

31

31

30

31

32

27

Top

30

29

30

35

32

31

29

28

21

23

Bottom

26

29

30

28

27

31

27

26

19

20

Top

25

24

29

29

30

28

32

26

23

26

Bottom

26

28

28

27

29

30

28

26

27

23

Top

29

25

32

34

30

35

32

32

37

33

Bottom

23

28

31

32

33

29

28

31

29

29

2: Outer

3: Inner

3: Outer

Method for Converting Cell Counts to Cell Densities
Each side of the small white boxes in Figure 3.7 is 100 µm, therefore each small white
box has an area of 10,000 µm2. To convert cell counts to cell densities, the average cell
count for each image was divided by the area of one small white box and then multiplied
by the following:

"1,000,000 µm % 2 " 1 m % 2
'$
'
$
& # 100 cm &
#
1m

!
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Appendix J: Minitab Output for Cell Deposition Study
Purpose
This appendix contains the Minitab output that was generated for the statistical analyses
of L- and U-shaped BVMs in Chapter 3 (Figures J.1–J.2).
Minitab Output
Kruskal-Wallis Test: Density versus Region
Kruskal-Wallis Test on Density
Region
Distal 2
Distal 1
Middle
Proximal 2
Proximal 1
Overall

N
24
24
24
24
24
120

H = 23.58
H = 23.93

DF = 4
DF = 4

Median
305000
320000
330000
320000
300000

Ave Rank
45.6
74.8
77.1
66.0
39.1
60.5

P = 0.000
P = 0.000

Z
-2.35
2.24
2.61
0.86
-3.37

(adjusted for ties)

Kruskal-Wallis Test: Density versus Inner/Outer
Kruskal-Wallis Test on Density
Inner/Outer
Inner
Outer
Overall
H = 6.39
H = 6.48

N
60
60
120

DF = 1
DF = 1

Median
310000
320000

Ave Rank
52.5
68.5
60.5

P = 0.011
P = 0.011

Z
-2.53
2.53

(adjusted for ties)

Kruskal-Wallis Test: Density versus Top/Bottom
Kruskal-Wallis Test on Density
Top/Bottom
Bottom
Top
Overall
H = 0.26
H = 0.27

N
60
60
120
DF = 1
DF = 1

Median
320000
310000

Ave Rank
62.1
58.9
60.5

P = 0.607
P = 0.604

Z
0.51
-0.51

(adjusted for ties)

Figure J.1. Minitab output for cell density comparisons throughout L-shaped BVMs. pvalues are written in red. A statistically significant difference existed between cell
densities in the 5 regions along the length of L-shaped BVMs (p = 0.000), between the
cell densities in the inner and outer halves of L-shaped BVMs (p = 0.011), but not
between the cell densities in the top and bottom halves of L-shaped BVMs (p = 0.607).
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One-way ANOVA: Density versus Region
Source
Region
Error
Total

DF
4
95
99

S = 35325

SS
18514000000
1.18545E+11
1.37059E+11

MS
4628500000
1247842105

R-Sq = 13.51%

F
3.71

P
0.008

R-Sq(adj) = 9.87%

One-way ANOVA: Density versus Inner/Outer
Source
Inner/Outer
Error
Total
S = 36711

DF
1
98
99

SS
4988166667
1.32071E+11
1.37059E+11

R-Sq = 3.64%

MS
4988166667
1347661565

F
3.70

P
0.057

R-Sq(adj) = 2.66%

One-way ANOVA: Density versus Top/Bottom
Source
Top/Bottom
Error
Total

DF
1
98
99

SS
81000000
1.36978E+11
1.37059E+11

S = 37386

R-Sq = 0.06%

MS
81000000
1397734694

F
0.06

P
0.810

R-Sq(adj) = 0.00%

Figure J.2. Minitab output for cell density comparisons throughout U-shaped BVMs. pvalues are written in red. A statistically significant difference existed between cell
densities in the 5 regions along the length of L-shaped BVMs (p = 0.008) but not between
the cell densities in the inner and outer halves of L-shaped BVMs (p = 0.057) nor
between the cell densities in the top and bottom halves of L-shaped BVMs (p = 0.810).
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Appendix K: SEM Imaging Protocol
Purpose
The following protocol was followed when carrying out any SEM imaging throughout
the research described in this thesis.
Components
•
•
•
•
•
•

100% Ethanol
Distilled water
Miniature glass jars
Forceps
Pipet-Aid
Pipettes

Protocol
1. Prepare the following solutions of ethanol by diluting 100% ethanol with water: 25%
ethanol, 50% ethanol, 70% ethanol, 90% ethanol.
2. Allot one miniature glass jar for each dilution, and place the dilutions in their
respective jars. Prepare two jars for 100% ethanol.
3. Place 2 mL of each dilution into its respective jar.
4. Dehydrate BVM samples by placing samples in each diltuion for 5 minutes starting
with 25% ethanol. Be careful not to disrupt samples or tip of miniature glass jars.
5. Place samples in dessicator overnight.
6. Image samples using Hitachi TM-1000 SEM.
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Appendix L: Histology and White Light Imaging Protocol
Purpose
The following protocol was followed when carrying out histology and white light
imaging of histology samples throughout the research described in this thesis.
Components
Histology reagents
Olympus BX41 microscope
Protocol
After embedding samples in paraffin, sectioning samples, and placing samples in oven,
run samples through the following reagents for the specified times.
1. 3 min – xylene 1
2. 3 min – xylene 2
3. 1 min – Air
4. 2 min – 100%
5. 2 min – 100%
6. 2 min – 95%
7. 2 min – Air
8. 4 min – Hematoxylin
9. 1 min – H2O (distilled)
10. 30 sec – Clarifier
11. 1 min – Bluing
12. 1 min – 95%
13. 1 min 30 sec – Eosin
14. 1 min – 100%
15. 1 min – Air
16. 1 min – xylene 1
17. 1 min – xylene 2
Mount samples on slides, place coverslips on slides, and allow slides to dry for 2 days.
With permission or help from Dr. Cardinal, use the white-light microscope to obtain
images of samples mounted on slides. The following steps detail operation of the whitelight microscope and correspond to figure L.1.
1.
2.
3.
4.
5.

Log into notebook (white; initials; date; time and lamp hours).
Turn turret to setting 1.
Turn on Optiscan wheels (black switch).
Turn on camera (black switch).
Set filter wheel 2 to 5.
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6.
7.
8.
9.

Open shutter:
Set Prior keypad to shutter S1.
Turn on white light (black switch on side of microscope arm).
Dial objectives to desired magnification (typically 10x for histology images of cellsodded scaffolds).
10. Set thin bar to icon of eye and camera.
11. Sign into computer by clicking Dr. Cardinal’s account (password can be obtained
from Dr. Cardinal).
12. Click QCapture Pro (on desktop).
13. Click camera icon at top of QCapture Pro window:
14. Place slide on microscope. Use joystick to move sample under microscope lens.
15. See figures L.2 and L.3.
16. Use dial on base of microscope to adjust exposure of live image.
17. Use course focus and fine focus on base of microscope to clarify live image.
18. See figure L.4.
19. Refocus live image if desired. Click Snap to take pictures. Save pictures if desired
(labeled with sample info and magnification).
20. Quit QCapture Pro. Log out of computer.
21. Shut down microscope by switching off Optiscan wheels, camera (on top of
microscope), and white light (on side of microscope arm).
22. Log out of notebook.

Figure L.1. Microscope anatomy. Numbers in figure correspond to steps above.
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Figure L.2. QCapture Pro home window and control panel.

Figure L.3. QCapture Pro displays live image of sample.
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Figure L.4. QCapture Pro adjusts lighting of live image.
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Appendix M: HUVSMC Media Preparation
Purpose
The following was the list of components used to make HUVSMC media and the
protocol that was followed to make this media. This protocol utilized SmGM®-2
SingleQuots® (Lonza).
Components
•
•

500 mL Smooth muscle cell medium
Other packaged components

Protocol
1. In a laminar flow hood, attach filter to bottle.
2. Attach vacuum to filter. Turn on vacuum.
3. Pour approximately 400 mL of smooth muscle cell medium into filter, leaving the
remaining 100 mL to wash down other components from sides of filter.
4. Add the remaining components into the filter, using a pipette to acquire the exact
quantities of each component.
5. Wash the filter with the remaining 100 mL of smooth muscle cell medium.
6. Detach the filter from the bottle. Cap the bottle. Place tape label on bottle that
includes “HUVSMC Media,” date, and initials.
7. Place labeled bottle in refrigerator (4˚C).
8. Before using media from refrigerator, warm media to 37˚C in water bath.
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Appendix N: Cell Tracker™ Preparation
Purpose
This appendix includes the components and protocol used to prepare the Cell Tracker™
solutions that were used during the tissue-engineering of dual-sodded U-shaped BVMs in
Chapter 6.
Components
•
•
•
•
•
•
•

5-20 µL pipette and sterile head
3-mL syringe with needle tip
DMSO 100-mL bottle (anhydrous, Sigma-Aldrich, catalog number 276855)
Cell Tracker™ Red (Invitrogen, Carlsbad, CA, catalog number C34522)
Cell Tracker™ Green (Invitrogen, Carlsbad, CA catalog number C7025)
Sterile serum-free media
Pipettes

Protocol
1.
2.
3.
4.

Warm media in water bath.
Use needle tip and syringe to pull out 1 mL of DMSO, and place in 15-mL conical.
Use micropipette to pull out 10.8µL of DMSO from 15-mL conical.
Add DMSO to vial of Cell Tracker™. Attempt to get most of powdered Cell
Tracker™ in with DMSO. This is a 10-mM concentration of stock solution.
5. Dilute stock solution to desired concentration to create working solution. Use
equation c1v1 = c2v2, where c1 = 10 mM (from stock solution), v1 = unknown, c2 =
desired concentration, and v2 = final volume needed.
6. Vortex working solution for use. Working solution can be stored in fridge for up to
one week.
7. Remove cell media from flasks of cells.
8. Add working solution to flasks of cells.
9. Incubate flasks containing Cell Tracker™ Green for 30 minutes and flasks containing
Cell Tracker™ Red for 15 minutes.
10. Remove working solution from flasks of cells.
11. Add cell media back into flasks of cells.
12. Incubate flasks for at least 30 minutes.
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Appendix O: Protocol for Developing Dual-Sodded Complex-Shaped BVMs
Purpose
The following protocol was used to tissue-engineer dual-sodded U-shaped BVMs. This
protocol has not been used to tissue-engineer any other complex-shaped BVM.
Components
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

ePTFE scaffold(s)
1.5 million HUVSMCs/cm2 of scaffold
1.5 million HUVECs/cm2 of scaffold
Conditioning media (See Appendix E)
Bioreactor media (See Appendix D)
HUVEC media (See Appendix C)
HUVSMC media (See Appendix M)
Cell Tracker™
Sterile 70% EtOH and sterile 100% EtOH
Silk Suture
Forceps
Degassing flask with rubber stopper
Multifunctional bioreactor (including 3 luer plugs and 2 rotating male-to-male luer
lock connectors)
Peristaltic pump
Sterile gloves

Protocol
Preparation (Approximately 1.5 weeks prior to “Setup”)
1. Wash all multifunctional bioreactors, bioreactor lids, and two-port lids with water,
and dry overnight.
2. Sterilize multifunctional bioreactors, bioreactor lids, and two-port lids by placing
them in individual sterilization bags and taking them to the Cal Poly Vet Clinic for
EtO gassing.
3. Thaw, plan out calendar of cell culture, and begin cell culture.
4. Cut ePTFE scaffolds to the dimensions described in Section 2.3.2, and wear gloves
while doing so.
Preparation (Approximately 1 day prior to “Setup”)
5. Sterilize ePTFE scaffolds, forceps, and degassing flask
6. Make media (listed in components list above).
7. Degass conditioning media
8. Denucleate scaffolds by first placing them in 70% EtOH for 10 minutes and then
100% EtOH for 10 minutes.
9. Protein-coat scaffolds by placing them in the degassed conditioning media overnight
in the small incubator at 37˚C.
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“Setup” Day
10. Warm up bioreactor media, conditioning media, HUVEC media, HUVSMC media.
11. Prepare Cell Tracker™ Green and Red solutions.
12. Fill biochamber with bioreactor media.
13. Insert sterile graft into biochamber.
14. Number biochamber lids with tape and marker.
15. Using syringe, flush lumen with conditioning media to prime graft.
a. Clamp lumen and continue to prime graft.
b. Repeat for all grafts.
16. Prime 2-port reservoirs with conditioning media.
17. Attach primed biochamber to 2-port reservoir and condition graft for 10 minutes.
a. Flow through lumen first to remove air, then clamp lumen and condition
transmurally on 150-rpm setting.
18. Leave primed biochambers in large incubator until ready for sodding step.
19. Prime 2-port reservoirs with 75% HUVEC media and 25% HUVSMC media.
a. Prepare one for each vessel.
b. Be sure that drip is visible and outlet is submerged.
c. Clamp tubing and leave in big incubator.
20. Take primed biochambers and reservoirs to hood.
21. Attach outlet of reservoir to inlet stopcock of biochamber.
a. Leave reservoir inlet unattached and biochamber outlet facing trough.
22. Place 9 mL of Cell Tracker™ Green solution in 15 mL conical.
23. Vortex solution.
24. Remove HUVSMC media from T225 of HUVSMCs.
25. Add 9 mL of Cell Tracker™ Green solution to T225 of HUVSMCs (to cover total
surface area of T225).
26. Place T225 in incubator for 30 minutes.
27. Remove Cell Tracker™ Green solution from T225.
28. Add 9 mL HUVSMC media to T225 (to keep cells alive before sodding).
29. Incubate T225 for 30 minutes.
30. Harvest HUVSMCs from T225.
a. Apply trypsin; deactivate with HUVSMC media.
31. Pellet cell suspension (on 4 for 4 minutes).
32. Resuspend pellet in 4 mL HUVSMC media.
33. Prepare one trough of 10 mL HUVSMC media and one trough of 4 mL cell
suspension.
34. Prime tubing by capping off proximal stopcock so fluid will flow back into reservoir.
Inject 5 mL HUVSMC media. Immediately replace stopcock to 45-degree angle.
Detach syringe.
35. Sod cells.
a. Take up 4 mL cell solution in syringe.
b. Slightly twist stopcock so fluid bulges out of tip of stopcock.
c. Attach syringe to stopcock.
d. Toggle stopcock to allow fluid to flow only distally through graft.
e. Inject 4 mL cell solution.
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f. While still pressuring syringe, cap off stopcock to 45-degree angle. Detach
syringe.
36. Chase cells by repeating step 35 with 4 mL HUVSMC media instead of 4 mL cell
solution.
37. Move BVM system to large incubator.
38. Maintain transmural flow at 10 rpm for 30 minutes.
39. Repeat steps 22 through 39 for each bioreactor.
40. Place 9 mL of Cell Tracker™ Red solution in 15 mL conical.
41. Vortex solution.
42. Remove HUVEC media from T225 of HUVECs.
43. Add 9 mL of Cell Tracker™ Red solution to T225 of HUVECs (to cover total surface
area of T225).
44. Place T225 in incubator for 15 minutes.
45. Remove Cell Tracker™ Red solution from T225.
46. Add 9 mL HUVEC media to T225 (to keep cells alive before sodding).
47. Incubate T225 for 30 minutes.
48. Harvest HUVECs from a T225.
a. Apply Trypsin; deactivate with HUVEC media.
49. Pellet cell suspension (on 4 for 4 minutes).
50. Resuspend pellet in 4 mL HUVEC media.
51. Prepare one trough of 10 mL HUVEC media and one trough of 4 mL cell suspension.
52. Prime tubing by capping off proximal stopcock so fluid will flow back into reservoir.
Inject 5 mL HUVEC media. Immediately replace stopcock to 45-degree angle.
Detach syringe.
53. Sod cells.
a. Take up 4 mL cell solution in syringe.
b. Slightly twist stopcock so fluid bulges out of tip of stopcock.
c. Attach syringe to stopcock.
d. Toggle stopcock to allow fluid to flow only distally through graft.
e. Inject 4 mL cell solution.
f. While still pressuring syringe, cap off stopcock to 45-degree angle. Detach
syringe.
54. Chase cells by repeating step 43 with 4 mL HUVEC media instead of 4 mL cell
solution.
55. Move BVM system to large incubator.
56. Maintain transmural flow at 10 rpm for 30 minutes.
57. Stop transmural flow, and maintain luminal flow at 10 rpm for 1 hour.
58. Increase luminal flow to 15 rpm, and maintain for 1 hour.
59. Increase luminal flow to 20 rpm, and maintain overnight.
60. Take down 1-day BVMs.
61. Increase flow by 15 rpm every hour to reach 150 rpm.
62. Take down 4-day BVMs.
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Appendix P: Copyright Reprint Permissions
Figure 1.1 A and B Reprint Permissions
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ZRUOGZLGHOLPLWHGOLFHQVHWRUHSURGXFHWKH0DWHULDOVIRUWKHSXUSRVHVSHFLILHGLQWKHOLFHQVLQJ
SURFHVV7KLVOLFHQVHLVIRUDRQHWLPHXVHRQO\ZLWKDPD[LPXPGLVWULEXWLRQHTXDOWRWKHQXPEHU
WKDW\RXLGHQWLILHGLQWKHOLFHQVLQJSURFHVV$Q\IRUPRIUHSXEOLFDWLRQJUDQWHGE\WKLVOLFHQFHPXVW
EHFRPSOHWHGZLWKLQWZR\HDUVRIWKHGDWHRIWKHJUDQWRIWKLVOLFHQFH DOWKRXJKFRSLHVSUHSDUHG
EHIRUHPD\EHGLVWULEXWHGWKHUHDIWHU 7KH0DWHULDOVVKDOOQRWEHXVHGLQDQ\RWKHUPDQQHURUIRU
DQ\RWKHUSXUSRVH3HUPLVVLRQLVJUDQWHGVXEMHFWWRDQDSSURSULDWHDFNQRZOHGJHPHQWJLYHQWRWKH
DXWKRUWLWOHRIWKHPDWHULDOERRNMRXUQDODQGWKHSXEOLVKHU<RXVKDOODOVRGXSOLFDWHWKHFRS\ULJKW
QRWLFHWKDWDSSHDUVLQWKH:LOH\SXEOLFDWLRQLQ\RXUXVHRIWKH0DWHULDO3HUPLVVLRQLVDOVRJUDQWHG
RQWKHXQGHUVWDQGLQJWKDWQRZKHUHLQWKHWH[WLVDSUHYLRXVO\SXEOLVKHGVRXUFHDFNQRZOHGJHGIRUDOO
RUSDUWRIWKLV0DWHULDO$Q\WKLUGSDUW\PDWHULDOLVH[SUHVVO\H[FOXGHGIURPWKLVSHUPLVVLRQ
:LWKUHVSHFWWRWKH0DWHULDOVDOOULJKWVDUHUHVHUYHG([FHSWDVH[SUHVVO\JUDQWHGE\WKHWHUPVRI
WKHOLFHQVHQRSDUWRIWKH0DWHULDOVPD\EHFRSLHGPRGLILHGDGDSWHG H[FHSWIRUPLQRU
UHIRUPDWWLQJUHTXLUHGE\WKHQHZ3XEOLFDWLRQ WUDQVODWHGUHSURGXFHGWUDQVIHUUHGRUGLVWULEXWHGLQ
DQ\IRUPRUE\DQ\PHDQVDQGQRGHULYDWLYHZRUNVPD\EHPDGHEDVHGRQWKH0DWHULDOVZLWKRXW
WKHSULRUSHUPLVVLRQRIWKHUHVSHFWLYHFRS\ULJKWRZQHU<RXPD\QRWDOWHUUHPRYHRUVXSSUHVVLQ
DQ\PDQQHUDQ\FRS\ULJKWWUDGHPDUNRURWKHUQRWLFHVGLVSOD\HGE\WKH0DWHULDOV<RXPD\QRW
OLFHQVHUHQWVHOOORDQOHDVHSOHGJHRIIHUDVVHFXULW\WUDQVIHURUDVVLJQWKH0DWHULDOVRUDQ\RI
WKHULJKWVJUDQWHGWR\RXKHUHXQGHUWRDQ\RWKHUSHUVRQ
7KH0DWHULDOVDQGDOORIWKHLQWHOOHFWXDOSURSHUW\ULJKWVWKHUHLQVKDOODWDOOWLPHVUHPDLQWKH
H[FOXVLYHSURSHUW\RI-RKQ:LOH\ 6RQV,QFRURQHRILWVUHODWHGFRPSDQLHV :,/(< RUWKHLU
UHVSHFWLYHOLFHQVRUVDQG\RXULQWHUHVWWKHUHLQLVRQO\WKDWRIKDYLQJSRVVHVVLRQRIDQGWKHULJKWWR
UHSURGXFHWKH0DWHULDOVSXUVXDQWWR6HFWLRQKHUHLQGXULQJWKHFRQWLQXDQFHRIWKLV$JUHHPHQW
<RXDJUHHWKDW\RXRZQQRULJKWWLWOHRULQWHUHVWLQRUWRWKH0DWHULDOVRUDQ\RIWKHLQWHOOHFWXDO
SURSHUW\ULJKWVWKHUHLQ<RXVKDOOKDYHQRULJKWVKHUHXQGHURWKHUWKDQWKHOLFHQVHDVSURYLGHGIRU
DERYHLQ6HFWLRQ1RULJKWOLFHQVHRULQWHUHVWWRDQ\WUDGHPDUNWUDGHQDPHVHUYLFHPDUNRU
RWKHUEUDQGLQJ 0DUNV RI:,/(<RULWVOLFHQVRUVLVJUDQWHGKHUHXQGHUDQG\RXDJUHHWKDW\RX
VKDOOQRWDVVHUWDQ\VXFKULJKWOLFHQVHRULQWHUHVWZLWKUHVSHFWWKHUHWR
1(,7+(5:,/(<125,76/,&(162560$.(6$1<:$55$17<255(35(6(17$7,212)$1<
.,1'72<2825$1<7+,5'3$57<(;35(66,03/,('2567$78725<:,7+5(63(&7727+(
0$7(5,$/6257+($&&85$&<2)$1<,1)250$7,21&217$,1(',17+(0$7(5,$/6
,1&/8',1*:,7+287/,0,7$7,21$1<,03/,(':$55$17<2)0(5&+$17$%,/,7<$&&85$&<
6$7,6)$&725<48$/,7<),71(66)25$3$57,&8/$5385326(86$%,/,7<,17(*5$7,2125
121,1)5,1*(0(17$1'$//68&+:$55$17,(6$5(+(5(%<(;&/8'('%<:,/(<$1',76
/,&(16256$1':$,9('%<<28
:,/(<VKDOOKDYHWKHULJKWWRWHUPLQDWHWKLV$JUHHPHQWLPPHGLDWHO\XSRQEUHDFKRIWKLV
$JUHHPHQWE\\RX
<RXVKDOOLQGHPQLI\GHIHQGDQGKROGKDUPOHVV:,/(<LWV/LFHQVRUVDQGWKHLUUHVSHFWLYH
GLUHFWRUVRIILFHUVDJHQWVDQGHPSOR\HHVIURPDQGDJDLQVWDQ\DFWXDORUWKUHDWHQHGFODLPV
GHPDQGVFDXVHVRIDFWLRQRUSURFHHGLQJVDULVLQJIURPDQ\EUHDFKRIWKLV$JUHHPHQWE\\RX
,112(9(176+$//:,/(<25,76/,&(16256%(/,$%/(72<2825$1<27+(53$57<25
$1<27+(53(562125(17,7<)25$1<63(&,$/&216(48(17,$/,1&,'(17$/,1',5(&7
(;(03/$5<25381,7,9('$0$*(6+2:(9(5&$86('$5,6,1*2872)25,1&211(&7,21
:,7+7+('2:1/2$',1*3529,6,21,1*9,(:,1*2586(2)7+(0$7(5,$/65(*$5'/(66
2)7+()2502)$&7,21:+(7+(5)25%5($&+2)&2175$&7%5($&+2):$55$17<7257
1(*/,*(1&(,1)5,1*(0(172527+(5:,6( ,1&/8',1*:,7+287/,0,7$7,21'$0$*(6
%$6('21/2662)352),76'$7$),/(686(%86,1(6623325781,7<25&/$,062)7+,5'
3$57,(6 $1':+(7+(5251277+(3$57<+$6%((1$'9,6('2)7+(3266,%,/,7<2)68&+
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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'$0$*(67+,6/,0,7$7,216+$//$33/<127:,7+67$1',1*$1<)$,/85(2)(66(17,$/
385326(2)$1</,0,7('5(0('<3529,'('+(5(,1
6KRXOGDQ\SURYLVLRQRIWKLV$JUHHPHQWEHKHOGE\DFRXUWRIFRPSHWHQWMXULVGLFWLRQWREHLOOHJDO
LQYDOLGRUXQHQIRUFHDEOHWKDWSURYLVLRQVKDOOEHGHHPHGDPHQGHGWRDFKLHYHDVQHDUO\DVSRVVLEOH
WKHVDPHHFRQRPLFHIIHFWDVWKHRULJLQDOSURYLVLRQDQGWKHOHJDOLW\YDOLGLW\DQGHQIRUFHDELOLW\RIWKH
UHPDLQLQJSURYLVLRQVRIWKLV$JUHHPHQWVKDOOQRWEHDIIHFWHGRULPSDLUHGWKHUHE\
7KHIDLOXUHRIHLWKHUSDUW\WRHQIRUFHDQ\WHUPRUFRQGLWLRQRIWKLV$JUHHPHQWVKDOOQRW
FRQVWLWXWHDZDLYHURIHLWKHUSDUW\ VULJKWWRHQIRUFHHDFKDQGHYHU\WHUPDQGFRQGLWLRQRIWKLV
$JUHHPHQW1REUHDFKXQGHUWKLVDJUHHPHQWVKDOOEHGHHPHGZDLYHGRUH[FXVHGE\HLWKHUSDUW\
XQOHVVVXFKZDLYHURUFRQVHQWLVLQZULWLQJVLJQHGE\WKHSDUW\JUDQWLQJVXFKZDLYHURUFRQVHQW
7KHZDLYHUE\RUFRQVHQWRIDSDUW\WRDEUHDFKRIDQ\SURYLVLRQRIWKLV$JUHHPHQWVKDOOQRWRSHUDWH
RUEHFRQVWUXHGDVDZDLYHURIRUFRQVHQWWRDQ\RWKHURUVXEVHTXHQWEUHDFKE\VXFKRWKHUSDUW\
7KLV$JUHHPHQWPD\QRWEHDVVLJQHG LQFOXGLQJE\RSHUDWLRQRIODZRURWKHUZLVH E\\RX
ZLWKRXW:,/(< VSULRUZULWWHQFRQVHQW
$Q\IHHUHTXLUHGIRUWKLVSHUPLVVLRQVKDOOEHQRQUHIXQGDEOHDIWHUWKLUW\  GD\VIURPUHFHLSW
7KHVHWHUPVDQGFRQGLWLRQVWRJHWKHUZLWK&&&¶V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQV
ZKLFKDUHLQFRUSRUDWHGKHUHLQ IRUPWKHHQWLUHDJUHHPHQWEHWZHHQ\RXDQG:,/(<FRQFHUQLQJ
WKLVOLFHQVLQJWUDQVDFWLRQDQG LQWKHDEVHQFHRIIUDXG VXSHUVHGHVDOOSULRUDJUHHPHQWVDQG
UHSUHVHQWDWLRQVRIWKHSDUWLHVRUDORUZULWWHQ7KLV$JUHHPHQWPD\QRWEHDPHQGHGH[FHSWLQ
ZULWLQJVLJQHGE\ERWKSDUWLHV7KLV$JUHHPHQWVKDOOEHELQGLQJXSRQDQGLQXUHWRWKHEHQHILWRIWKH
SDUWLHV VXFFHVVRUVOHJDOUHSUHVHQWDWLYHVDQGDXWKRUL]HGDVVLJQV
,QWKHHYHQWRIDQ\FRQIOLFWEHWZHHQ\RXUREOLJDWLRQVHVWDEOLVKHGE\WKHVHWHUPVDQGFRQGLWLRQV
DQGWKRVHHVWDEOLVKHGE\&&&¶V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVWKHVHWHUPVDQG
FRQGLWLRQVVKDOOSUHYDLO
:,/(<H[SUHVVO\UHVHUYHVDOOULJKWVQRWVSHFLILFDOO\JUDQWHGLQWKHFRPELQDWLRQRI L WKHOLFHQVH
GHWDLOVSURYLGHGE\\RXDQGDFFHSWHGLQWKHFRXUVHRIWKLVOLFHQVLQJWUDQVDFWLRQ LL WKHVHWHUPVDQG
FRQGLWLRQVDQG LLL &&&¶V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQV
7KLV$JUHHPHQWZLOOEHYRLGLIWKH7\SHRI8VH)RUPDW&LUFXODWLRQRU5HTXHVWRU7\SHZDV
PLVUHSUHVHQWHGGXULQJWKHOLFHQVLQJSURFHVV
7KLV$JUHHPHQWVKDOOEHJRYHUQHGE\DQGFRQVWUXHGLQDFFRUGDQFHZLWKWKHODZVRIWKH6WDWHRI
1HZ<RUN86$ZLWKRXWUHJDUGVWRVXFKVWDWH¶VFRQIOLFWRIODZUXOHV$Q\OHJDODFWLRQVXLWRU
SURFHHGLQJDULVLQJRXWRIRUUHODWLQJWRWKHVH7HUPVDQG&RQGLWLRQVRUWKHEUHDFKWKHUHRIVKDOOEH
LQVWLWXWHGLQDFRXUWRIFRPSHWHQWMXULVGLFWLRQLQ1HZ<RUN&RXQW\LQWKH6WDWHRI1HZ<RUNLQWKH
8QLWHG6WDWHVRI$PHULFDDQGHDFKSDUW\KHUHE\FRQVHQWVDQGVXEPLWVWRWKHSHUVRQDOMXULVGLFWLRQ
RIVXFKFRXUWZDLYHVDQ\REMHFWLRQWRYHQXHLQVXFKFRXUWDQGFRQVHQWVWRVHUYLFHRISURFHVVE\
UHJLVWHUHGRUFHUWLILHGPDLOUHWXUQUHFHLSWUHTXHVWHGDWWKHODVWNQRZQDGGUHVVRIVXFKSDUW\
:LOH\2SHQ$FFHVV7HUPVDQG&RQGLWLRQV
$OOUHVHDUFKDUWLFOHVSXEOLVKHGLQ:LOH\2SHQ$FFHVVMRXUQDOVDUHIXOO\RSHQDFFHVVLPPHGLDWHO\
IUHHO\DYDLODEOHWRUHDGGRZQORDGDQGVKDUH$UWLFOHVDUHSXEOLVKHGXQGHUWKHWHUPVRIWKH&UHDWLYH
&RPPRQV$WWULEXWLRQ1RQ&RPPHUFLDO/LFHQVHZKLFKSHUPLWVXVHGLVWULEXWLRQDQGUHSURGXFWLRQLQ
DQ\PHGLXPSURYLGHGWKHRULJLQDOZRUNLVSURSHUO\FLWHGDQGLVQRWXVHGIRUFRPPHUFLDOSXUSRVHV
7KHOLFHQVHLVVXEMHFWWRWKH:LOH\2SHQ$FFHVVWHUPVDQGFRQGLWLRQV
:LOH\2SHQ$FFHVVDUWLFOHVDUHSURWHFWHGE\FRS\ULJKWDQGDUHSRVWHGWRUHSRVLWRULHVDQGZHEVLWHVLQ
DFFRUGDQFHZLWKWKHWHUPVRIWKH&UHDWLYH&RPPRQV$WWULEXWLRQ1RQ&RPPHUFLDO/LFHQVH$WWKH
WLPHRIGHSRVLW:LOH\2SHQ$FFHVVDUWLFOHVLQFOXGHDOOFKDQJHVPDGHGXULQJSHHUUHYLHZ
FRS\HGLWLQJDQGSXEOLVKLQJ5HSRVLWRULHVDQGZHEVLWHVWKDWKRVWWKHDUWLFOHDUHUHVSRQVLEOHIRU
LQFRUSRUDWLQJDQ\SXEOLVKHUVXSSOLHGDPHQGPHQWVRUUHWUDFWLRQVLVVXHGVXEVHTXHQWO\
:LOH\2SHQ$FFHVVDUWLFOHVDUHDOVRDYDLODEOHZLWKRXWFKDUJHRQ:LOH\ VSXEOLVKLQJSODWIRUP:LOH\
2QOLQH/LEUDU\RUDQ\VXFFHVVRUVLWHV
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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8VHE\QRQFRPPHUFLDOXVHUV
)RUQRQFRPPHUFLDODQGQRQSURPRWLRQDOSXUSRVHVLQGLYLGXDOXVHUVPD\DFFHVVGRZQORDGFRS\
GLVSOD\DQGUHGLVWULEXWHWRFROOHDJXHV:LOH\2SHQ$FFHVVDUWLFOHVDVZHOODVDGDSWWUDQVODWHWH[W
DQGGDWDPLQHWKHFRQWHQWVXEMHFWWRWKHIROORZLQJFRQGLWLRQV

7KHDXWKRUV PRUDOULJKWVDUHQRWFRPSURPLVHG7KHVHULJKWVLQFOXGHWKHULJKWRISDWHUQLW\
DOVRNQRZQDVDWWULEXWLRQWKHULJKWIRUWKHDXWKRUWREHLGHQWLILHGDVVXFK DQGLQWHJULW\
WKHULJKWIRUWKHDXWKRUQRWWRKDYHWKHZRUNDOWHUHGLQVXFKDZD\WKDWWKHDXWKRU VUHSXWDWLRQ
RULQWHJULW\PD\EHLPSXJQHG 
:KHUHFRQWHQWLQWKHDUWLFOHLVLGHQWLILHGDVEHORQJLQJWRDWKLUGSDUW\LWLVWKHREOLJDWLRQRI
WKHXVHUWRHQVXUHWKDWDQ\UHXVHFRPSOLHVZLWKWKHFRS\ULJKWSROLFLHVRIWKHRZQHURIWKDW
FRQWHQW
,IDUWLFOHFRQWHQWLVFRSLHGGRZQORDGHGRURWKHUZLVHUHXVHGIRUQRQFRPPHUFLDOUHVHDUFK
DQGHGXFDWLRQSXUSRVHVDOLQNWRWKHDSSURSULDWHELEOLRJUDSKLFFLWDWLRQ DXWKRUVMRXUQDODUWLFOH
WLWOHYROXPHLVVXHSDJHQXPEHUV'2,DQGWKHOLQNWRWKHGHILQLWLYHSXEOLVKHGYHUVLRQRQ
:LOH\2QOLQH/LEUDU\ VKRXOGEHPDLQWDLQHG&RS\ULJKWQRWLFHVDQGGLVFODLPHUVPXVWQRWEH
GHOHWHG
$Q\WUDQVODWLRQVIRUZKLFKDSULRUWUDQVODWLRQDJUHHPHQWZLWK:LOH\KDVQRWEHHQDJUHHG
PXVWSURPLQHQWO\GLVSOD\WKHVWDWHPHQW7KLVLVDQXQRIILFLDOWUDQVODWLRQRIDQDUWLFOHWKDW
DSSHDUHGLQD:LOH\SXEOLFDWLRQ7KHSXEOLVKHUKDVQRWHQGRUVHGWKLVWUDQVODWLRQ
8VHE\FRPPHUFLDOIRUSURILWRUJDQLVDWLRQV
8VHRI:LOH\2SHQ$FFHVVDUWLFOHVIRUFRPPHUFLDOSURPRWLRQDORUPDUNHWLQJSXUSRVHV
UHTXLUHVIXUWKHUH[SOLFLWSHUPLVVLRQIURP:LOH\DQGZLOOEHVXEMHFWWRDIHH&RPPHUFLDO
SXUSRVHVLQFOXGH
&RS\LQJRUGRZQORDGLQJRIDUWLFOHVRUOLQNLQJWRVXFKDUWLFOHVIRUIXUWKHUUHGLVWULEXWLRQVDOH
RUOLFHQVLQJ
&RS\LQJGRZQORDGLQJRUSRVWLQJE\DVLWHRUVHUYLFHWKDWLQFRUSRUDWHVDGYHUWLVLQJZLWKVXFK
FRQWHQW
7KHLQFOXVLRQRULQFRUSRUDWLRQRIDUWLFOHFRQWHQWLQRWKHUZRUNVRUVHUYLFHV RWKHUWKDQ
QRUPDOTXRWDWLRQVZLWKDQDSSURSULDWHFLWDWLRQ WKDWLVWKHQDYDLODEOHIRUVDOHRUOLFHQVLQJIRUD
IHH IRUH[DPSOHDFRPSLODWLRQSURGXFHGIRUPDUNHWLQJSXUSRVHVLQFOXVLRQLQDVDOHVSDFN
8VHRIDUWLFOHFRQWHQW RWKHUWKDQQRUPDOTXRWDWLRQVZLWKDSSURSULDWHFLWDWLRQ E\IRUSURILW
RUJDQLVDWLRQVIRUSURPRWLRQDOSXUSRVHV
/LQNLQJWRDUWLFOHFRQWHQWLQHPDLOVUHGLVWULEXWHGIRUSURPRWLRQDOPDUNHWLQJRUHGXFDWLRQDO
SXUSRVHV
8VHIRUWKHSXUSRVHVRIPRQHWDU\UHZDUGE\PHDQVRIVDOHUHVDOHOLFHQFHORDQWUDQVIHURU
RWKHUIRUPRIFRPPHUFLDOH[SORLWDWLRQVXFKDVPDUNHWLQJSURGXFWV
3ULQWUHSULQWVRI:LOH\2SHQ$FFHVVDUWLFOHVFDQEHSXUFKDVHGIURP
FRUSRUDWHVDOHV#ZLOH\FRP
2WKHU7HUPVDQG&RQGLWLRQV
%<&/,&.,1*217+(,$*5((%2;<28$&.12:/('*(7+$7<28
+$9(5($'$1')8//<81'(567$1'($&+2)7+(6(&7,2162)$1'
3529,6,2166(7)257+,17+,6$*5((0(17$1'7+$7<28$5(,1
$*5((0(17:,7+$1'$5(:,//,1*72$&&(37$//2)<285
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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2%/,*$7,216$66(7)257+,17+,6$*5((0(17
Y
,I\RXZRXOGOLNHWRSD\IRUWKLVOLFHQVHQRZSOHDVHUHPLWWKLVOLFHQVHDORQJZLWK\RXU
SD\PHQWPDGHSD\DEOHWR&23<5,*+7&/($5$1&(&(17(5RWKHUZLVH\RXZLOOEH
LQYRLFHGZLWKLQKRXUVRIWKHOLFHQVHGDWH3D\PHQWVKRXOGEHLQWKHIRUPRIDFKHFN
RUPRQH\RUGHUUHIHUHQFLQJ\RXUDFFRXQWQXPEHUDQGWKLVLQYRLFHQXPEHU
5/1.
2QFH\RXUHFHLYH\RXULQYRLFHIRUWKLVRUGHU\RXPD\SD\\RXULQYRLFHE\FUHGLWFDUG
3OHDVHIROORZLQVWUXFWLRQVSURYLGHGDWWKDWWLPH
0DNH3D\PHQW7R
&RS\ULJKW&OHDUDQFH&HQWHU
'HSW
32%R[
%RVWRQ0$
)RUVXJJHVWLRQVRUFRPPHQWVUHJDUGLQJWKLVRUGHUFRQWDFW5LJKWV/LQN&XVWRPHU
6XSSRUWFXVWRPHUFDUH#FRS\ULJKWFRPRU WROOIUHHLQWKH86 RU

*UDWLVOLFHQVHV UHIHUHQFLQJLQWKH7RWDOILHOG DUHIUHH3OHDVHUHWDLQWKLVSULQWDEOH
OLFHQVHIRU\RXUUHIHUHQFH1RSD\PHQWLVUHTXLUHG

KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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Figure 1.2 A Reprint Permissions
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635,1*(5/,&(16(
7(506$1'&21',7,216
$SU

7KLVLVD/LFHQVH$JUHHPHQWEHWZHHQ5REHUW'&KDYH] <RX DQG6SULQJHU 6SULQJHU
SURYLGHGE\&RS\ULJKW&OHDUDQFH&HQWHU &&& 7KHOLFHQVHFRQVLVWVRI\RXURUGHUGHWDLOV
WKHWHUPVDQGFRQGLWLRQVSURYLGHGE\6SULQJHUDQGWKHSD\PHQWWHUPVDQGFRQGLWLRQV
$OOSD\PHQWVPXVWEHPDGHLQIXOOWR&&&)RUSD\PHQWLQVWUXFWLRQVSOHDVHVHH
LQIRUPDWLRQOLVWHGDWWKHERWWRPRIWKLVIRUP
/LFHQVH1XPEHU



/LFHQVHGDWH

$SU

/LFHQVHGFRQWHQWSXEOLVKHU

6SULQJHU

/LFHQVHGFRQWHQWSXEOLFDWLRQ $QQDOVRI%LRPHGLFDO(QJLQHHULQJ
/LFHQVHGFRQWHQWWLWOH

)DFWRUV,QIOXHQFLQJ%ORRG)ORZ3DWWHUQVLQWKH+XPDQ5LJKW&RURQDU\
$UWHU\

/LFHQVHGFRQWHQWDXWKRU

-*0\HUV

/LFHQVHGFRQWHQWGDWH

)HE

9ROXPHQXPEHU



,VVXHQXPEHU



7\SHRI8VH

7KHVLV'LVVHUWDWLRQ

3RUWLRQ

)LJXUHV

$XWKRURIWKLV6SULQJHUDUWLFOH 1R
2UGHUUHIHUHQFHQXPEHU
7LWOHRI\RXUWKHVLV
GLVVHUWDWLRQ

'HYHORSPHQWRI,Q9LWUR7LVVXH(QJLQHHUHG%ORRG9HVVHO0LPLFVLQ
&RPSOH[*HRPHWULHVIRU&RURQDU\6WHQW7HVWLQJ

([SHFWHGFRPSOHWLRQGDWH

0D\

(VWLPDWHGVL]H SDJHV



7RWDO

86'

7HUPVDQG&RQGLWLRQV

,QWURGXFWLRQ
7KHSXEOLVKHUIRUWKLVFRS\ULJKWHGPDWHULDOLV6SULQJHU6FLHQFH%XVLQHVV0HGLD%\FOLFNLQJ
DFFHSWLQFRQQHFWLRQZLWKFRPSOHWLQJWKLVOLFHQVLQJWUDQVDFWLRQ\RXDJUHHWKDWWKHIROORZLQJ
WHUPVDQGFRQGLWLRQVDSSO\WRWKLVWUDQVDFWLRQ DORQJZLWKWKH%LOOLQJDQG3D\PHQWWHUPVDQG
FRQGLWLRQVHVWDEOLVKHGE\&RS\ULJKW&OHDUDQFH&HQWHU,QF &&& DWWKHWLPHWKDW\RX
RSHQHG\RXU5LJKWVOLQNDFFRXQWDQGWKDWDUHDYDLODEOHDWDQ\WLPHDW
KWWSP\DFFRXQWFRS\ULJKWFRP 
/LPLWHG/LFHQVH
:LWKUHIHUHQFHWR\RXUUHTXHVWWRUHSULQWLQ\RXUWKHVLVPDWHULDORQZKLFK6SULQJHU6FLHQFHDQG
%XVLQHVV0HGLDFRQWUROWKHFRS\ULJKWSHUPLVVLRQLVJUDQWHGIUHHRIFKDUJHIRUWKHXVH
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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LQGLFDWHGLQ\RXUHQTXLU\
/LFHQVHVDUHIRURQHWLPHXVHRQO\ZLWKDPD[LPXPGLVWULEXWLRQHTXDOWRWKHQXPEHUWKDW\RX
LGHQWLILHGLQWKHOLFHQVLQJSURFHVV
7KLV/LFHQVHLQFOXGHVXVHLQDQHOHFWURQLFIRUPSURYLGHGLWVSDVVZRUGSURWHFWHGRURQWKH
XQLYHUVLW\·VLQWUDQHWRUUHSRVLWRU\LQFOXGLQJ80, DFFRUGLQJWRWKHGHILQLWLRQDWWKH6KHUSD
ZHEVLWHKWWSZZZVKHUSDDFXNURPHR )RUDQ\RWKHUHOHFWURQLFXVHSOHDVHFRQWDFW
6SULQJHUDW SHUPLVVLRQVGRUGUHFKW#VSULQJHUFRPRUSHUPLVVLRQVKHLGHOEHUJ#VSULQJHUFRP 
7KHPDWHULDOFDQRQO\EHXVHGIRUWKHSXUSRVHRIGHIHQGLQJ\RXUWKHVLVDQGZLWKDPD[LPXP
RIH[WUDFRSLHVLQSDSHU
$OWKRXJK6SULQJHUKROGVFRS\ULJKWWRWKHPDWHULDODQGLVHQWLWOHGWRQHJRWLDWHRQULJKWVWKLV
OLFHQVHLVRQO\YDOLGSURYLGHGSHUPLVVLRQLVDOVRREWDLQHGIURPWKH FR DXWKRU DGGUHVVLV
JLYHQZLWKWKHDUWLFOHFKDSWHU DQGSURYLGHGLWFRQFHUQVRULJLQDOPDWHULDOZKLFKGRHVQRWFDUU\
UHIHUHQFHVWRRWKHUVRXUFHV LIPDWHULDOLQTXHVWLRQDSSHDUVZLWKFUHGLWWRDQRWKHUVRXUFH
DXWKRUL]DWLRQIURPWKDWVRXUFHLVUHTXLUHGDVZHOO 
3HUPLVVLRQIUHHRIFKDUJHRQWKLVRFFDVLRQGRHVQRWSUHMXGLFHDQ\ULJKWVZHPLJKWKDYHWR
FKDUJHIRUUHSURGXFWLRQRIRXUFRS\ULJKWHGPDWHULDOLQWKHIXWXUH
$OWHULQJ0RGLI\LQJ0DWHULDO1RW3HUPLWWHG
<RXPD\QRWDOWHURUPRGLI\WKHPDWHULDOLQDQ\PDQQHU$EEUHYLDWLRQVDGGLWLRQVGHOHWLRQV
DQGRUDQ\RWKHUDOWHUDWLRQVVKDOOEHPDGHRQO\ZLWKSULRUZULWWHQDXWKRUL]DWLRQRIWKHDXWKRU V
DQGRU6SULQJHU6FLHQFH%XVLQHVV0HGLD 3OHDVHFRQWDFW6SULQJHUDW
SHUPLVVLRQVGRUGUHFKW#VSULQJHUFRPRUSHUPLVVLRQVKHLGHOEHUJ#VSULQJHUFRP
5HVHUYDWLRQRI5LJKWV
6SULQJHU6FLHQFH%XVLQHVV0HGLDUHVHUYHVDOOULJKWVQRWVSHFLILFDOO\JUDQWHGLQWKH
FRPELQDWLRQRI L WKHOLFHQVHGHWDLOVSURYLGHGE\\RXDQGDFFHSWHGLQWKHFRXUVHRIWKLV
OLFHQVLQJWUDQVDFWLRQ LL WKHVHWHUPVDQGFRQGLWLRQVDQG LLL &&& V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV
&RS\ULJKW1RWLFH'LVFODLPHU
<RXPXVWLQFOXGHWKHIROORZLQJFRS\ULJKWDQGSHUPLVVLRQQRWLFHLQFRQQHFWLRQZLWKDQ\
UHSURGXFWLRQRIWKHOLFHQVHGPDWHULDO6SULQJHUDQGWKHRULJLQDOSXEOLVKHUMRXUQDOWLWOH
YROXPH\HDURISXEOLFDWLRQSDJHFKDSWHUDUWLFOHWLWOHQDPH V RIDXWKRU V ILJXUHQXPEHU V 
RULJLQDOFRS\ULJKWQRWLFH LVJLYHQWRWKHSXEOLFDWLRQLQZKLFKWKHPDWHULDOZDVRULJLQDOO\
SXEOLVKHGE\DGGLQJZLWKNLQGSHUPLVVLRQIURP6SULQJHU6FLHQFHDQG%XVLQHVV0HGLD
:DUUDQWLHV1RQH
([DPSOH6SULQJHU6FLHQFH%XVLQHVV0HGLDPDNHVQRUHSUHVHQWDWLRQVRUZDUUDQWLHVZLWK
UHVSHFWWRWKHOLFHQVHGPDWHULDO
([DPSOH6SULQJHU6FLHQFH%XVLQHVV0HGLDPDNHVQRUHSUHVHQWDWLRQVRUZDUUDQWLHVZLWK
UHVSHFWWRWKHOLFHQVHGPDWHULDODQGDGRSWVRQLWVRZQEHKDOIWKHOLPLWDWLRQVDQGGLVFODLPHUV
HVWDEOLVKHGE\&&&RQLWVEHKDOILQLWV%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVIRUWKLV
OLFHQVLQJWUDQVDFWLRQ
,QGHPQLW\
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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<RXKHUHE\LQGHPQLI\DQGDJUHHWRKROGKDUPOHVV6SULQJHU6FLHQFH%XVLQHVV0HGLDDQG
&&&DQGWKHLUUHVSHFWLYHRIILFHUVGLUHFWRUVHPSOR\HHVDQGDJHQWVIURPDQGDJDLQVWDQ\DQG
DOOFODLPVDULVLQJRXWRI\RXUXVHRIWKHOLFHQVHGPDWHULDORWKHUWKDQDVVSHFLILFDOO\DXWKRUL]HG
SXUVXDQWWRWKLVOLFHQVH
1R7UDQVIHURI/LFHQVH
7KLVOLFHQVHLVSHUVRQDOWR\RXDQGPD\QRWEHVXEOLFHQVHGDVVLJQHGRUWUDQVIHUUHGE\\RXWR
DQ\RWKHUSHUVRQZLWKRXW6SULQJHU6FLHQFH%XVLQHVV0HGLD VZULWWHQSHUPLVVLRQ
1R$PHQGPHQW([FHSWLQ:ULWLQJ
7KLVOLFHQVHPD\QRWEHDPHQGHGH[FHSWLQDZULWLQJVLJQHGE\ERWKSDUWLHV RULQWKHFDVHRI
6SULQJHU6FLHQFH%XVLQHVV0HGLDE\&&&RQ6SULQJHU6FLHQFH%XVLQHVV0HGLD VEHKDOI 
2EMHFWLRQWR&RQWUDU\7HUPV
6SULQJHU6FLHQFH%XVLQHVV0HGLDKHUHE\REMHFWVWRDQ\WHUPVFRQWDLQHGLQDQ\SXUFKDVH
RUGHUDFNQRZOHGJPHQWFKHFNHQGRUVHPHQWRURWKHUZULWLQJSUHSDUHGE\\RXZKLFKWHUPVDUH
LQFRQVLVWHQWZLWKWKHVHWHUPVDQGFRQGLWLRQVRU&&& V%LOOLQJDQG3D\PHQWWHUPVDQG
FRQGLWLRQV7KHVHWHUPVDQGFRQGLWLRQVWRJHWKHUZLWK&&& V%LOOLQJDQG3D\PHQWWHUPVDQG
FRQGLWLRQV ZKLFKDUHLQFRUSRUDWHGKHUHLQ FRPSULVHWKHHQWLUHDJUHHPHQWEHWZHHQ\RXDQG
6SULQJHU6FLHQFH%XVLQHVV0HGLD DQG&&& FRQFHUQLQJWKLVOLFHQVLQJWUDQVDFWLRQ,QWKH
HYHQWRIDQ\FRQIOLFWEHWZHHQ\RXUREOLJDWLRQVHVWDEOLVKHGE\WKHVHWHUPVDQGFRQGLWLRQVDQG
WKRVHHVWDEOLVKHGE\&&& V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVWKHVHWHUPVDQG
FRQGLWLRQVVKDOOFRQWURO
-XULVGLFWLRQ
$OOGLVSXWHVWKDWPD\DULVHLQFRQQHFWLRQZLWKWKLVSUHVHQW/LFHQVHRUWKHEUHDFKWKHUHRIVKDOO
EHVHWWOHGH[FOXVLYHO\E\DUELWUDWLRQWREHKHOGLQ7KH1HWKHUODQGVLQDFFRUGDQFHZLWK'XWFK
ODZDQGWREHFRQGXFWHGXQGHUWKH5XOHVRIWKH 1HWKHUODQGV$UELWUDJH,QVWLWXXW  1HWKHUODQGV
,QVWLWXWHRI$UELWUDWLRQ 25
$OOGLVSXWHVWKDWPD\DULVHLQFRQQHFWLRQZLWKWKLVSUHVHQW/LFHQVHRUWKHEUHDFK
WKHUHRIVKDOOEHVHWWOHGH[FOXVLYHO\E\DUELWUDWLRQWREHKHOGLQWKH)HGHUDO5HSXEOLFRI
*HUPDQ\LQDFFRUGDQFHZLWK*HUPDQODZ
2WKHUWHUPVDQGFRQGLWLRQV
Y
,I\RXZRXOGOLNHWRSD\IRUWKLVOLFHQVHQRZSOHDVHUHPLWWKLVOLFHQVHDORQJZLWK\RXU
SD\PHQWPDGHSD\DEOHWR&23<5,*+7&/($5$1&(&(17(5RWKHUZLVH\RXZLOOEH
LQYRLFHGZLWKLQKRXUVRIWKHOLFHQVHGDWH3D\PHQWVKRXOGEHLQWKHIRUPRIDFKHFN
RUPRQH\RUGHUUHIHUHQFLQJ\RXUDFFRXQWQXPEHUDQGWKLVLQYRLFHQXPEHU
5/1.
2QFH\RXUHFHLYH\RXULQYRLFHIRUWKLVRUGHU\RXPD\SD\\RXULQYRLFHE\FUHGLWFDUG
3OHDVHIROORZLQVWUXFWLRQVSURYLGHGDWWKDWWLPH
0DNH3D\PHQW7R
&RS\ULJKW&OHDUDQFH&HQWHU
'HSW
32%R[
%RVWRQ0$
)RUVXJJHVWLRQVRUFRPPHQWVUHJDUGLQJWKLVRUGHUFRQWDFW5LJKWV/LQN&XVWRPHU
6XSSRUWFXVWRPHUFDUH#FRS\ULJKWFRPRU WROOIUHHLQWKH86 RU

KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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*UDWLVOLFHQVHV UHIHUHQFLQJLQWKH7RWDOILHOG DUHIUHH3OHDVHUHWDLQWKLVSULQWDEOH
OLFHQVHIRU\RXUUHIHUHQFH1RSD\PHQWLVUHTXLUHG

KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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Figure 1.3 Reprint Permissions


5LJKWVOLQN3ULQWDEOH/LFHQVH

(/6(9,(5/,&(16(
7(506$1'&21',7,216
$SU

7KLVLVD/LFHQVH$JUHHPHQWEHWZHHQ5REHUW'&KDYH] <RX DQG(OVHYLHU (OVHYLHU
SURYLGHGE\&RS\ULJKW&OHDUDQFH&HQWHU &&& 7KHOLFHQVHFRQVLVWVRI\RXURUGHUGHWDLOV
WKHWHUPVDQGFRQGLWLRQVSURYLGHGE\(OVHYLHUDQGWKHSD\PHQWWHUPVDQGFRQGLWLRQV
$OOSD\PHQWVPXVWEHPDGHLQIXOOWR&&&)RUSD\PHQWLQVWUXFWLRQVSOHDVHVHH
LQIRUPDWLRQOLVWHGDWWKHERWWRPRIWKLVIRUP
6XSSOLHU

(OVHYLHU/LPLWHG
7KH%RXOHYDUG/DQJIRUG/DQH
.LGOLQJWRQ2[IRUG2;*%8.

5HJLVWHUHG&RPSDQ\1XPEHU 
&XVWRPHUQDPH

5REHUW'&KDYH]

&XVWRPHUDGGUHVV

5H\QROGV'ULYH



)UHPRQW&$

/LFHQVHQXPEHU



/LFHQVHGDWH

$SU

/LFHQVHGFRQWHQWSXEOLVKHU

(OVHYLHU

/LFHQVHGFRQWHQWSXEOLFDWLRQ -RXUQDORIWKH$PHULFDQ&ROOHJHRI&DUGLRORJ\
/LFHQVHGFRQWHQWWLWOH

5ROHRI(QGRWKHOLDO6KHDU6WUHVVLQWKH1DWXUDO+LVWRU\RI&RURQDU\
$WKHURVFOHURVLVDQG9DVFXODU5HPRGHOLQJ0ROHFXODU&HOOXODUDQG
9DVFXODU%HKDYLRU

/LFHQVHGFRQWHQWDXWKRU

<LDQQLV6&KDW]L]LVLV$KPHW8PLW&RVNXQ0LFKDHO-RQDV(OD]HU5
(GHOPDQ&KDUOHV/)HOGPDQ3HWHU+6WRQH

/LFHQVHGFRQWHQWGDWH

-XQH

/LFHQVHGFRQWHQWYROXPH
QXPEHU



/LFHQVHGFRQWHQWLVVXH
QXPEHU



1XPEHURISDJHV



6WDUW3DJH



(QG3DJH



7\SHRI8VH

UHXVHLQDWKHVLVGLVVHUWDWLRQ

3RUWLRQ

ILJXUHVWDEOHVLOOXVWUDWLRQV

1XPEHURI
ILJXUHVWDEOHVLOOXVWUDWLRQV



)RUPDW

ERWKSULQWDQGHOHFWURQLF

$UH\RXWKHDXWKRURIWKLV
(OVHYLHUDUWLFOH"

1R

KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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:LOO\RXEHWUDQVODWLQJ"
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1R

2UGHUUHIHUHQFHQXPEHU
7LWOHRI\RXU
WKHVLVGLVVHUWDWLRQ

'HYHORSPHQWRI,Q9LWUR7LVVXH(QJLQHHUHG%ORRG9HVVHO0LPLFVLQ
&RPSOH[*HRPHWULHVIRU&RURQDU\6WHQW7HVWLQJ

([SHFWHGFRPSOHWLRQGDWH

0D\

(VWLPDWHGVL]H QXPEHURI
SDJHV



(OVHYLHU9$7QXPEHU

*%

3HUPLVVLRQVSULFH

86'

9$7/RFDO6DOHV7D[

86'*%3

7RWDO

86'

7HUPVDQG&RQGLWLRQV

,1752'8&7,21
7KHSXEOLVKHUIRUWKLVFRS\ULJKWHGPDWHULDOLV(OVHYLHU%\FOLFNLQJDFFHSWLQFRQQHFWLRQ
ZLWKFRPSOHWLQJWKLVOLFHQVLQJWUDQVDFWLRQ\RXDJUHHWKDWWKHIROORZLQJWHUPVDQGFRQGLWLRQV
DSSO\WRWKLVWUDQVDFWLRQ DORQJZLWKWKH%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVHVWDEOLVKHG
E\&RS\ULJKW&OHDUDQFH&HQWHU,QF &&& DWWKHWLPHWKDW\RXRSHQHG\RXU5LJKWVOLQN
DFFRXQWDQGWKDWDUHDYDLODEOHDWDQ\WLPHDWKWWSP\DFFRXQWFRS\ULJKWFRP 
*(1(5$/7(506
(OVHYLHUKHUHE\JUDQWV\RXSHUPLVVLRQWRUHSURGXFHWKHDIRUHPHQWLRQHGPDWHULDOVXEMHFWWR
WKHWHUPVDQGFRQGLWLRQVLQGLFDWHG
$FNQRZOHGJHPHQW,IDQ\SDUWRIWKHPDWHULDOWREHXVHG IRUH[DPSOHILJXUHV KDV
DSSHDUHGLQRXUSXEOLFDWLRQZLWKFUHGLWRUDFNQRZOHGJHPHQWWRDQRWKHUVRXUFHSHUPLVVLRQ
PXVWDOVREHVRXJKWIURPWKDWVRXUFH,IVXFKSHUPLVVLRQLVQRWREWDLQHGWKHQWKDWPDWHULDOPD\
QRWEHLQFOXGHGLQ\RXUSXEOLFDWLRQFRSLHV6XLWDEOHDFNQRZOHGJHPHQWWRWKHVRXUFHPXVWEH
PDGHHLWKHUDVDIRRWQRWHRULQDUHIHUHQFHOLVWDWWKHHQGRI\RXUSXEOLFDWLRQDVIROORZV
´5HSULQWHGIURP3XEOLFDWLRQWLWOH9ROHGLWLRQQXPEHU$XWKRU V 7LWOHRIDUWLFOHWLWOHRI
FKDSWHU3DJHV1R&RS\ULJKW <HDU ZLWKSHUPLVVLRQIURP(OVHYLHU>25$33/,&$%/(
62&,(7<&23<5,*+72:1(5@µ$OVR/DQFHWVSHFLDOFUHGLW´5HSULQWHGIURP7KH
/DQFHW9ROQXPEHU$XWKRU V 7LWOHRIDUWLFOH3DJHV1R&RS\ULJKW <HDU ZLWKSHUPLVVLRQ
IURP(OVHYLHUµ
5HSURGXFWLRQRIWKLVPDWHULDOLVFRQILQHGWRWKHSXUSRVHDQGRUPHGLDIRUZKLFKSHUPLVVLRQ
LVKHUHE\JLYHQ
$OWHULQJ0RGLI\LQJ0DWHULDO1RW3HUPLWWHG+RZHYHUILJXUHVDQGLOOXVWUDWLRQVPD\EH
DOWHUHGDGDSWHGPLQLPDOO\WRVHUYH\RXUZRUN$Q\RWKHUDEEUHYLDWLRQVDGGLWLRQVGHOHWLRQV
DQGRUDQ\RWKHUDOWHUDWLRQVVKDOOEHPDGHRQO\ZLWKSULRUZULWWHQDXWKRUL]DWLRQRI(OVHYLHU/WG
3OHDVHFRQWDFW(OVHYLHUDWSHUPLVVLRQV#HOVHYLHUFRP
,IWKHSHUPLVVLRQIHHIRUWKHUHTXHVWHGXVHRIRXUPDWHULDOLVZDLYHGLQWKLVLQVWDQFHSOHDVH
EHDGYLVHGWKDW\RXUIXWXUHUHTXHVWVIRU(OVHYLHUPDWHULDOVPD\DWWUDFWDIHH
5HVHUYDWLRQRI5LJKWV3XEOLVKHUUHVHUYHVDOOULJKWVQRWVSHFLILFDOO\JUDQWHGLQWKH
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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FRPELQDWLRQRI L WKHOLFHQVHGHWDLOVSURYLGHGE\\RXDQGDFFHSWHGLQWKHFRXUVHRIWKLV
OLFHQVLQJWUDQVDFWLRQ LL WKHVHWHUPVDQGFRQGLWLRQVDQG LLL &&& V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV
/LFHQVH&RQWLQJHQW8SRQ3D\PHQW:KLOH\RXPD\H[HUFLVHWKHULJKWVOLFHQVHGLPPHGLDWHO\
XSRQLVVXDQFHRIWKHOLFHQVHDWWKHHQGRIWKHOLFHQVLQJSURFHVVIRUWKHWUDQVDFWLRQSURYLGHG
WKDW\RXKDYHGLVFORVHGFRPSOHWHDQGDFFXUDWHGHWDLOVRI\RXUSURSRVHGXVHQROLFHQVHLV
ILQDOO\HIIHFWLYHXQOHVVDQGXQWLOIXOOSD\PHQWLVUHFHLYHGIURP\RX HLWKHUE\SXEOLVKHURUE\
&&& DVSURYLGHGLQ&&& V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQV,IIXOOSD\PHQWLVQRW
UHFHLYHGRQDWLPHO\EDVLVWKHQDQ\OLFHQVHSUHOLPLQDULO\JUDQWHGVKDOOEHGHHPHG
DXWRPDWLFDOO\UHYRNHGDQGVKDOOEHYRLGDVLIQHYHUJUDQWHG)XUWKHULQWKHHYHQWWKDW\RX
EUHDFKDQ\RIWKHVHWHUPVDQGFRQGLWLRQVRUDQ\RI&&& V%LOOLQJDQG3D\PHQWWHUPVDQG
FRQGLWLRQVWKHOLFHQVHLVDXWRPDWLFDOO\UHYRNHGDQGVKDOOEHYRLGDVLIQHYHUJUDQWHG8VHRI
PDWHULDOVDVGHVFULEHGLQDUHYRNHGOLFHQVHDVZHOODVDQ\XVHRIWKHPDWHULDOVEH\RQGWKH
VFRSHRIDQXQUHYRNHGOLFHQVHPD\FRQVWLWXWHFRS\ULJKWLQIULQJHPHQWDQGSXEOLVKHUUHVHUYHV
WKHULJKWWRWDNHDQ\DQGDOODFWLRQWRSURWHFWLWVFRS\ULJKWLQWKHPDWHULDOV
:DUUDQWLHV3XEOLVKHUPDNHVQRUHSUHVHQWDWLRQVRUZDUUDQWLHVZLWKUHVSHFWWRWKHOLFHQVHG
PDWHULDO
,QGHPQLW\<RXKHUHE\LQGHPQLI\DQGDJUHHWRKROGKDUPOHVVSXEOLVKHUDQG&&&DQG
WKHLUUHVSHFWLYHRIILFHUVGLUHFWRUVHPSOR\HHVDQGDJHQWVIURPDQGDJDLQVWDQ\DQGDOOFODLPV
DULVLQJRXWRI\RXUXVHRIWKHOLFHQVHGPDWHULDORWKHUWKDQDVVSHFLILFDOO\DXWKRUL]HGSXUVXDQWWR
WKLVOLFHQVH
1R7UDQVIHURI/LFHQVH7KLVOLFHQVHLVSHUVRQDOWR\RXDQGPD\QRWEHVXEOLFHQVHG
DVVLJQHGRUWUDQVIHUUHGE\\RXWRDQ\RWKHUSHUVRQZLWKRXWSXEOLVKHU VZULWWHQSHUPLVVLRQ
1R$PHQGPHQW([FHSWLQ:ULWLQJ7KLVOLFHQVHPD\QRWEHDPHQGHGH[FHSWLQDZULWLQJ
VLJQHGE\ERWKSDUWLHV RULQWKHFDVHRISXEOLVKHUE\&&&RQSXEOLVKHU VEHKDOI 
2EMHFWLRQWR&RQWUDU\7HUPV3XEOLVKHUKHUHE\REMHFWVWRDQ\WHUPVFRQWDLQHGLQDQ\
SXUFKDVHRUGHUDFNQRZOHGJPHQWFKHFNHQGRUVHPHQWRURWKHUZULWLQJSUHSDUHGE\\RXZKLFK
WHUPVDUHLQFRQVLVWHQWZLWKWKHVHWHUPVDQGFRQGLWLRQVRU&&& V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV7KHVHWHUPVDQGFRQGLWLRQVWRJHWKHUZLWK&&& V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV ZKLFKDUHLQFRUSRUDWHGKHUHLQ FRPSULVHWKHHQWLUHDJUHHPHQWEHWZHHQ\RX
DQGSXEOLVKHU DQG&&& FRQFHUQLQJWKLVOLFHQVLQJWUDQVDFWLRQ,QWKHHYHQWRIDQ\FRQIOLFW
EHWZHHQ\RXUREOLJDWLRQVHVWDEOLVKHGE\WKHVHWHUPVDQGFRQGLWLRQVDQGWKRVHHVWDEOLVKHGE\
&&& V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVWKHVHWHUPVDQGFRQGLWLRQVVKDOOFRQWURO
5HYRFDWLRQ(OVHYLHURU&RS\ULJKW&OHDUDQFH&HQWHUPD\GHQ\WKHSHUPLVVLRQVGHVFULEHG
LQWKLV/LFHQVHDWWKHLUVROHGLVFUHWLRQIRUDQ\UHDVRQRUQRUHDVRQZLWKDIXOOUHIXQGSD\DEOH
WR\RX1RWLFHRIVXFKGHQLDOZLOOEHPDGHXVLQJWKHFRQWDFWLQIRUPDWLRQSURYLGHGE\\RX
)DLOXUHWRUHFHLYHVXFKQRWLFHZLOOQRWDOWHURULQYDOLGDWHWKHGHQLDO,QQRHYHQWZLOO(OVHYLHU
RU&RS\ULJKW&OHDUDQFH&HQWHUEHUHVSRQVLEOHRUOLDEOHIRUDQ\FRVWVH[SHQVHVRUGDPDJH
LQFXUUHGE\\RXDVDUHVXOWRIDGHQLDORI\RXUSHUPLVVLRQUHTXHVWRWKHUWKDQDUHIXQGRIWKH
DPRXQW V SDLGE\\RXWR(OVHYLHUDQGRU&RS\ULJKW&OHDUDQFH&HQWHUIRUGHQLHGSHUPLVVLRQV
/,0,7('/,&(16(
7KHIROORZLQJWHUPVDQGFRQGLWLRQVDSSO\RQO\WRVSHFLILFOLFHQVHW\SHV
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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7UDQVODWLRQ7KLVSHUPLVVLRQLVJUDQWHGIRUQRQH[FOXVLYHZRUOG(QJOLVKULJKWVRQO\
XQOHVV\RXUOLFHQVHZDVJUDQWHGIRUWUDQVODWLRQULJKWV,I\RXOLFHQVHGWUDQVODWLRQULJKWV\RX
PD\RQO\WUDQVODWHWKLVFRQWHQWLQWRWKHODQJXDJHV\RXUHTXHVWHG$SURIHVVLRQDOWUDQVODWRU
PXVWSHUIRUPDOOWUDQVODWLRQVDQGUHSURGXFHWKHFRQWHQWZRUGIRUZRUGSUHVHUYLQJWKHLQWHJULW\
RIWKHDUWLFOH,IWKLVOLFHQVHLVWRUHXVHRUILJXUHVWKHQSHUPLVVLRQLVJUDQWHGIRUQRQ
H[FOXVLYHZRUOGULJKWVLQDOOODQJXDJHV
:HEVLWH7KHIROORZLQJWHUPVDQGFRQGLWLRQVDSSO\WRHOHFWURQLFUHVHUYHDQGDXWKRU
ZHEVLWHV
(OHFWURQLFUHVHUYH,IOLFHQVHGPDWHULDOLVWREHSRVWHGWRZHEVLWHWKHZHEVLWHLVWREH
SDVVZRUGSURWHFWHGDQGPDGHDYDLODEOHRQO\WRERQDILGHVWXGHQWVUHJLVWHUHGRQDUHOHYDQW
FRXUVHLI
7KLVOLFHQVHZDVPDGHLQFRQQHFWLRQZLWKDFRXUVH
7KLVSHUPLVVLRQLVJUDQWHGIRU\HDURQO\<RXPD\REWDLQDOLFHQVHIRUIXWXUHZHEVLWH
SRVWLQJ
$OOFRQWHQWSRVWHGWRWKHZHEVLWHPXVWPDLQWDLQWKHFRS\ULJKWLQIRUPDWLRQOLQHRQWKHERWWRP
RIHDFKLPDJH
$K\SHUWH[WPXVWEHLQFOXGHGWRWKH+RPHSDJHRIWKHMRXUQDOIURPZKLFK\RXDUHOLFHQVLQJDW
KWWSZZZVFLHQFHGLUHFWFRPVFLHQFHMRXUQDO[[[[[RUWKH(OVHYLHUKRPHSDJHIRUERRNVDW
KWWSZZZHOVHYLHUFRPDQG
&HQWUDO6WRUDJH7KLVOLFHQVHGRHVQRWLQFOXGHSHUPLVVLRQIRUDVFDQQHGYHUVLRQRIWKHPDWHULDO
WREHVWRUHGLQDFHQWUDOUHSRVLWRU\VXFKDVWKDWSURYLGHGE\+HURQ;DQ(GX
$XWKRUZHEVLWHIRUMRXUQDOVZLWKWKHIROORZLQJDGGLWLRQDOFODXVHV
$OOFRQWHQWSRVWHGWRWKHZHEVLWHPXVWPDLQWDLQWKHFRS\ULJKWLQIRUPDWLRQOLQHRQWKHERWWRP
RIHDFKLPDJHDQG
KHSHUPLVVLRQJUDQWHGLVOLPLWHGWRWKHSHUVRQDOYHUVLRQRI\RXUSDSHU<RXDUHQRWDOORZHGWR
GRZQORDGDQGSRVWWKHSXEOLVKHGHOHFWURQLFYHUVLRQRI\RXUDUWLFOH ZKHWKHU3')RU+70/
SURRIRUILQDOYHUVLRQ QRUPD\\RXVFDQWKHSULQWHGHGLWLRQWRFUHDWHDQHOHFWURQLFYHUVLRQ
$K\SHUWH[WPXVWEHLQFOXGHGWRWKH+RPHSDJHRIWKHMRXUQDOIURPZKLFK\RXDUHOLFHQVLQJDW
KWWSZZZVFLHQFHGLUHFWFRPVFLHQFHMRXUQDO[[[[[$VSDUWRIRXUQRUPDOSURGXFWLRQ
SURFHVV\RXZLOOUHFHLYHDQHPDLOQRWLFHZKHQ\RXUDUWLFOHDSSHDUVRQ(OVHYLHU·VRQOLQH
VHUYLFH6FLHQFH'LUHFW ZZZVFLHQFHGLUHFWFRP 7KDWHPDLOZLOOLQFOXGHWKHDUWLFOH·V'LJLWDO
2EMHFW,GHQWLILHU '2, 7KLVQXPEHUSURYLGHVWKHHOHFWURQLFOLQNWRWKHSXEOLVKHGDUWLFOHDQG
VKRXOGEHLQFOXGHGLQWKHSRVWLQJRI\RXUSHUVRQDOYHUVLRQ:HDVNWKDW\RXZDLWXQWLO\RX
UHFHLYHWKLVHPDLODQGKDYHWKH'2,WRGRDQ\SRVWLQJ
&HQWUDO6WRUDJH7KLVOLFHQVHGRHVQRWLQFOXGHSHUPLVVLRQIRUDVFDQQHGYHUVLRQRIWKHPDWHULDO
WREHVWRUHGLQDFHQWUDOUHSRVLWRU\VXFKDVWKDWSURYLGHGE\+HURQ;DQ(GX
$XWKRUZHEVLWHIRUERRNVZLWKWKHIROORZLQJDGGLWLRQDOFODXVHV
$XWKRUVDUHSHUPLWWHGWRSODFHDEULHIVXPPDU\RIWKHLUZRUNRQOLQHRQO\
$K\SHUWH[WPXVWEHLQFOXGHGWRWKH(OVHYLHUKRPHSDJHDWKWWSZZZHOVHYLHUFRP
$OOFRQWHQWSRVWHGWRWKHZHEVLWHPXVWPDLQWDLQWKHFRS\ULJKWLQIRUPDWLRQOLQHRQWKHERWWRP
RIHDFKLPDJH
<RXDUHQRWDOORZHGWRGRZQORDGDQGSRVWWKHSXEOLVKHGHOHFWURQLFYHUVLRQRI\RXUFKDSWHU
QRUPD\\RXVFDQWKHSULQWHGHGLWLRQWRFUHDWHDQHOHFWURQLFYHUVLRQ
&HQWUDO6WRUDJH7KLVOLFHQVHGRHVQRWLQFOXGHSHUPLVVLRQIRUDVFDQQHGYHUVLRQRIWKHPDWHULDO
WREHVWRUHGLQDFHQWUDOUHSRVLWRU\VXFKDVWKDWSURYLGHGE\+HURQ;DQ(GX
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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:HEVLWH UHJXODUDQGIRUDXWKRU $K\SHUWH[WPXVWEHLQFOXGHGWRWKH+RPHSDJHRIWKH
MRXUQDOIURPZKLFK\RXDUHOLFHQVLQJDWKWWSZZZVFLHQFHGLUHFWFRPVFLHQFHMRXUQDO[[[[[
RUIRUERRNVWRWKH(OVHYLHUKRPHSDJHDWKWWSZZZHOVHYLHUFRP
7KHVLV'LVVHUWDWLRQ,I\RXUOLFHQVHLVIRUXVHLQDWKHVLVGLVVHUWDWLRQ\RXUWKHVLVPD\EH
VXEPLWWHGWR\RXULQVWLWXWLRQLQHLWKHUSULQWRUHOHFWURQLFIRUP6KRXOG\RXUWKHVLVEHSXEOLVKHG
FRPPHUFLDOO\SOHDVHUHDSSO\IRUSHUPLVVLRQ7KHVHUHTXLUHPHQWVLQFOXGHSHUPLVVLRQIRUWKH
/LEUDU\DQG$UFKLYHVRI&DQDGDWRVXSSO\VLQJOHFRSLHVRQGHPDQGRIWKHFRPSOHWHWKHVLV
DQGLQFOXGHSHUPLVVLRQIRU80,WRVXSSO\VLQJOHFRSLHVRQGHPDQGRIWKHFRPSOHWHWKHVLV
6KRXOG\RXUWKHVLVEHSXEOLVKHGFRPPHUFLDOO\SOHDVHUHDSSO\IRUSHUPLVVLRQ
2WKHU&RQGLWLRQV

Y
,I\RXZRXOGOLNHWRSD\IRUWKLVOLFHQVHQRZSOHDVHUHPLWWKLVOLFHQVHDORQJZLWK\RXU
SD\PHQWPDGHSD\DEOHWR&23<5,*+7&/($5$1&(&(17(5RWKHUZLVH\RXZLOOEH
LQYRLFHGZLWKLQKRXUVRIWKHOLFHQVHGDWH3D\PHQWVKRXOGEHLQWKHIRUPRIDFKHFN
RUPRQH\RUGHUUHIHUHQFLQJ\RXUDFFRXQWQXPEHUDQGWKLVLQYRLFHQXPEHU
5/1.
2QFH\RXUHFHLYH\RXULQYRLFHIRUWKLVRUGHU\RXPD\SD\\RXULQYRLFHE\FUHGLWFDUG
3OHDVHIROORZLQVWUXFWLRQVSURYLGHGDWWKDWWLPH
0DNH3D\PHQW7R
&RS\ULJKW&OHDUDQFH&HQWHU
'HSW
32%R[
%RVWRQ0$
)RUVXJJHVWLRQVRUFRPPHQWVUHJDUGLQJWKLVRUGHUFRQWDFW5LJKWV/LQN&XVWRPHU
6XSSRUWFXVWRPHUFDUH#FRS\ULJKWFRPRU WROOIUHHLQWKH86 RU

*UDWLVOLFHQVHV UHIHUHQFLQJLQWKH7RWDOILHOG DUHIUHH3OHDVHUHWDLQWKLVSULQWDEOH
OLFHQVHIRU\RXUUHIHUHQFH1RSD\PHQWLVUHTXLUHG

KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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Figure 1.4 Reprint Permissions


5LJKWVOLQN3ULQWDEOH/LFHQVH

(/6(9,(5/,&(16(
7(506$1'&21',7,216
$SU

7KLVLVD/LFHQVH$JUHHPHQWEHWZHHQ5REHUW'&KDYH] <RX DQG(OVHYLHU (OVHYLHU
SURYLGHGE\&RS\ULJKW&OHDUDQFH&HQWHU &&& 7KHOLFHQVHFRQVLVWVRI\RXURUGHUGHWDLOV
WKHWHUPVDQGFRQGLWLRQVSURYLGHGE\(OVHYLHUDQGWKHSD\PHQWWHUPVDQGFRQGLWLRQV
$OOSD\PHQWVPXVWEHPDGHLQIXOOWR&&&)RUSD\PHQWLQVWUXFWLRQVSOHDVHVHH
LQIRUPDWLRQOLVWHGDWWKHERWWRPRIWKLVIRUP
6XSSOLHU

(OVHYLHU/LPLWHG
7KH%RXOHYDUG/DQJIRUG/DQH
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/LFHQVHGFRQWHQWSXEOLFDWLRQ ,QWHUQDWLRQDO-RXUQDORI&DUGLRORJ\
/LFHQVHGFRQWHQWWLWOH

$FXWHP\RFDUGLDOLQIDUFWLRQIURPVLPXOWDQHRXVWRWDORFFOXVLRQRIWKH
OHIWFLUFXPIOH[DQGULJKWFRURQDU\DUWHU\$FDVHUHSRUW

/LFHQVHGFRQWHQWDXWKRU

:LVVDP'HULDQ$QQD+HUWVEHUJ

/LFHQVHGFRQWHQWGDWH

-XO\

/LFHQVHGFRQWHQWYROXPH
QXPEHU



/LFHQVHGFRQWHQWLVVXH
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6WDUW3DJH

H

(QG3DJH

H

7\SHRI8VH
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3RUWLRQ

ILJXUHVWDEOHVLOOXVWUDWLRQV

1XPEHURI
ILJXUHVWDEOHVLOOXVWUDWLRQV



)RUPDW
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(OVHYLHUDUWLFOH"
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2UGHUUHIHUHQFHQXPEHU
7LWOHRI\RXU
WKHVLVGLVVHUWDWLRQ

'HYHORSPHQWRI,Q9LWUR7LVVXH(QJLQHHUHG%ORRG9HVVHO0LPLFVLQ
&RPSOH[*HRPHWULHVIRU&RURQDU\6WHQW7HVWLQJ

([SHFWHGFRPSOHWLRQGDWH

0D\

(VWLPDWHGVL]H QXPEHURI
SDJHV



(OVHYLHU9$7QXPEHU

*%

3HUPLVVLRQVSULFH

86'

9$7/RFDO6DOHV7D[

86'*%3

7RWDO

86'

7HUPVDQG&RQGLWLRQV

,1752'8&7,21
7KHSXEOLVKHUIRUWKLVFRS\ULJKWHGPDWHULDOLV(OVHYLHU%\FOLFNLQJDFFHSWLQFRQQHFWLRQ
ZLWKFRPSOHWLQJWKLVOLFHQVLQJWUDQVDFWLRQ\RXDJUHHWKDWWKHIROORZLQJWHUPVDQGFRQGLWLRQV
DSSO\WRWKLVWUDQVDFWLRQ DORQJZLWKWKH%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVHVWDEOLVKHG
E\&RS\ULJKW&OHDUDQFH&HQWHU,QF &&& DWWKHWLPHWKDW\RXRSHQHG\RXU5LJKWVOLQN
DFFRXQWDQGWKDWDUHDYDLODEOHDWDQ\WLPHDWKWWSP\DFFRXQWFRS\ULJKWFRP 
*(1(5$/7(506
(OVHYLHUKHUHE\JUDQWV\RXSHUPLVVLRQWRUHSURGXFHWKHDIRUHPHQWLRQHGPDWHULDOVXEMHFWWR
WKHWHUPVDQGFRQGLWLRQVLQGLFDWHG
$FNQRZOHGJHPHQW,IDQ\SDUWRIWKHPDWHULDOWREHXVHG IRUH[DPSOHILJXUHV KDV
DSSHDUHGLQRXUSXEOLFDWLRQZLWKFUHGLWRUDFNQRZOHGJHPHQWWRDQRWKHUVRXUFHSHUPLVVLRQ
PXVWDOVREHVRXJKWIURPWKDWVRXUFH,IVXFKSHUPLVVLRQLVQRWREWDLQHGWKHQWKDWPDWHULDOPD\
QRWEHLQFOXGHGLQ\RXUSXEOLFDWLRQFRSLHV6XLWDEOHDFNQRZOHGJHPHQWWRWKHVRXUFHPXVWEH
PDGHHLWKHUDVDIRRWQRWHRULQDUHIHUHQFHOLVWDWWKHHQGRI\RXUSXEOLFDWLRQDVIROORZV
´5HSULQWHGIURP3XEOLFDWLRQWLWOH9ROHGLWLRQQXPEHU$XWKRU V 7LWOHRIDUWLFOHWLWOHRI
FKDSWHU3DJHV1R&RS\ULJKW <HDU ZLWKSHUPLVVLRQIURP(OVHYLHU>25$33/,&$%/(
62&,(7<&23<5,*+72:1(5@µ$OVR/DQFHWVSHFLDOFUHGLW´5HSULQWHGIURP7KH
/DQFHW9ROQXPEHU$XWKRU V 7LWOHRIDUWLFOH3DJHV1R&RS\ULJKW <HDU ZLWKSHUPLVVLRQ
IURP(OVHYLHUµ
5HSURGXFWLRQRIWKLVPDWHULDOLVFRQILQHGWRWKHSXUSRVHDQGRUPHGLDIRUZKLFKSHUPLVVLRQ
LVKHUHE\JLYHQ
$OWHULQJ0RGLI\LQJ0DWHULDO1RW3HUPLWWHG+RZHYHUILJXUHVDQGLOOXVWUDWLRQVPD\EH
DOWHUHGDGDSWHGPLQLPDOO\WRVHUYH\RXUZRUN$Q\RWKHUDEEUHYLDWLRQVDGGLWLRQVGHOHWLRQV
DQGRUDQ\RWKHUDOWHUDWLRQVVKDOOEHPDGHRQO\ZLWKSULRUZULWWHQDXWKRUL]DWLRQRI(OVHYLHU/WG
3OHDVHFRQWDFW(OVHYLHUDWSHUPLVVLRQV#HOVHYLHUFRP
,IWKHSHUPLVVLRQIHHIRUWKHUHTXHVWHGXVHRIRXUPDWHULDOLVZDLYHGLQWKLVLQVWDQFHSOHDVH
EHDGYLVHGWKDW\RXUIXWXUHUHTXHVWVIRU(OVHYLHUPDWHULDOVPD\DWWUDFWDIHH
5HVHUYDWLRQRI5LJKWV3XEOLVKHUUHVHUYHVDOOULJKWVQRWVSHFLILFDOO\JUDQWHGLQWKH
FRPELQDWLRQRI L WKHOLFHQVHGHWDLOVSURYLGHGE\\RXDQGDFFHSWHGLQWKHFRXUVHRIWKLV
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW



203



5LJKWVOLQN3ULQWDEOH/LFHQVH

OLFHQVLQJWUDQVDFWLRQ LL WKHVHWHUPVDQGFRQGLWLRQVDQG LLL &&& V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV
/LFHQVH&RQWLQJHQW8SRQ3D\PHQW:KLOH\RXPD\H[HUFLVHWKHULJKWVOLFHQVHGLPPHGLDWHO\
XSRQLVVXDQFHRIWKHOLFHQVHDWWKHHQGRIWKHOLFHQVLQJSURFHVVIRUWKHWUDQVDFWLRQSURYLGHG
WKDW\RXKDYHGLVFORVHGFRPSOHWHDQGDFFXUDWHGHWDLOVRI\RXUSURSRVHGXVHQROLFHQVHLV
ILQDOO\HIIHFWLYHXQOHVVDQGXQWLOIXOOSD\PHQWLVUHFHLYHGIURP\RX HLWKHUE\SXEOLVKHURUE\
&&& DVSURYLGHGLQ&&& V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQV,IIXOOSD\PHQWLVQRW
UHFHLYHGRQDWLPHO\EDVLVWKHQDQ\OLFHQVHSUHOLPLQDULO\JUDQWHGVKDOOEHGHHPHG
DXWRPDWLFDOO\UHYRNHGDQGVKDOOEHYRLGDVLIQHYHUJUDQWHG)XUWKHULQWKHHYHQWWKDW\RX
EUHDFKDQ\RIWKHVHWHUPVDQGFRQGLWLRQVRUDQ\RI&&& V%LOOLQJDQG3D\PHQWWHUPVDQG
FRQGLWLRQVWKHOLFHQVHLVDXWRPDWLFDOO\UHYRNHGDQGVKDOOEHYRLGDVLIQHYHUJUDQWHG8VHRI
PDWHULDOVDVGHVFULEHGLQDUHYRNHGOLFHQVHDVZHOODVDQ\XVHRIWKHPDWHULDOVEH\RQGWKH
VFRSHRIDQXQUHYRNHGOLFHQVHPD\FRQVWLWXWHFRS\ULJKWLQIULQJHPHQWDQGSXEOLVKHUUHVHUYHV
WKHULJKWWRWDNHDQ\DQGDOODFWLRQWRSURWHFWLWVFRS\ULJKWLQWKHPDWHULDOV
:DUUDQWLHV3XEOLVKHUPDNHVQRUHSUHVHQWDWLRQVRUZDUUDQWLHVZLWKUHVSHFWWRWKHOLFHQVHG
PDWHULDO
,QGHPQLW\<RXKHUHE\LQGHPQLI\DQGDJUHHWRKROGKDUPOHVVSXEOLVKHUDQG&&&DQG
WKHLUUHVSHFWLYHRIILFHUVGLUHFWRUVHPSOR\HHVDQGDJHQWVIURPDQGDJDLQVWDQ\DQGDOOFODLPV
DULVLQJRXWRI\RXUXVHRIWKHOLFHQVHGPDWHULDORWKHUWKDQDVVSHFLILFDOO\DXWKRUL]HGSXUVXDQWWR
WKLVOLFHQVH
1R7UDQVIHURI/LFHQVH7KLVOLFHQVHLVSHUVRQDOWR\RXDQGPD\QRWEHVXEOLFHQVHG
DVVLJQHGRUWUDQVIHUUHGE\\RXWRDQ\RWKHUSHUVRQZLWKRXWSXEOLVKHU VZULWWHQSHUPLVVLRQ
1R$PHQGPHQW([FHSWLQ:ULWLQJ7KLVOLFHQVHPD\QRWEHDPHQGHGH[FHSWLQDZULWLQJ
VLJQHGE\ERWKSDUWLHV RULQWKHFDVHRISXEOLVKHUE\&&&RQSXEOLVKHU VEHKDOI 
2EMHFWLRQWR&RQWUDU\7HUPV3XEOLVKHUKHUHE\REMHFWVWRDQ\WHUPVFRQWDLQHGLQDQ\
SXUFKDVHRUGHUDFNQRZOHGJPHQWFKHFNHQGRUVHPHQWRURWKHUZULWLQJSUHSDUHGE\\RXZKLFK
WHUPVDUHLQFRQVLVWHQWZLWKWKHVHWHUPVDQGFRQGLWLRQVRU&&& V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV7KHVHWHUPVDQGFRQGLWLRQVWRJHWKHUZLWK&&& V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV ZKLFKDUHLQFRUSRUDWHGKHUHLQ FRPSULVHWKHHQWLUHDJUHHPHQWEHWZHHQ\RX
DQGSXEOLVKHU DQG&&& FRQFHUQLQJWKLVOLFHQVLQJWUDQVDFWLRQ,QWKHHYHQWRIDQ\FRQIOLFW
EHWZHHQ\RXUREOLJDWLRQVHVWDEOLVKHGE\WKHVHWHUPVDQGFRQGLWLRQVDQGWKRVHHVWDEOLVKHGE\
&&& V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVWKHVHWHUPVDQGFRQGLWLRQVVKDOOFRQWURO
5HYRFDWLRQ(OVHYLHURU&RS\ULJKW&OHDUDQFH&HQWHUPD\GHQ\WKHSHUPLVVLRQVGHVFULEHG
LQWKLV/LFHQVHDWWKHLUVROHGLVFUHWLRQIRUDQ\UHDVRQRUQRUHDVRQZLWKDIXOOUHIXQGSD\DEOH
WR\RX1RWLFHRIVXFKGHQLDOZLOOEHPDGHXVLQJWKHFRQWDFWLQIRUPDWLRQSURYLGHGE\\RX
)DLOXUHWRUHFHLYHVXFKQRWLFHZLOOQRWDOWHURULQYDOLGDWHWKHGHQLDO,QQRHYHQWZLOO(OVHYLHU
RU&RS\ULJKW&OHDUDQFH&HQWHUEHUHVSRQVLEOHRUOLDEOHIRUDQ\FRVWVH[SHQVHVRUGDPDJH
LQFXUUHGE\\RXDVDUHVXOWRIDGHQLDORI\RXUSHUPLVVLRQUHTXHVWRWKHUWKDQDUHIXQGRIWKH
DPRXQW V SDLGE\\RXWR(OVHYLHUDQGRU&RS\ULJKW&OHDUDQFH&HQWHUIRUGHQLHGSHUPLVVLRQV
/,0,7('/,&(16(
7KHIROORZLQJWHUPVDQGFRQGLWLRQVDSSO\RQO\WRVSHFLILFOLFHQVHW\SHV
7UDQVODWLRQ7KLVSHUPLVVLRQLVJUDQWHGIRUQRQH[FOXVLYHZRUOG(QJOLVKULJKWVRQO\
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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XQOHVV\RXUOLFHQVHZDVJUDQWHGIRUWUDQVODWLRQULJKWV,I\RXOLFHQVHGWUDQVODWLRQULJKWV\RX
PD\RQO\WUDQVODWHWKLVFRQWHQWLQWRWKHODQJXDJHV\RXUHTXHVWHG$SURIHVVLRQDOWUDQVODWRU
PXVWSHUIRUPDOOWUDQVODWLRQVDQGUHSURGXFHWKHFRQWHQWZRUGIRUZRUGSUHVHUYLQJWKHLQWHJULW\
RIWKHDUWLFOH,IWKLVOLFHQVHLVWRUHXVHRUILJXUHVWKHQSHUPLVVLRQLVJUDQWHGIRUQRQ
H[FOXVLYHZRUOGULJKWVLQDOOODQJXDJHV
:HEVLWH7KHIROORZLQJWHUPVDQGFRQGLWLRQVDSSO\WRHOHFWURQLFUHVHUYHDQGDXWKRU
ZHEVLWHV
(OHFWURQLFUHVHUYH,IOLFHQVHGPDWHULDOLVWREHSRVWHGWRZHEVLWHWKHZHEVLWHLVWREH
SDVVZRUGSURWHFWHGDQGPDGHDYDLODEOHRQO\WRERQDILGHVWXGHQWVUHJLVWHUHGRQDUHOHYDQW
FRXUVHLI
7KLVOLFHQVHZDVPDGHLQFRQQHFWLRQZLWKDFRXUVH
7KLVSHUPLVVLRQLVJUDQWHGIRU\HDURQO\<RXPD\REWDLQDOLFHQVHIRUIXWXUHZHEVLWH
SRVWLQJ
$OOFRQWHQWSRVWHGWRWKHZHEVLWHPXVWPDLQWDLQWKHFRS\ULJKWLQIRUPDWLRQOLQHRQWKHERWWRP
RIHDFKLPDJH
$K\SHUWH[WPXVWEHLQFOXGHGWRWKH+RPHSDJHRIWKHMRXUQDOIURPZKLFK\RXDUHOLFHQVLQJDW
KWWSZZZVFLHQFHGLUHFWFRPVFLHQFHMRXUQDO[[[[[RUWKH(OVHYLHUKRPHSDJHIRUERRNVDW
KWWSZZZHOVHYLHUFRPDQG
&HQWUDO6WRUDJH7KLVOLFHQVHGRHVQRWLQFOXGHSHUPLVVLRQIRUDVFDQQHGYHUVLRQRIWKHPDWHULDO
WREHVWRUHGLQDFHQWUDOUHSRVLWRU\VXFKDVWKDWSURYLGHGE\+HURQ;DQ(GX
$XWKRUZHEVLWHIRUMRXUQDOVZLWKWKHIROORZLQJDGGLWLRQDOFODXVHV
$OOFRQWHQWSRVWHGWRWKHZHEVLWHPXVWPDLQWDLQWKHFRS\ULJKWLQIRUPDWLRQOLQHRQWKHERWWRP
RIHDFKLPDJHDQG
KHSHUPLVVLRQJUDQWHGLVOLPLWHGWRWKHSHUVRQDOYHUVLRQRI\RXUSDSHU<RXDUHQRWDOORZHGWR
GRZQORDGDQGSRVWWKHSXEOLVKHGHOHFWURQLFYHUVLRQRI\RXUDUWLFOH ZKHWKHU3')RU+70/
SURRIRUILQDOYHUVLRQ QRUPD\\RXVFDQWKHSULQWHGHGLWLRQWRFUHDWHDQHOHFWURQLFYHUVLRQ
$K\SHUWH[WPXVWEHLQFOXGHGWRWKH+RPHSDJHRIWKHMRXUQDOIURPZKLFK\RXDUHOLFHQVLQJDW
KWWSZZZVFLHQFHGLUHFWFRPVFLHQFHMRXUQDO[[[[[$VSDUWRIRXUQRUPDOSURGXFWLRQ
SURFHVV\RXZLOOUHFHLYHDQHPDLOQRWLFHZKHQ\RXUDUWLFOHDSSHDUVRQ(OVHYLHU·VRQOLQH
VHUYLFH6FLHQFH'LUHFW ZZZVFLHQFHGLUHFWFRP 7KDWHPDLOZLOOLQFOXGHWKHDUWLFOH·V'LJLWDO
2EMHFW,GHQWLILHU '2, 7KLVQXPEHUSURYLGHVWKHHOHFWURQLFOLQNWRWKHSXEOLVKHGDUWLFOHDQG
VKRXOGEHLQFOXGHGLQWKHSRVWLQJRI\RXUSHUVRQDOYHUVLRQ:HDVNWKDW\RXZDLWXQWLO\RX
UHFHLYHWKLVHPDLODQGKDYHWKH'2,WRGRDQ\SRVWLQJ
&HQWUDO6WRUDJH7KLVOLFHQVHGRHVQRWLQFOXGHSHUPLVVLRQIRUDVFDQQHGYHUVLRQRIWKHPDWHULDO
WREHVWRUHGLQDFHQWUDOUHSRVLWRU\VXFKDVWKDWSURYLGHGE\+HURQ;DQ(GX
$XWKRUZHEVLWHIRUERRNVZLWKWKHIROORZLQJDGGLWLRQDOFODXVHV
$XWKRUVDUHSHUPLWWHGWRSODFHDEULHIVXPPDU\RIWKHLUZRUNRQOLQHRQO\
$K\SHUWH[WPXVWEHLQFOXGHGWRWKH(OVHYLHUKRPHSDJHDWKWWSZZZHOVHYLHUFRP
$OOFRQWHQWSRVWHGWRWKHZHEVLWHPXVWPDLQWDLQWKHFRS\ULJKWLQIRUPDWLRQOLQHRQWKHERWWRP
RIHDFKLPDJH
<RXDUHQRWDOORZHGWRGRZQORDGDQGSRVWWKHSXEOLVKHGHOHFWURQLFYHUVLRQRI\RXUFKDSWHU
QRUPD\\RXVFDQWKHSULQWHGHGLWLRQWRFUHDWHDQHOHFWURQLFYHUVLRQ
&HQWUDO6WRUDJH7KLVOLFHQVHGRHVQRWLQFOXGHSHUPLVVLRQIRUDVFDQQHGYHUVLRQRIWKHPDWHULDO
WREHVWRUHGLQDFHQWUDOUHSRVLWRU\VXFKDVWKDWSURYLGHGE\+HURQ;DQ(GX

KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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:HEVLWH UHJXODUDQGIRUDXWKRU $K\SHUWH[WPXVWEHLQFOXGHGWRWKH+RPHSDJHRIWKH
MRXUQDOIURPZKLFK\RXDUHOLFHQVLQJDWKWWSZZZVFLHQFHGLUHFWFRPVFLHQFHMRXUQDO[[[[[
RUIRUERRNVWRWKH(OVHYLHUKRPHSDJHDWKWWSZZZHOVHYLHUFRP
7KHVLV'LVVHUWDWLRQ,I\RXUOLFHQVHLVIRUXVHLQDWKHVLVGLVVHUWDWLRQ\RXUWKHVLVPD\EH
VXEPLWWHGWR\RXULQVWLWXWLRQLQHLWKHUSULQWRUHOHFWURQLFIRUP6KRXOG\RXUWKHVLVEHSXEOLVKHG
FRPPHUFLDOO\SOHDVHUHDSSO\IRUSHUPLVVLRQ7KHVHUHTXLUHPHQWVLQFOXGHSHUPLVVLRQIRUWKH
/LEUDU\DQG$UFKLYHVRI&DQDGDWRVXSSO\VLQJOHFRSLHVRQGHPDQGRIWKHFRPSOHWHWKHVLV
DQGLQFOXGHSHUPLVVLRQIRU80,WRVXSSO\VLQJOHFRSLHVRQGHPDQGRIWKHFRPSOHWHWKHVLV
6KRXOG\RXUWKHVLVEHSXEOLVKHGFRPPHUFLDOO\SOHDVHUHDSSO\IRUSHUPLVVLRQ
2WKHU&RQGLWLRQV

Y
,I\RXZRXOGOLNHWRSD\IRUWKLVOLFHQVHQRZSOHDVHUHPLWWKLVOLFHQVHDORQJZLWK\RXU
SD\PHQWPDGHSD\DEOHWR&23<5,*+7&/($5$1&(&(17(5RWKHUZLVH\RXZLOOEH
LQYRLFHGZLWKLQKRXUVRIWKHOLFHQVHGDWH3D\PHQWVKRXOGEHLQWKHIRUPRIDFKHFN
RUPRQH\RUGHUUHIHUHQFLQJ\RXUDFFRXQWQXPEHUDQGWKLVLQYRLFHQXPEHU
5/1.
2QFH\RXUHFHLYH\RXULQYRLFHIRUWKLVRUGHU\RXPD\SD\\RXULQYRLFHE\FUHGLWFDUG
3OHDVHIROORZLQVWUXFWLRQVSURYLGHGDWWKDWWLPH
0DNH3D\PHQW7R
&RS\ULJKW&OHDUDQFH&HQWHU
'HSW
32%R[
%RVWRQ0$
)RUVXJJHVWLRQVRUFRPPHQWVUHJDUGLQJWKLVRUGHUFRQWDFW5LJKWV/LQN&XVWRPHU
6XSSRUWFXVWRPHUFDUH#FRS\ULJKWFRPRU WROOIUHHLQWKH86 RU

*UDWLVOLFHQVHV UHIHUHQFLQJLQWKH7RWDOILHOG DUHIUHH3OHDVHUHWDLQWKLVSULQWDEOH
OLFHQVHIRU\RXUUHIHUHQFH1RSD\PHQWLVUHTXLUHG

KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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Figure 1.5 and 1.6 Reprint Permissions


*PDLO5(5HTXHVW3HUPLVVLRQWR8VH$QJLRSODVW\)LJXUHV&50

'DOWRQ&KDYH]GDOWRQFKDYH]#JPDLOFRP!

5(5HTXHVW3HUPLVVLRQWR8VH$QJLRSODVW\)LJXUHV&50
1+/%,+HDOWK,QIRUPDWLRQ&HQWHUQKOELLQIR#QKOELQLKJRY!
7R&KDYH]5REHUWUFKDYH]#FDOSRO\HGX!

0RQ$SUDW$0

'HDU0U&KDYH]

7KDQN\RXIRU\RXULQTXLU\WRWKH1DWLRQDO+HDUW/XQJDQG%ORRG,QVWLWXWH 1+/%, +HDOWK
,QIRUPDWLRQ&HQWHUUHJDUGLQJWKH1+/%,FRS\ULJKWSHUPLVVLRQSROLF\
7KHWH[WRIDQGLQIRUPDWLRQFRQWDLQHGLQPDWHULDOVSXEOLVKHGE\WKH1DWLRQDO+HDUW/XQJDQG
%ORRG,QVWLWXWH 1+/%, DUHLQWKHSXEOLFGRPDLQ1RIXUWKHUSHUPLVVLRQLVUHTXLUHGWR
UHSURGXFHRUUHSULQWWKHWH[WLQZKROHRULQSDUW7KLVDSSOLHVWRSULQWSXEOLFDWLRQVJUDSKLFV
DQGDQLPDWLRQVLQWKH1+/%,¶V+HDOWK7RSLFVLQGH[DVZHOODVGRFXPHQWVDQGFRQWHQWIURP
WKH1+/%,:HEVLWH2UJDQL]DWLRQVPD\DGGWKHLURZQORJRRUQDPH7KH1+/%,DVNVRQO\
WKDWQRFKDQJHVEHPDGHWRWKHFRQWHQWRIWKHPDWHULDOVDQGWKDWWKHPDWHULDODVZHOODQ\
1+/%,,QWHUQHWOLQNVQRWEHXVHGLQDQ\GLUHFWRULQGLUHFWSURGXFWHQGRUVHPHQWRUDGYHUWLVLQJ
5HTXHVWHGVRXUFLQJODQJXDJH6RXUFH1DWLRQDO+HDUW/XQJDQG%ORRG,QVWLWXWH1DWLRQDO
,QVWLWXWHVRI+HDOWK86'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV

:H&DQ7KH+HDUW7UXWK&23'/HDUQ0RUH%UHDWKH%HWWHUDQG.HHSWKH%HDWDUH
WUDGHPDUNVRIWKH86'HSD UWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV ++6 :HHQFRXUDJH
\RXWRXVHWKHVHEUDQGVORJRVDQGZRUGPDUNVLQEDQQHUVSXEOLFDWLRQVSRVWHUVDQG
SURPRWLRQDOPDWHULDOVWKDWSURPRWHKHDOWKSURJUDPPLQJLQ\RXUFRPPXQLW\+RZHYHUWR
PDLQWDLQWKHLQWHJULW\RIWKHPHVVDJHVWRQHDQGPHDQLQJRIWKHORJRVDQGZRUGPDUNVZH
UHTXLUHWKDWWKH\RQO\EHXVHGZLWKSURJUDPVHYHQWVDQGLQIRUPDWLRQZKRVHJRDOVDUH
F RQVLVWHQWZLWKWKHREMHFWLYHVRIWKH1+/%,SURJUDPV,QDGGLWLRQZHDVNWKDW\RXKHOSXVE\
SURSHUO\XVLQJDQGFUHGLWLQJ++6WUDGHPDUNVLQDFFRUGDQFHZLWKWKHWHUPVRIXVHIRU:H
&DQ7KH+HDUW7UXWK&23'/HDUQ0RUH%UHDWKH%HWWHUDQG.HHSWKH%HDW)RU
DSSURYDOIRUXVHRIWKHVH++6SURJUDPPDUNVFRQWDFWWKH1+/%,DW
QKOELLQIR#QKOELQLKJRY

<RXUDVVLVWDQFHLQPDNLQJRXUUHVHDUFKDQGKHDOWKUHODWHGLQIRUPDWLRQDYDLODEOHWRWKH
ODUJHVWQXPEHURISHRSOHSRVVLEOHLVJUHDWO\DSSUHFLDWHG


6LQFHUHO\
1+/%,+HDOWK,QIRUPDWLRQ&HQWHU
32%R[
%HWKHVGD0'
3KRQH
)D[
(PDLOQKOELLQIR#QKOELQLKJRY
:HEVLWHKWWSZZZQKOELQLKJRY


KWWSVPDLOJRRJOHFRPPDLO"XL  LN DEEGH YLHZ SW VHDUFK LQER[ PVJ EEGEFIGD

207





*PDLO5(5HTXHVW3HUPLVVLRQWR8VH$QJLRSODVW\)LJXUHV&50

$SULOLV1DWLRQDO0LQRULW\+HDOWK0RQWK7KH1+/%,KDVDYDULHW\RIPXOWLFXOWXUDOUHVRXUFHV
DYDLODEOHRQOLQHDQGLQSULQW9LVLWWKH1+/%,¶V+HDOWK'LVSDULWLHV:HESDJHWRYLHZ
GRZQORDGRURUGHUWKHVHPDWHULDOV

2ULJLQDO0HVVDJH
)URP&KDYH]5REHUW
5HFHLYHG$0
7R$GPLQ8VHU,QIRUPDWLRQ&HQWHU1+/%,1+/%,+HDOWK,QIRUPDWLRQ&HQWHU
6XEMHFW5HTXHVW3HUPLVVLRQWR8VH$QJLRSODVW\)LJXUHV
7R:KRP,W0D\&RQFHUQ
,DPDJUDGXDWHVWXGHQWDW&DOLIRUQLD3RO\WHFKQLF6WDWH8QLYHUVLW\6DQ/XLV2ELVSR &DO3RO\ ,DPFRPSOHWLQJ
P\WKHVLVRQFRURQDU\GHYLFHVDQGZRXOGOLNHWRXVHWZRLPDJHVIURPWKH1+/%,ZHEVLWHLQWKHLQWURGXFWLRQRI
P\WKHVLV,DPUHTXHVWLQJSHUPLVVLRQWRXVHWKHLPDJHVWLWOHG&RURQDU\%DOORRQ$QJLRSODVW\DQG$QJLRSODVW\
:LWK6WHQW3ODFHPHQWZKLFKDUHORFDWHGDWWKHIROORZLQJ85/
KWWSZZZQKOELQLKJRYKHDOWKKHDOWKWRSLFVWRSLFVDQJLRSODVW\KRZGRQHKWPO
$QHOHFWURQLFFRS\RIP\WKHVLVZLOOEHXSORDGHGWRP\XQLYHUVLW\ VRQOLQHDUFKLYHRIWKHVHVDQGZLOOWKHQEH
IUHHO\DYDLODEOHWRWKHSXEOLF0D\,XVHWKHVHWZRLPDJHVLQP\WKHVLVZKLFKZLOOEHIUHHO\DYDLODEOHRQOLQH"
7KDQN\RXIRU\RXUWLPH
6LQFHUHO\
5REHUW&KDYH]
%LRPHGLFDO(QJLQHHULQJ
&DO3RO\6DQ/XLV2ELVSR
UFKDYH]#FDOSRO\HGX
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Figure 1.7 A and B Reprint Permissions


*PDLO5HTXHVW3HUPLVVLRQWR8VH,PDJHVRI,'7(

'DOWRQ&KDYH]GDOWRQFKDYH]#JPDLOFRP!

5HTXHVW3HUPLVVLRQWR8VH,PDJHVRI,'7(
PHVVDJHV
5REHUW'DOWRQ&KDYH]UFKDYH]#FDOSRO\HGX!
7RLQIR#PDFKLQHVROXWLRQVFRP

6DW$SUDW$0

'HDU0DFKLQH6ROXWLRQV5HSUHVHQWDWLYH
,DPDJUDGXDWHVWXGHQWDW&DOLIRUQLD3RO\WHFKQLF6WDWH8QLYHUVLW\6DQ/XLV2ELVSR DOVRNQRZQDV&DO3RO\ ,
DPFRPSOHWLQJP\WKHVLVRQFRURQDU\GHYLFHWHVWLQJDQGZRXOGOLNHWRXVHWZRLPDJHVIURP\RXUZHEVLWHLQWKH
LQWURGXFWLRQRIP\WKHVLVWRLOOXVWUDWHDQH[DPSOHRIHTXLSPHQWWKDWPD\EHXVHGIRUFRURQDU\GHYLFHWHVWLQJ,
DPUHTXHVWLQJSHUPLVVLRQWRXVHLPDJHVORFDWHGDWWKHIROORZLQJ85/
KWWSZZZPDFKLQHVROXWLRQVFRP0HGLFDO'HYLFH3HUIRUPDQFH7HVWLQJ7HVWLQJ(TXLSPHQW&DWKHWHU*XLGHZLUH
7HVWLQJ(TXLSPHQW,'7(KWP
7KHUHLVDVHFWLRQRQWKHDERYHZHESDJHWKDWDOORZVPHWRYLHZVHYHQLPDJHVRI\RXU,'7(DQG,DP
UHTXHVWLQJSHUPLVVLRQWRXVHLPDJHVRXWRIDQGRXWRI$QHOHFWURQLFFRS\RIP\WKHVLVZLOOEH
XSORDGHGWRP\XQLYHUVLW\ VRQOLQHDUFKLYHRIWKHVHVDQGZLOOWKHQEHIUHHO\DYDLODEOHWRWKHSXEOLF0D\,XVH
WKHVHWZRLPDJHVLQP\WKHVLVZKLFKZLOOEHIUHHO\DYDLODEOHRQOLQH"
7KDQN\RXIRU\RXUWLPH
6LQFHUHO\
5REHUW&KDYH]
%LRPHGLFDO(QJLQHHULQJ
&DO3RO\6DQ/XLV2ELVSR
UFKDYH]#FDOSRO\HGX
-DVRQ&URQZDOOMFURQZDOO#PDFKLQHVROXWLRQVFRP!
7R5REHUW'DOWRQ&KDYH]UFKDYH]#FDOSRO\HGX!

6DW$SUDW$0

ZŽďĞƌƚ͕
zĞƐ͕ǁĞĂƉƉƌŽǀĞŽĨƚŚĂƚƵƐĞ͘/ĨǇŽƵŶĞĞĚĂŶǇƚŚŝŶŐĨƵƌƚŚĞƌ͕ƉůĞĂƐĞĚŽŶΖƚŚĞƐŝƚĂƚĞƚŽĐŽŶƚĂĐƚŵĞ͘
ĞƐƚƌĞŐĂƌĚƐ͕

:ĂƐŽŶƌŽŶǁĂůů
ŝƌĞĐƚŽƌŽĨ'ůŽďĂůDĂƌŬĞƚŝŶŐ
DĂĐŚŝŶĞ^ŽůƵƚŝŽŶƐ/ŶĐ͘
нϭϵϮϴϱϱϲϯϭϬϵWŚŽŶĞ
нϭϵϮϴϱϱϲϯϬϴϰ&Ăǆ
нϭϵϮϴϮϲϲϲϯϴϱDŽďŝůĞ
ũĐƌŽŶǁĂůůΛŵĂĐŚŝŶĞƐŽůƵƚŝŽŶƐ͘ĐŽŵ
KE&/Ed/>͗dŚŝƐĞŵĂŝů;ĂŶĚĂŶǇĂƚƚĂĐŚŵĞŶƚͿŝƐĐŽŶĨŝĚĞŶƚŝĂůĂŶĚŵĂǇďĞƉƌŽƚĞĐƚĞĚďǇůĞŐĂůƉƌŝǀŝůĞŐĞ͕ĐŽŶĨŝĚĞŶƚŝĂůŝƚǇĂŐƌĞĞŵĞŶƚƐ͕
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*PDLO5HTXHVW3HUPLVVLRQWR8VH,PDJHVRI,'7(

ĂŶĚĐŽŵŵŽŶŽƌƐƚĂƚƵƚŽƌǇůĂǁ͘/ĨǇŽƵĂƌĞŶŽƚƚŚĞŝŶƚĞŶĚĞĚƌĞĐŝƉŝĞŶƚ͕ďĞĂǁĂƌĞƚŚĂƚĂŶǇĚŝƐĐůŽƐƵƌĞ͕ĐŽƉǇŝŶŐ͕ĚŝƐƚƌŝďƵƚŝŽŶŽƌƵƐĞŽĨƚŚŝƐ
ĞŵĂŝůŽƌĂŶǇĂƚƚĂĐŚŵĞŶƚŝƐƉƌŽŚŝďŝƚĞĚ͘/ĨǇŽƵŚĂǀĞƌĞĐĞŝǀĞĚƚŚŝƐĞŵĂŝůŝŶĞƌƌŽƌ͕ƉůĞĂƐĞŶŽƚŝĨǇƵƐĂƚŽŶĐĞďǇƌĞƚƵƌŶŝŶŐŝƚƚŽƚŚĞƐĞŶĚĞƌ
ĂŶĚƚŚĞŶĚĞůĞƚŝŶŐƚŚŝƐĐŽƉǇĨƌŽŵǇŽƵƌƐǇƐƚĞŵ͘dŚĂŶŬǇŽƵ͘

&ƌŽŵ͗ZŽďĞƌƚĂůƚŽŶŚĂǀĞǌфƌĐŚĂǀĞǌΛĐĂůƉŽůǇ͘ĞĚƵх
ĂƚĞ͗^Ăƚ͕ϭϰƉƌϮϬϭϮϬϱ͗Ϯϵ͗ϬϲͲϬϳϬϬ
dŽ͗фŝŶĨŽΛŵĂĐŚŝŶĞƐŽůƵƚŝŽŶƐ͘ĐŽŵх
^ƵďũĞĐƚ͗ZĞƋƵĞƐƚWĞƌŵŝƐƐŝŽŶƚŽhƐĞ/ŵĂŐĞƐŽĨ/dϮϬϬϬ
YƵŽƚĞĚƚĞǆƚŚŝĚĚĞŶ

KE&/Ed/>͗dŚŝƐĞŵĂŝů;ĂŶĚĂŶǇĂƚƚĂĐŚŵĞŶƚͿŝƐĐŽŶĨŝĚĞŶƚŝĂůĂŶĚŵĂǇďĞƉƌŽƚĞĐƚĞĚďǇůĞŐĂů
ƉƌŝǀŝůĞŐĞ͕ĐŽŶĨŝĚĞŶƚŝĂůŝƚǇĂŐƌĞĞŵĞŶƚƐ͕ĂŶĚĐŽŵŵŽŶŽƌƐƚĂƚƵƚŽƌǇůĂǁ͘/ĨǇŽƵĂƌĞŶŽƚƚŚĞŝŶƚĞŶĚĞĚ
ƌĞĐŝƉŝĞŶƚ͕ďĞĂǁĂƌĞƚŚĂƚĂŶǇĚŝƐĐůŽƐƵƌĞ͕ĐŽƉǇŝŶŐ͕ĚŝƐƚƌŝďƵƚŝŽŶŽƌƵƐĞŽĨƚŚŝƐĞŵĂŝůŽƌĂŶǇĂƚƚĂĐŚŵĞŶƚ
ŝƐƉƌŽŚŝďŝƚĞĚ͘/ĨǇŽƵŚĂǀĞƌĞĐĞŝǀĞĚƚŚŝƐĞŵĂŝůŝŶĞƌƌŽƌ͕ƉůĞĂƐĞŶŽƚŝĨǇƵƐĂƚŽŶĐĞďǇƌĞƚƵƌŶŝŶŐŝƚƚŽƚŚĞ
ƐĞŶĚĞƌĂŶĚƚŚĞŶĚĞůĞƚŝŶŐƚŚŝƐĐŽƉǇĨƌŽŵǇŽƵƌƐǇƐƚĞŵ͘dŚĂŶŬǇŽƵ͘
5REHUW'DOWRQ&KDYH]UFKDYH]#FDOSRO\HGX!
7R-DVRQ&URQZDOOMFURQZDOO#PDFKLQHVROXWLRQVFRP!

6XQ$SUDW$0

+L-DVRQ
7KDQN\RXYHU\PXFKIRU\RXUDSSURYDO,ZRXOGOLNHWRLQFOXGH\RXUHPDLOLQDQDSSHQGL[RIP\WKHVLVDV
HYLGHQFHRI\RXUDSSURYDO0D\,LQFOXGH\RXUDSSURYDOHPDLOLQP\WKHVLV" <RXUHPDLOKDVDFRQILGHQWLDOLW\
VWDWHPHQWDWWKHERWWRPVR,ZDQWHGWRJHW\RXUSHUPLVVLRQWRLQFOXGHWKHHPDLOLQP\WKHVLV
5REHUW
>4XRWHGWH[WKLGGHQ@

-DVRQ&URQZDOOMFURQZDOO#PDFKLQHVROXWLRQVFRP!
7R5REHUW'DOWRQ&KDYH]UFKDYH]#FDOSRO\HGX!

7XH$SUDW30

ZŽďĞƌƚ͕
zĞƐ͕ƚŚĂƚΖƐĨŝŶĞ͘
ĞƐƚƌĞŐĂƌĚƐ͕

:ĂƐŽŶƌŽŶǁĂůů
ŝƌĞĐƚŽƌŽĨ'ůŽďĂůDĂƌŬĞƚŝŶŐ
DĂĐŚŝŶĞ^ŽůƵƚŝŽŶƐ/ŶĐ͘
нϭϵϮϴϱϱϲϯϭϬϵWŚŽŶĞ
нϭϵϮϴϱϱϲϯϬϴϰ&Ăǆ
нϭϵϮϴϮϲϲϲϯϴϱDŽďŝůĞ
ũĐƌŽŶǁĂůůΛŵĂĐŚŝŶĞƐŽůƵƚŝŽŶƐ͘ĐŽŵ
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*PDLO5HTXHVW3HUPLVVLRQWR8VH,PDJHVRI,'7(

KE&/Ed/>͗dŚŝƐĞŵĂŝů;ĂŶĚĂŶǇĂƚƚĂĐŚŵĞŶƚͿŝƐĐŽŶĨŝĚĞŶƚŝĂůĂŶĚŵĂǇďĞƉƌŽƚĞĐƚĞĚďǇůĞŐĂůƉƌŝǀŝůĞŐĞ͕ĐŽŶĨŝĚĞŶƚŝĂůŝƚǇĂŐƌĞĞŵĞŶƚƐ͕
ĂŶĚĐŽŵŵŽŶŽƌƐƚĂƚƵƚŽƌǇůĂǁ͘/ĨǇŽƵĂƌĞŶŽƚƚŚĞŝŶƚĞŶĚĞĚƌĞĐŝƉŝĞŶƚ͕ďĞĂǁĂƌĞƚŚĂƚĂŶǇĚŝƐĐůŽƐƵƌĞ͕ĐŽƉǇŝŶŐ͕ĚŝƐƚƌŝďƵƚŝŽŶŽƌƵƐĞŽĨƚŚŝƐ
ĞŵĂŝůŽƌĂŶǇĂƚƚĂĐŚŵĞŶƚŝƐƉƌŽŚŝďŝƚĞĚ͘/ĨǇŽƵŚĂǀĞƌĞĐĞŝǀĞĚƚŚŝƐĞŵĂŝůŝŶĞƌƌŽƌ͕ƉůĞĂƐĞŶŽƚŝĨǇƵƐĂƚŽŶĐĞďǇƌĞƚƵƌŶŝŶŐŝƚƚŽƚŚĞƐĞŶĚĞƌ
ĂŶĚƚŚĞŶĚĞůĞƚŝŶŐƚŚŝƐĐŽƉǇĨƌŽŵǇŽƵƌƐǇƐƚĞŵ͘dŚĂŶŬǇŽƵ͘

&ƌŽŵ͗ZŽďĞƌƚĂůƚŽŶŚĂǀĞǌфƌĐŚĂǀĞǌΛĐĂůƉŽůǇ͘ĞĚƵх
ĂƚĞ͗^ƵŶ͕ϭϱƉƌϮϬϭϮϬϱ͗ϯϳ͗ϬϯͲϬϳϬϬ
dŽ͗:ĂƐŽŶƌŽŶǁĂůůфũĐƌŽŶǁĂůůΛŵĂĐŚŝŶĞƐŽůƵƚŝŽŶƐ͘ĐŽŵх
^ƵďũĞĐƚ͗ZĞ͗ZĞƋƵĞƐƚWĞƌŵŝƐƐŝŽŶƚŽhƐĞ/ŵĂŐĞƐŽĨ/dϮϬϬϬ
YƵŽƚĞĚƚĞǆƚŚŝĚĚĞŶ
YƵŽƚĞĚƚĞǆƚŚŝĚĚĞŶ
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Figure 1.8 Reprint Permissions


*PDLO5HTXHVW3HUPLVVLRQWR8VH,PDJHRI6LOLFRQH9DVFXODWXUH

'DOWRQ&KDYH]GDOWRQFKDYH]#JPDLOFRP!

5HTXHVW3HUPLVVLRQWR8VH,PDJHRI6LOLFRQH9DVFXODWXUH
&ROOHHQ-RKQVRQFROOHHQM#XQLWHGELRORJLFVFRP!
6XQ$SUDW30
7R5REHUW'DOWRQ&KDYH]UFKDYH]#FDOSRO\HGX!
&F0DU\-DUWFN\PDU\M#XQLWHGELRORJLFVFRP!&UDLJ-RKQVRQFUDLJM#XQLWHGELRORJLFVFRP!
KL5REHUW
KHUH\RXJR
8QLWHG%LRORJLFV,QFJUDQWVSHUPLVVLRQWR5REHUW'DOWRQ&KDYH]WRXVH
WKHIROORZLQJLPDJHLQSULQWHGYHUVLRQVRIKLVWKHVLVDQGLQDQHOHFWURQLFYHUVLRQRIKLVWKHVLVWKDWZLOOEHIUHHO\
DYDLODEOHWRWKHSXEOLFRQWKHXQLYHUVLW\ VRQOLQHDUFKLYHRIWKHVHV
KWWSZZZXQLWHGELRORJLFVFRPFDWDORJSURGXFWJDOOHU\LGLPDJH
%HVWUHJDUGV
&ROOHHQ-RKQVRQ51061
&OLQLFDO&RRUGLQDWRU
8QLWHG%LRORJLFV,QF
ZZZXQLWHGELRORJLFVFRP
5HGKLOO$YH6XLWH%
7XVWLQ&DOLIRUQLD
S
I

>4XRWHGWH[WKLGGHQ@
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Figure 1.9 A and C Reprint Permissions


5LJKWVOLQN3ULQWDEOH/LFHQVH

:2/7(56./8:(5+($/7+/,&(16(
7(506$1'&21',7,216
$SU

7KLVLVD/LFHQVH$JUHHPHQWEHWZHHQ5REHUW'&KDYH] <RX DQG:ROWHUV.OXZHU+HDOWK
:ROWHUV.OXZHU+HDOWK SURYLGHGE\&RS\ULJKW&OHDUDQFH&HQWHU &&& 7KHOLFHQVH
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 $FUHGLWOLQHZLOOEHSURPLQHQWO\SODFHGDQGLQFOXGHIRUERRNVWKHDXWKRU V WLWOHRI
ERRNHGLWRUFRS\ULJKWKROGHU\HDURISXEOLFDWLRQ)RUMRXUQDOVWKHDXWKRU V WLWOHRI
DUWLFOHWLWOHRIMRXUQDOYROXPHQXPEHULVVXHQXPEHUDQGLQFOXVLYHSDJHV
 7KHUHTXHVWRUZDUUDQWVWKDWWKHPDWHULDOVKDOOQRWEHXVHGLQDQ\PDQQHUZKLFKPD\EH
FRQVLGHUHGGHURJDWRU\WRWKHWLWOHFRQWHQWRUDXWKRUVRIWKHPDWHULDORUWR:ROWHUV
.OXZHU
 3HUPLVVLRQLVJUDQWHGIRURQHWLPHXVHRQO\DVVSHFLILHGLQ\RXUFRUUHVSRQGHQFH5LJKWV
KHUHLQGRQRWDSSO\WRIXWXUHUHSURGXFWLRQVHGLWLRQVUHYLVLRQVRURWKHUGHULYDWLYH
ZRUNV2QFHWHUPKDVH[SLUHGSHUPLVVLRQWRUHQHZPXVWEHPDGHLQZULWLQJ
 3HUPLVVLRQJUDQWHGLVQRQH[FOXVLYHDQGLVYDOLGWKURXJKRXWWKHZRUOGLQWKH(QJOLVK
ODQJXDJHDQGWKHODQJXDJHVVSHFLILHGLQ\RXURULJLQDOUHTXHVW
 :ROWHUV.OXZHUFDQQRWVXSSO\WKHUHTXHVWRUZLWKWKHRULJLQDODUWZRUNRUDFOHDQFRS\
 7KHUHTXHVWRUDJUHHVWRVHFXUHZULWWHQSHUPLVVLRQIURPWKHDXWKRU IRUERRNPDWHULDO
RQO\ 
 3HUPLVVLRQLVYDOLGLIWKHERUURZHGPDWHULDOLVRULJLQDOWRD:ROWHUV.OXZHULPSULQW
$GLV/LSSLQFRWW5DYHQ3XEOLVKHUV:LOOLDPV :LONLQV/HD )HELJHU+DUZDO
,JDNX6KRLQ5DSLG6FLHQFH/LWWOH%URZQ &RPSDQ\+DUSHU 5RZ0HGLFDO
$PHULFDQ-RXUQDORI1XUVLQJ&RDQG8UEDQ 6FKZDU]HQEHUJ(QJOLVK/DQJXDJH 
 ,I\RXRSWQRWWRXVHWKHPDWHULDOUHTXHVWHGDERYHSOHDVHQRWLI\5LJKWVOLQNZLWKLQ
GD\VRIWKHRULJLQDOLQYRLFHGDWH
 3OHDVHQRWHWKDWDUWLFOHVLQWKHDKHDGRISULQWVWDJHRISXEOLFDWLRQFDQEHFLWHGDQGWKH
FRQWHQWPD\EHUHXVHGE\LQFOXGLQJWKHGDWHRIDFFHVVDQGWKHXQLTXH'2,QXPEHU
$Q\ILQDOFKDQJHVLQPDQXVFULSWVZLOOEHPDGHDWWKHWLPHRISULQWSXEOLFDWLRQDQGZLOO
EHUHIOHFWHGLQWKHILQDOHOHFWURQLFYHUVLRQRIWKHLVVXH
'LVFODLPHU$UWLFOHVDSSHDULQJLQWKH3XEOLVKHG$KHDGRI3ULQWVHFWLRQKDYHEHHQSHHU
UHYLHZHGDQGDFFHSWHGIRUSXEOLFDWLRQLQWKHUHOHYDQWMRXUQDODQGSRVWHGRQOLQHEHIRUH
SULQWSXEOLFDWLRQ$UWLFOHVDSSHDULQJDVSXEOLVKDKHDGRISULQWPD\FRQWDLQVWDWHPHQWV
RSLQLRQVDQGLQIRUPDWLRQWKDWKDYHHUURUVLQIDFWVILJXUHVRULQWHUSUHWDWLRQ
$FFRUGLQJO\/LSSLQFRWW:LOOLDPV :LONLQVWKHHGLWRUVDQGDXWKRUVDQGWKHLU
UHVSHFWLYHHPSOR\HHVDUHQRWUHVSRQVLEOHRUOLDEOHIRUWKHXVHRIDQ\VXFKLQDFFXUDWHRU
PLVOHDGLQJGDWDRSLQLRQRULQIRUPDWLRQFRQWDLQHGLQWKHDUWLFOHVLQWKLVVHFWLRQ
 2WKHU7HUPVDQG&RQGLWLRQV
Y
,I\RXZRXOGOLNHWRSD\IRUWKLVOLFHQVHQRZSOHDVHUHPLWWKLVOLFHQVHDORQJZLWK\RXU
SD\PHQWPDGHSD\DEOHWR&23<5,*+7&/($5$1&(&(17(5RWKHUZLVH\RXZLOOEH
LQYRLFHGZLWKLQKRXUVRIWKHOLFHQVHGDWH3D\PHQWVKRXOGEHLQWKHIRUPRIDFKHFN
RUPRQH\RUGHUUHIHUHQFLQJ\RXUDFFRXQWQXPEHUDQGWKLVLQYRLFHQXPEHU
5/1.
2QFH\RXUHFHLYH\RXULQYRLFHIRUWKLVRUGHU\RXPD\SD\\RXULQYRLFHE\FUHGLWFDUG
3OHDVHIROORZLQVWUXFWLRQVSURYLGHGDWWKDWWLPH
0DNH3D\PHQW7R
&RS\ULJKW&OHDUDQFH&HQWHU
'HSW
32%R[
%RVWRQ0$
)RUVXJJHVWLRQVRUFRPPHQWVUHJDUGLQJWKLVRUGHUFRQWDFW5LJKWV/LQN&XVWRPHU
6XSSRUWFXVWRPHUFDUH#FRS\ULJKWFRPRU WROOIUHHLQWKH86 RU
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*UDWLVOLFHQVHV UHIHUHQFLQJLQWKH7RWDOILHOG DUHIUHH3OHDVHUHWDLQWKLVSULQWDEOH
OLFHQVHIRU\RXUUHIHUHQFH1RSD\PHQWLVUHTXLUHG
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Figure 1.10 Reprint Permissions


5LJKWVOLQN3ULQWDEOH/LFHQVH
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SXEOLVKLQJULJKWVLQUHODWLRQWRDSDUWLFXODUMRXUQDO FROOHFWLYHO\:,/(< %\FOLFNLQJDFFHSWLQ
FRQQHFWLRQZLWKFRPSOHWLQJWKLVOLFHQVLQJWUDQVDFWLRQ\RXDJUHHWKDWWKHIROORZLQJWHUPVDQG
FRQGLWLRQVDSSO\WRWKLVWUDQVDFWLRQ DORQJZLWKWKHELOOLQJDQGSD\PHQWWHUPVDQGFRQGLWLRQV
HVWDEOLVKHGE\WKH&RS\ULJKW&OHDUDQFH&HQWHU,QF &&&¶V%LOOLQJDQG3D\PHQWWHUPVDQG
FRQGLWLRQV DWWKHWLPHWKDW\RXRSHQHG\RXU5LJKWVOLQNDFFRXQW WKHVHDUHDYDLODEOHDWDQ\WLPH
DWKWWSP\DFFRXQWFRS\ULJKWFRP 
7HUPVDQG&RQGLWLRQV
7KHPDWHULDOV\RXKDYHUHTXHVWHGSHUPLVVLRQWRUHSURGXFH WKH0DWHULDOV DUHSURWHFWHGE\
FRS\ULJKW
<RXDUHKHUHE\JUDQWHGDSHUVRQDOQRQH[FOXVLYHQRQVXEOLFHQVDEOHQRQWUDQVIHUDEOH
ZRUOGZLGHOLPLWHGOLFHQVHWRUHSURGXFHWKH0DWHULDOVIRUWKHSXUSRVHVSHFLILHGLQWKHOLFHQVLQJ
SURFHVV7KLVOLFHQVHLVIRUDRQHWLPHXVHRQO\ZLWKDPD[LPXPGLVWULEXWLRQHTXDOWRWKHQXPEHU
WKDW\RXLGHQWLILHGLQWKHOLFHQVLQJSURFHVV$Q\IRUPRIUHSXEOLFDWLRQJUDQWHGE\WKLVOLFHQFHPXVW
EHFRPSOHWHGZLWKLQWZR\HDUVRIWKHGDWHRIWKHJUDQWRIWKLVOLFHQFH DOWKRXJKFRSLHVSUHSDUHG
EHIRUHPD\EHGLVWULEXWHGWKHUHDIWHU 7KH0DWHULDOVVKDOOQRWEHXVHGLQDQ\RWKHUPDQQHURUIRU
DQ\RWKHUSXUSRVH3HUPLVVLRQLVJUDQWHGVXEMHFWWRDQDSSURSULDWHDFNQRZOHGJHPHQWJLYHQWRWKH
DXWKRUWLWOHRIWKHPDWHULDOERRNMRXUQDODQGWKHSXEOLVKHU<RXVKDOODOVRGXSOLFDWHWKHFRS\ULJKW
QRWLFHWKDWDSSHDUVLQWKH:LOH\SXEOLFDWLRQLQ\RXUXVHRIWKH0DWHULDO3HUPLVVLRQLVDOVRJUDQWHG
RQWKHXQGHUVWDQGLQJWKDWQRZKHUHLQWKHWH[WLVDSUHYLRXVO\SXEOLVKHGVRXUFHDFNQRZOHGJHGIRUDOO
RUSDUWRIWKLV0DWHULDO$Q\WKLUGSDUW\PDWHULDOLVH[SUHVVO\H[FOXGHGIURPWKLVSHUPLVVLRQ
:LWKUHVSHFWWRWKH0DWHULDOVDOOULJKWVDUHUHVHUYHG([FHSWDVH[SUHVVO\JUDQWHGE\WKHWHUPVRI
WKHOLFHQVHQRSDUWRIWKH0DWHULDOVPD\EHFRSLHGPRGLILHGDGDSWHG H[FHSWIRUPLQRU
UHIRUPDWWLQJUHTXLUHGE\WKHQHZ3XEOLFDWLRQ WUDQVODWHGUHSURGXFHGWUDQVIHUUHGRUGLVWULEXWHGLQ
DQ\IRUPRUE\DQ\PHDQVDQGQRGHULYDWLYHZRUNVPD\EHPDGHEDVHGRQWKH0DWHULDOVZLWKRXW
WKHSULRUSHUPLVVLRQRIWKHUHVSHFWLYHFRS\ULJKWRZQHU<RXPD\QRWDOWHUUHPRYHRUVXSSUHVVLQ
DQ\PDQQHUDQ\FRS\ULJKWWUDGHPDUNRURWKHUQRWLFHVGLVSOD\HGE\WKH0DWHULDOV<RXPD\QRW
OLFHQVHUHQWVHOOORDQOHDVHSOHGJHRIIHUDVVHFXULW\WUDQVIHURUDVVLJQWKH0DWHULDOVRUDQ\RI
WKHULJKWVJUDQWHGWR\RXKHUHXQGHUWRDQ\RWKHUSHUVRQ
7KH0DWHULDOVDQGDOORIWKHLQWHOOHFWXDOSURSHUW\ULJKWVWKHUHLQVKDOODWDOOWLPHVUHPDLQWKH
H[FOXVLYHSURSHUW\RI-RKQ:LOH\ 6RQV,QFRURQHRILWVUHODWHGFRPSDQLHV :,/(< RUWKHLU
UHVSHFWLYHOLFHQVRUVDQG\RXULQWHUHVWWKHUHLQLVRQO\WKDWRIKDYLQJSRVVHVVLRQRIDQGWKHULJKWWR
UHSURGXFHWKH0DWHULDOVSXUVXDQWWR6HFWLRQKHUHLQGXULQJWKHFRQWLQXDQFHRIWKLV$JUHHPHQW
<RXDJUHHWKDW\RXRZQQRULJKWWLWOHRULQWHUHVWLQRUWRWKH0DWHULDOVRUDQ\RIWKHLQWHOOHFWXDO
SURSHUW\ULJKWVWKHUHLQ<RXVKDOOKDYHQRULJKWVKHUHXQGHURWKHUWKDQWKHOLFHQVHDVSURYLGHGIRU
DERYHLQ6HFWLRQ1RULJKWOLFHQVHRULQWHUHVWWRDQ\WUDGHPDUNWUDGHQDPHVHUYLFHPDUNRU
RWKHUEUDQGLQJ 0DUNV RI:,/(<RULWVOLFHQVRUVLVJUDQWHGKHUHXQGHUDQG\RXDJUHHWKDW\RX
VKDOOQRWDVVHUWDQ\VXFKULJKWOLFHQVHRULQWHUHVWZLWKUHVSHFWWKHUHWR
1(,7+(5:,/(<125,76/,&(162560$.(6$1<:$55$17<255(35(6(17$7,212)$1<
.,1'72<2825$1<7+,5'3$57<(;35(66,03/,('2567$78725<:,7+5(63(&7727+(
0$7(5,$/6257+($&&85$&<2)$1<,1)250$7,21&217$,1(',17+(0$7(5,$/6
,1&/8',1*:,7+287/,0,7$7,21$1<,03/,(':$55$17<2)0(5&+$17$%,/,7<$&&85$&<
6$7,6)$&725<48$/,7<),71(66)25$3$57,&8/$5385326(86$%,/,7<,17(*5$7,2125
121,1)5,1*(0(17$1'$//68&+:$55$17,(6$5(+(5(%<(;&/8'('%<:,/(<$1',76
/,&(16256$1':$,9('%<<28
:,/(<VKDOOKDYHWKHULJKWWRWHUPLQDWHWKLV$JUHHPHQWLPPHGLDWHO\XSRQEUHDFKRIWKLV
$JUHHPHQWE\\RX
<RXVKDOOLQGHPQLI\GHIHQGDQGKROGKDUPOHVV:,/(<LWV/LFHQVRUVDQGWKHLUUHVSHFWLYH
GLUHFWRUVRIILFHUVDJHQWVDQGHPSOR\HHVIURPDQGDJDLQVWDQ\DFWXDORUWKUHDWHQHGFODLPV
GHPDQGVFDXVHVRIDFWLRQRUSURFHHGLQJVDULVLQJIURPDQ\EUHDFKRIWKLV$JUHHPHQWE\\RX
,112(9(176+$//:,/(<25,76/,&(16256%(/,$%/(72<2825$1<27+(53$57<25
$1<27+(53(562125(17,7<)25$1<63(&,$/&216(48(17,$/,1&,'(17$/,1',5(&7
(;(03/$5<25381,7,9('$0$*(6+2:(9(5&$86('$5,6,1*2872)25,1&211(&7,21
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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:,7+7+('2:1/2$',1*3529,6,21,1*9,(:,1*2586(2)7+(0$7(5,$/65(*$5'/(66
2)7+()2502)$&7,21:+(7+(5)25%5($&+2)&2175$&7%5($&+2):$55$17<7257
1(*/,*(1&(,1)5,1*(0(172527+(5:,6( ,1&/8',1*:,7+287/,0,7$7,21'$0$*(6
%$6('21/2662)352),76'$7$),/(686(%86,1(6623325781,7<25&/$,062)7+,5'
3$57,(6 $1':+(7+(5251277+(3$57<+$6%((1$'9,6('2)7+(3266,%,/,7<2)68&+
'$0$*(67+,6/,0,7$7,216+$//$33/<127:,7+67$1',1*$1<)$,/85(2)(66(17,$/
385326(2)$1</,0,7('5(0('<3529,'('+(5(,1
6KRXOGDQ\SURYLVLRQRIWKLV$JUHHPHQWEHKHOGE\DFRXUWRIFRPSHWHQWMXULVGLFWLRQWREHLOOHJDO
LQYDOLGRUXQHQIRUFHDEOHWKDWSURYLVLRQVKDOOEHGHHPHGDPHQGHGWRDFKLHYHDVQHDUO\DVSRVVLEOH
WKHVDPHHFRQRPLFHIIHFWDVWKHRULJLQDOSURYLVLRQDQGWKHOHJDOLW\YDOLGLW\DQGHQIRUFHDELOLW\RIWKH
UHPDLQLQJSURYLVLRQVRIWKLV$JUHHPHQWVKDOOQRWEHDIIHFWHGRULPSDLUHGWKHUHE\
7KHIDLOXUHRIHLWKHUSDUW\WRHQIRUFHDQ\WHUPRUFRQGLWLRQRIWKLV$JUHHPHQWVKDOOQRW
FRQVWLWXWHDZDLYHURIHLWKHUSDUW\ VULJKWWRHQIRUFHHDFKDQGHYHU\WHUPDQGFRQGLWLRQRIWKLV
$JUHHPHQW1REUHDFKXQGHUWKLVDJUHHPHQWVKDOOEHGHHPHGZDLYHGRUH[FXVHGE\HLWKHUSDUW\
XQOHVVVXFKZDLYHURUFRQVHQWLVLQZULWLQJVLJQHGE\WKHSDUW\JUDQWLQJVXFKZDLYHURUFRQVHQW
7KHZDLYHUE\RUFRQVHQWRIDSDUW\WRDEUHDFKRIDQ\SURYLVLRQRIWKLV$JUHHPHQWVKDOOQRWRSHUDWH
RUEHFRQVWUXHGDVDZDLYHURIRUFRQVHQWWRDQ\RWKHURUVXEVHTXHQWEUHDFKE\VXFKRWKHUSDUW\
7KLV$JUHHPHQWPD\QRWEHDVVLJQHG LQFOXGLQJE\RSHUDWLRQRIODZRURWKHUZLVH E\\RX
ZLWKRXW:,/(< VSULRUZULWWHQFRQVHQW
$Q\IHHUHTXLUHGIRUWKLVSHUPLVVLRQVKDOOEHQRQUHIXQGDEOHDIWHUWKLUW\  GD\VIURPUHFHLSW
7KHVHWHUPVDQGFRQGLWLRQVWRJHWKHUZLWK&&&¶V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQV
ZKLFKDUHLQFRUSRUDWHGKHUHLQ IRUPWKHHQWLUHDJUHHPHQWEHWZHHQ\RXDQG:,/(<FRQFHUQLQJ
WKLVOLFHQVLQJWUDQVDFWLRQDQG LQWKHDEVHQFHRIIUDXG VXSHUVHGHVDOOSULRUDJUHHPHQWVDQG
UHSUHVHQWDWLRQVRIWKHSDUWLHVRUDORUZULWWHQ7KLV$JUHHPHQWPD\QRWEHDPHQGHGH[FHSWLQ
ZULWLQJVLJQHGE\ERWKSDUWLHV7KLV$JUHHPHQWVKDOOEHELQGLQJXSRQDQGLQXUHWRWKHEHQHILWRIWKH
SDUWLHV VXFFHVVRUVOHJDOUHSUHVHQWDWLYHVDQGDXWKRUL]HGDVVLJQV
,QWKHHYHQWRIDQ\FRQIOLFWEHWZHHQ\RXUREOLJDWLRQVHVWDEOLVKHGE\WKHVHWHUPVDQGFRQGLWLRQV
DQGWKRVHHVWDEOLVKHGE\&&&¶V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVWKHVHWHUPVDQG
FRQGLWLRQVVKDOOSUHYDLO
:,/(<H[SUHVVO\UHVHUYHVDOOULJKWVQRWVSHFLILFDOO\JUDQWHGLQWKHFRPELQDWLRQRI L WKHOLFHQVH
GHWDLOVSURYLGHGE\\RXDQGDFFHSWHGLQWKHFRXUVHRIWKLVOLFHQVLQJWUDQVDFWLRQ LL WKHVHWHUPVDQG
FRQGLWLRQVDQG LLL &&&¶V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQV
7KLV$JUHHPHQWZLOOEHYRLGLIWKH7\SHRI8VH)RUPDW&LUFXODWLRQRU5HTXHVWRU7\SHZDV
PLVUHSUHVHQWHGGXULQJWKHOLFHQVLQJSURFHVV
7KLV$JUHHPHQWVKDOOEHJRYHUQHGE\DQGFRQVWUXHGLQDFFRUGDQFHZLWKWKHODZVRIWKH6WDWHRI
1HZ<RUN86$ZLWKRXWUHJDUGVWRVXFKVWDWH¶VFRQIOLFWRIODZUXOHV$Q\OHJDODFWLRQVXLWRU
SURFHHGLQJDULVLQJRXWRIRUUHODWLQJWRWKHVH7HUPVDQG&RQGLWLRQVRUWKHEUHDFKWKHUHRIVKDOOEH
LQVWLWXWHGLQDFRXUWRIFRPSHWHQWMXULVGLFWLRQLQ1HZ<RUN&RXQW\LQWKH6WDWHRI1HZ<RUNLQWKH
8QLWHG6WDWHVRI$PHULFDDQGHDFKSDUW\KHUHE\FRQVHQWVDQGVXEPLWVWRWKHSHUVRQDOMXULVGLFWLRQ
RIVXFKFRXUWZDLYHVDQ\REMHFWLRQWRYHQXHLQVXFKFRXUWDQGFRQVHQWVWRVHUYLFHRISURFHVVE\
UHJLVWHUHGRUFHUWLILHGPDLOUHWXUQUHFHLSWUHTXHVWHGDWWKHODVWNQRZQDGGUHVVRIVXFKSDUW\
:LOH\2SHQ$FFHVV7HUPVDQG&RQGLWLRQV
$OOUHVHDUFKDUWLFOHVSXEOLVKHGLQ:LOH\2SHQ$FFHVVMRXUQDOVDUHIXOO\RSHQDFFHVVLPPHGLDWHO\
IUHHO\DYDLODEOHWRUHDGGRZQORDGDQGVKDUH$UWLFOHVDUHSXEOLVKHGXQGHUWKHWHUPVRIWKH&UHDWLYH
&RPPRQV$WWULEXWLRQ1RQ&RPPHUFLDO/LFHQVHZKLFKSHUPLWVXVHGLVWULEXWLRQDQGUHSURGXFWLRQLQ
DQ\PHGLXPSURYLGHGWKHRULJLQDOZRUNLVSURSHUO\FLWHGDQGLVQRWXVHGIRUFRPPHUFLDOSXUSRVHV
7KHOLFHQVHLVVXEMHFWWRWKH:LOH\2SHQ$FFHVVWHUPVDQGFRQGLWLRQV
:LOH\2SHQ$FFHVVDUWLFOHVDUHSURWHFWHGE\FRS\ULJKWDQGDUHSRVWHGWRUHSRVLWRULHVDQGZHEVLWHVLQ
DFFRUGDQFHZLWKWKHWHUPVRIWKH&UHDWLYH&RPPRQV$WWULEXWLRQ1RQ&RPPHUFLDO/LFHQVH$WWKH
WLPHRIGHSRVLW:LOH\2SHQ$FFHVVDUWLFOHVLQFOXGHDOOFKDQJHVPDGHGXULQJSHHUUHYLHZ
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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FRS\HGLWLQJDQGSXEOLVKLQJ5HSRVLWRULHVDQGZHEVLWHVWKDWKRVWWKHDUWLFOHDUHUHVSRQVLEOHIRU
LQFRUSRUDWLQJDQ\SXEOLVKHUVXSSOLHGDPHQGPHQWVRUUHWUDFWLRQVLVVXHGVXEVHTXHQWO\
:LOH\2SHQ$FFHVVDUWLFOHVDUHDOVRDYDLODEOHZLWKRXWFKDUJHRQ:LOH\ VSXEOLVKLQJSODWIRUP:LOH\
2QOLQH/LEUDU\RUDQ\VXFFHVVRUVLWHV
8VHE\QRQFRPPHUFLDOXVHUV
)RUQRQFRPPHUFLDODQGQRQSURPRWLRQDOSXUSRVHVLQGLYLGXDOXVHUVPD\DFFHVVGRZQORDGFRS\
GLVSOD\DQGUHGLVWULEXWHWRFROOHDJXHV:LOH\2SHQ$FFHVVDUWLFOHVDVZHOODVDGDSWWUDQVODWHWH[W
DQGGDWDPLQHWKHFRQWHQWVXEMHFWWRWKHIROORZLQJFRQGLWLRQV

7KHDXWKRUV PRUDOULJKWVDUHQRWFRPSURPLVHG7KHVHULJKWVLQFOXGHWKHULJKWRISDWHUQLW\
DOVRNQRZQDVDWWULEXWLRQWKHULJKWIRUWKHDXWKRUWREHLGHQWLILHGDVVXFK DQGLQWHJULW\
WKHULJKWIRUWKHDXWKRUQRWWRKDYHWKHZRUNDOWHUHGLQVXFKDZD\WKDWWKHDXWKRU VUHSXWDWLRQ
RULQWHJULW\PD\EHLPSXJQHG 
:KHUHFRQWHQWLQWKHDUWLFOHLVLGHQWLILHGDVEHORQJLQJWRDWKLUGSDUW\LWLVWKHREOLJDWLRQRI
WKHXVHUWRHQVXUHWKDWDQ\UHXVHFRPSOLHVZLWKWKHFRS\ULJKWSROLFLHVRIWKHRZQHURIWKDW
FRQWHQW
,IDUWLFOHFRQWHQWLVFRSLHGGRZQORDGHGRURWKHUZLVHUHXVHGIRUQRQFRPPHUFLDOUHVHDUFK
DQGHGXFDWLRQSXUSRVHVDOLQNWRWKHDSSURSULDWHELEOLRJUDSKLFFLWDWLRQ DXWKRUVMRXUQDODUWLFOH
WLWOHYROXPHLVVXHSDJHQXPEHUV'2,DQGWKHOLQNWRWKHGHILQLWLYHSXEOLVKHGYHUVLRQRQ
:LOH\2QOLQH/LEUDU\ VKRXOGEHPDLQWDLQHG&RS\ULJKWQRWLFHVDQGGLVFODLPHUVPXVWQRWEH
GHOHWHG
$Q\WUDQVODWLRQVIRUZKLFKDSULRUWUDQVODWLRQDJUHHPHQWZLWK:LOH\KDVQRWEHHQDJUHHG
PXVWSURPLQHQWO\GLVSOD\WKHVWDWHPHQW7KLVLVDQXQRIILFLDOWUDQVODWLRQRIDQDUWLFOHWKDW
DSSHDUHGLQD:LOH\SXEOLFDWLRQ7KHSXEOLVKHUKDVQRWHQGRUVHGWKLVWUDQVODWLRQ
8VHE\FRPPHUFLDOIRUSURILWRUJDQLVDWLRQV
8VHRI:LOH\2SHQ$FFHVVDUWLFOHVIRUFRPPHUFLDOSURPRWLRQDORUPDUNHWLQJSXUSRVHV
UHTXLUHVIXUWKHUH[SOLFLWSHUPLVVLRQIURP:LOH\DQGZLOOEHVXEMHFWWRDIHH&RPPHUFLDO
SXUSRVHVLQFOXGH
&RS\LQJRUGRZQORDGLQJRIDUWLFOHVRUOLQNLQJWRVXFKDUWLFOHVIRUIXUWKHUUHGLVWULEXWLRQVDOH
RUOLFHQVLQJ
&RS\LQJGRZQORDGLQJRUSRVWLQJE\DVLWHRUVHUYLFHWKDWLQFRUSRUDWHVDGYHUWLVLQJZLWKVXFK
FRQWHQW
7KHLQFOXVLRQRULQFRUSRUDWLRQRIDUWLFOHFRQWHQWLQRWKHUZRUNVRUVHUYLFHV RWKHUWKDQ
QRUPDOTXRWDWLRQVZLWKDQDSSURSULDWHFLWDWLRQ WKDWLVWKHQDYDLODEOHIRUVDOHRUOLFHQVLQJIRUD
IHH IRUH[DPSOHDFRPSLODWLRQSURGXFHGIRUPDUNHWLQJSXUSRVHVLQFOXVLRQLQDVDOHVSDFN
8VHRIDUWLFOHFRQWHQW RWKHUWKDQQRUPDOTXRWDWLRQVZLWKDSSURSULDWHFLWDWLRQ E\IRUSURILW
RUJDQLVDWLRQVIRUSURPRWLRQDOSXUSRVHV
/LQNLQJWRDUWLFOHFRQWHQWLQHPDLOVUHGLVWULEXWHGIRUSURPRWLRQDOPDUNHWLQJRUHGXFDWLRQDO
SXUSRVHV
8VHIRUWKHSXUSRVHVRIPRQHWDU\UHZDUGE\PHDQVRIVDOHUHVDOHOLFHQFHORDQWUDQVIHURU
RWKHUIRUPRIFRPPHUFLDOH[SORLWDWLRQVXFKDVPDUNHWLQJSURGXFWV
3ULQWUHSULQWVRI:LOH\2SHQ$FFHVVDUWLFOHVFDQEHSXUFKDVHGIURP
FRUSRUDWHVDOHV#ZLOH\FRP
2WKHU7HUPVDQG&RQGLWLRQV
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW



219



5LJKWVOLQN3ULQWDEOH/LFHQVH

%<&/,&.,1*217+(,$*5((%2;<28$&.12:/('*(7+$7<28
+$9(5($'$1')8//<81'(567$1'($&+2)7+(6(&7,2162)$1'
3529,6,2166(7)257+,17+,6$*5((0(17$1'7+$7<28$5(,1
$*5((0(17:,7+$1'$5(:,//,1*72$&&(37$//2)<285
2%/,*$7,216$66(7)257+,17+,6$*5((0(17
Y
,I\RXZRXOGOLNHWRSD\IRUWKLVOLFHQVHQRZSOHDVHUHPLWWKLVOLFHQVHDORQJZLWK\RXU
SD\PHQWPDGHSD\DEOHWR&23<5,*+7&/($5$1&(&(17(5RWKHUZLVH\RXZLOOEH
LQYRLFHGZLWKLQKRXUVRIWKHOLFHQVHGDWH3D\PHQWVKRXOGEHLQWKHIRUPRIDFKHFN
RUPRQH\RUGHUUHIHUHQFLQJ\RXUDFFRXQWQXPEHUDQGWKLVLQYRLFHQXPEHU
5/1.
2QFH\RXUHFHLYH\RXULQYRLFHIRUWKLVRUGHU\RXPD\SD\\RXULQYRLFHE\FUHGLWFDUG
3OHDVHIROORZLQVWUXFWLRQVSURYLGHGDWWKDWWLPH
0DNH3D\PHQW7R
&RS\ULJKW&OHDUDQFH&HQWHU
'HSW
32%R[
%RVWRQ0$
)RUVXJJHVWLRQVRUFRPPHQWVUHJDUGLQJWKLVRUGHUFRQWDFW5LJKWV/LQN&XVWRPHU
6XSSRUWFXVWRPHUFDUH#FRS\ULJKWFRPRU WROOIUHHLQWKH86 RU

*UDWLVOLFHQVHV UHIHUHQFLQJLQWKH7RWDOILHOG DUHIUHH3OHDVHUHWDLQWKLVSULQWDEOH
OLFHQVHIRU\RXUUHIHUHQFH1RSD\PHQWLVUHTXLUHG

KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW
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